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introduction
Since the introduction and widespread use of abdominal imaging technologies there 
has been an increase in the frequency of detection of space-occupying lesions in the 
liver. In particular due to the use of ultrasound imaging which is frequently used because 
of its safety and non-invasive nature and its accessibility [1]. Liver tumors that are found 
by incidence are defined as findings unrelated to the clinical indication for which the 
imaging examination was performed. To decide which of these tumors needs therapy 
further characterization with highly advanced imaging modalities (magnetic resonance 
imaging (MRI)) or needle biopsy is needed. Core needle biopsy is still accepted as the 
gold standard for diagnosing tumors in various organs. However, there is an increasing 
role for radiology in the diagnosis of focal liver tumors, especially by the use of state-of-
the-art MRI. Moreover, most hepatic tumors can be diagnosed with confidence by the 
use state-of-the-art MRI, which may have consequences for the role of needle biopsy 
during work-up of focal liver lesions [2].
A tumor is a space occupying mass of tissue. The word tumor is not synonymous with 
cancer, because a tumor may be either benign or malignant. Malignant primary liver 
tumors can spread to other areas of the body and can be fatal. Malignant liver tumors 
frequently need therapy or long term follow-up. Benign liver tumors do not spread to 
other areas of the body and are generally not life-threatening. Various benign focal liver 
lesions can occur in patients. The most common benign liver lesions are hemangiomas 
(masses of blood vessels), simple cysts (fluid-filled cavities), focal nodular hyperplasia 
(FNH) and hepatocellular adenomas (HCA). In most cases, benign liver tumors are not 
detected because they cause no symptoms and these masses are typically found during 
a routine examination. The indication for the treatment of benign liver tumors frequently 
depends on their size, presence of symptoms and the type of tumor. In this thesis we 
focus on solid benign liver tumors, in particular HCA.
HePAtocellulAr AdenoMA
Complex situations may arise in case of HCA with confusion for doctors and patients. 
HCA is a rare benign tumor of the liver that typically presents in women within their 
reproductive years. Although the etiology and pathogenesis of HCA is unknown, an as-
sociation of HCA with the use of estrogen containing oral contraceptives (OC) was first 
described in 1973 [3]. In subsequent years many authors supported the hypothesis of an 
association between OC and HCA [4-8]. It should be noted that HCA were rarely reported 
before the commercial introduction of OC in the 1960s. Regression of HCA may occur 
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when OC are withdrawn [9-12]. The mechanism by which estrogen or other steroids 
contributes to the development of HCA is still not understood.
Despites its benign character, HCA can be complicated by hormone induced growth 
and rupture and bleeding of the tumor. Moreover, malignant transformation has been 
reported in rare instances [13]. Symptomatic patients with HCA present with right upper 
quadrant abdominal pain or discomfort secondary to bleeding within the HCA, elevated 
liver enzymes and symptoms of life treating hemorrhage into the peritoneal cavity. But 
most patients with HCA are asymptomatic and present as an incidental finding during 
ultrasonographic examination of the abdomen for unrelated reasons or are noted dur-
ing laparoscopic cholecystectomy.
HCA can be solitary or multiple. In 1985, Flejou et al. defined more than 10 nodules 
found in an otherwise normal liver parenchyma as liver adenomatosis. Macroscopically 
the HCA lesion is smooth and soft on palpation. Microscopic examination shows well-
circumscribed tumors with cords of hepatocytes having a glycogen and lipid content 
and showing loss of the normal lobular architecture with absence of portal tracts and 
hepatic veins. The hepatic plate may be two or more cells thick separated by dilated 
sinusoids. Bile ductules are absent, a key histologic feature that helps distinguish it from 
FNH [14, 15]. The cut surface of the adenoma has a characteristic yellow appearance, 
which comes from the lipid accumulation. A proportion of HCA also shows cytonuclear 
atypia. It may be difficult to distinguish HCA from other benign or malignant liver tu-
mors. The differential diagnosis of HCA includes FNH and well differentiated hepatocel-
lular carcinoma. FNH is a benign solid tumor of the liver of vascular etiology, usually 
observed in female patients. Microscopically there is a central scar that contains larger 
arteries and smaller bile ducts surrounded by regenerative hepatocyte nodules [16, 17]. 
Differentiation may also be difficult based on radiological imaging because both tumors 
have radiological similarities. Many imaging modalities are available to detect benign 
liver tumors, however state-of-the-art MRI provides the most comprehensive and non-
invasive imaging work-up of patients with suspected HCA [18].
Unlike FNH, HCA frequently requires treatment because of possible life-threatening 
complications in case of large tumors and in case there is a pregnancy wish in women 
with child bearing potential. Women with HCA seem to be at greater risk of bleeding 
during pregnancy. The debate whether to manage HCA by surveillance or surgical 
resection continues. Conservative management of HCA frequently implies cessation of 
the use of OC and intermittent follow-up by radiological imaging. Whereas aggressive 
treatment may include surgical resection of the tumor(s), transarterial embolization 
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(selective occlusion of blood vessels) or radiofrequency ablation therapy (destroys tis-
sue by application of interstitial hyperthermia resulting in coagulative necrosis).
AiM of tHe tHeSiS
The overall aim of this thesis was to analyze the clinical, pathologic and radiologic char-
acteristics of patients presenting with HCA and to establish a decision-making model for 
the management of HCA.
The management of HCA may pose clinical dilemmas since there is a lack of standard-
ized protocols. The debate whether to manage solitary adenomas by surveillance or 
surgical resection continues. chapter 2 describes the present day-to-day management 
of HCA in the Netherlands based on expert opinions on diagnosis and treatment of HCA.
The Bordeaux group established a pathological and molecular classification system for 
HCA. HCA were divided into four different subgroups based on morphological criteria, 
molecular characteristics and by the use of an immunohistochemical panel of markers. 
In chapter 3 we asked ourselves the following questions: Is it possible to distinguish 
subgroups of HCA based on pathological findings and is it possible to correlate patho-
logical findings with imaging characteristics on state-of-the-art MRI?
HCA in pregnant women requires special considerations because of the risk of hormone 
induced growth and spontaneous rupture, due to increased levels of steroid hormones 
during pregnancy that may threaten the life of both mother and child. Most experts 
advocate that women with HCA should not get pregnant or advise surgical resection 
before pregnancy [19, 20]. chapter 4 describes the management of HCA during preg-
nancy and a proposal is made for a multicenter prospective study to give more insight 
in the behavior of HCA during pregnancy. We hypothesized that pregnancy may be 
allowed in case of one or more known HCA < 5 cm, because HCA < 5 cm will not disturb 
the course of pregnancy.
Treatment is indicated in selective cases. The management of HCA might become com-
plex in patients with centrally located HCA or multiple HCA in both lobes of the liver. 
In chapter 5 the safety and efficacy of radiofrequency ablation (RFA) for the treatment 
of HCA and liver adenomatosis is investigated. RFA destroys tissue by application of 
interstitial hyperthermia resulting in coagulative necrosis.
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Although HCA is a benign tumor of the liver, the diagnosis has a great impact on the 
lives of young women. HCA can be complicated by hormone induced growth and sub-
sequently spontaneous rupture. chapter 6 of this thesis gives a systematic review of the 
literature on the risk on hemorrhage and rupture of HCA.
In chapter 7 the current knowledge about diagnosis and treatment modalities of HCA is 
discussed and a decision-making model for the management of HCA is proposed.
Finally, in chapter 8 the results of the studies performed in this thesis are summarized 
and discussed.
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AbStrAct
background: The diagnosis of hepatocellular adenoma (HCA) has a great impact on the 
lives of young women and may pose clinical dilemmas to the clinician since there are 
no standardized protocols to follow. We aimed to establish expert opinions on diagnosis 
and treatment of HCA by collecting data from a nationwide questionnaire in the Neth-
erlands. 
Methods: A questionnaire was sent to 20 Dutch hospitals known to offer hepatologic 
and surgical experience on liver tumours.
results: 17 hospitals (85%) responded to the questionnaire. Annually, a median of 52 pa-
tients presented with a solid liver tumour. In 15 (88%) hospitals, hepatic adenomas were 
diagnosed with contrast-enhanced, multiphase spiral CT or MRI. In 2 (12%) hospitals, 
histology was required as part of a management protocol. Surveillance after withdrawal 
of oral contraceptives was the initial policy in all clinics. MRI, CT or ultrasound was used 
for follow-up. Criteria for surgical resection were a tumour size > 5 cm and abdominal 
complaints. In 5 (29%) hospitals, patients were dismissed from follow-up after surgery. 
In complex cases (e.g. large, multiple or centrally localized lesions, a wish for pregnancy), 
the treatment policy was highly variable. Pregnancy was not discouraged in 15 hospi-
tals, but in 11 (65%) of these, strictly defined conditions were noted: frequent follow-up, 
peripheral tumour localization that makes surgery easier if necessary, stable tumour 
size, and a good informed consent. 
conclusion: The management of HCAs in the Netherlands is rather uniform, except in 
complex cases in which multiple factors may influence policy.
Diagnosis and treatment of HCA in the Netherlands 17
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introduction
The diagnosis of hepatocellular adenoma (HCA) has a great impact on the lives of 
young women. HCA is a benign tumour that usually presents as a solitary nodule; in 
a minority, multiple lesions are seen. This tumour is mostly detected in females within 
their reproductive years, associated with a long-term use of oral contraceptives (OC). 
The incidence is low, estimated to be 3–4/100,000 in long-term OC users [1]. During 
pregnancy the presence of HCA can be complicated by growth and rupture which is 
induced by elevated hormone levels. Rupture and bleeding is associated with high 
maternal and fetal mortality [2–5]. Malignant transformation of HCA to hepatocellular 
carcinoma (HCC) occurs rarely, but the true incidence of malignancy arising within HCA 
is not known [6, 7]. Patients with HCA may present with right upper quadrant abdominal 
pain secondary to bleeding, elevated liver enzymes and symptoms of life-threatening 
haemorrhage. However, most patients are asymptomatic. Since the introduction and 
widespread use of highly advanced imaging modalities, the number of solitary nodules 
that are found by accident has greatly increased in the last decennium [8].
The debate whether to manage solitary adenomas by surveillance or surgical resec-
tion continues. Conservative management of HCA frequently implies cessation of the 
use of OC, intermittent follow-up by radiological imaging and negative advice regarding 
pregnancy. Surgical treatment of HCA is associated with a risk of morbidity and mortal-
ity and does not guarantee relief of complaints. The most important reason for surgery 
is size of the lesion, since rupture as well as malignant transformation is seldom reported 
in lesions <5 cm [7]. Patients with an adenoma which is <5 cm and who do have a wish 
for pregnancy might also benefit from an early intervention in order to avoid an invasive 
treatment during pregnancy [9]. In practice, management strategy is not only deter-
mined by the size of the HCA, but may also depend on complaints, the number and 
localization of nodules, a wish for pregnancy and surgical risks. Therefore, the policy for 
HCA should be standardized while there is a place for a custom-made approach when 
considering these factors. For this purpose, we collected data by a nationwide question-
naire in order to establish the most common approach in diagnosis and treatment of 
HCA in the Netherlands.
MetHodS
In January 2005, a questionnaire was sent to 20 Dutch university centres and hospitals 
with a large programme of hepatobiliary surgery (Table 1). Hepatobiliary surgeons in 
these hospitals all participate in the Dutch Liver Surgery Working Group of which is a 
division of the Dutch Society for Surgery. Both the departments of surgery and gastroin-
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testinal diseases were invited to take part in this questionnaire. In May 2005, a reminder 
was sent to those who had not responded. The questionnaire included multiple-choice 
questions concerning incidence, diagnosis, treatment and follow-up of HCA in the Neth-
erlands. There was a possibility to add a comment next to each question. Specialists 
were asked what they would advise a women with a HCA and a wish for pregnancy. In 
questions concerning treatment, we proposed that a conservative policy was followed 
initially. Thereafter, the question was asked on what criteria invasive treatment could 
have been chosen. Clinical dilemmas on HCA were discussed on the basis of 5 imaginary 
cases. These cases had an open-answer option. Statistical data were analyzed using SPSS 
for Windows Version 13.0 (SPSS, Chicago, Ill., USA).
reSultS
Of the 20 hospitals (8 university centres and 9 general hospitals), 17 (85%) responded. 
In 8 (47%) of these 17 hospitals, data on incidence were from prospective databases. 
Data from the remaining hospitals were based on retrospective analyses or estimates 
by specialists.
table 1. Summary of questionnaire concerning policy in case of HCA held in The Netherlands
Incidence
Are patients with solid liver tumours registered?
How many liver tumours are seen each year?
How many of them are benign?
Is there a multidisciplinary consultation team to determine treatment policy?
Diagnosis
Which imaging tools are being used for diagnosis?
Is there a role for liver biopsy in diagnosis of hepatocellular adenoma?
Are patients being tested for hepatitis B or C infection?
Therapy
Define surveillance
What are criteria to switch to invasive therapy?
What would be the first option?
Is the histological diagnosis of the resected specimen always conform preoperative histological diagnosis?
Follow-up
Is there a follow-up after conservative management?
Is there a follow-up after surgery?
What kind of follow-up is being used and for how long?
What are the reasons for follow-up?
Pregnancy
What do you advise a patient with a wish for pregnancy?
Did you ever had a pregnant patient with an adenoma in situ?
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incidence
A median of 52 patients with a solid liver tumour presented annually per hospital (range 
3–415). Between 1 and 40% of these patients had benign lesions with a differential 
diagnosis of adenoma, focal nodular hyperplasia, and haemangioma.
diagnostics
In 16 (94%) hospitals the policy for individual patients was determined by a multidisci-
plinary consultation of a surgeon, hepatologist, radiologist, oncologist and pathologist. 
The diagnosis of HCA was usually based on imaging modalities. Multiphase spiral CT 
series were performed in 12 (71%) hospitals. Multiphase contrast-enhanced MRI series 
were also applied in 12 hospitals. These data show that in 15 (88%) hospitals HCAs were 
diagnosed with contrast-enhanced, multiphase spiral CT or MRI series. In 2 (12%) hospi-
tals a liver biopsy was required for histological diagnosis. 13 (76%) hospitals followed the 
standard policy to test patients with a solid nodule for hepatitis B and C. Additional tests 
included serum analyses for iron overload (8 (53%) hospitals), α1-antitrypsin deficiency 
and alcohol consumption (both in 2 (12%) hospitals).
treatment
In 12 (71%) hospitals the policy for HCA was not structured in a protocol. Surveillance 
was the initial strategy in all hospitals. This policy consisted of withdrawal of OC and 
outpatient control by an imaging modality at least once. The kind of imaging tool that 
was used varied; MRI, CT or ultrasound was performed for follow-up in respectively 7 
(41%), 10 (59%) and 8 (47%) hospitals. The interval between follow-up episodes also 
varied. Follow-up after 6 months was mentioned in 10 (59%) hospitals, but intervals 
of 3, 4, or 12 months were also reported. Another question concerned the situation 
in which a patient could resume the use of OC. This was assumed to be possible in 8 
(47%) hospitals. Six hospitals reported that in patients who did not show a regression 
of the lesion up to 1 year after stopping, the use of OC could be resumed. Comments 
were made that patients tended not to resume the use of OC and often wanted to have 
imaging information about renewed growth. Major criteria for surgical resection were 
a tumour size >5 cm (16 (94%) hospitals) and abdominal complaints (15 clinics, 88%). 
In those cases the decision for radical resection of the liver tumour was unanimous. In 
case of multiple adenomas the motivation for surgical intervention was determined by 
the pattern of complaints, size and localization of the lesions, opportunities to treat all 
tumours and the availability and use of alternative treatments such as radiofrequency 
ablation. Other criteria were a wish for pregnancy, signs of malignancy, tumour growth, 
diagnostic doubt and localization in respectively 7 (41%), 10 (59%), 4 (24%), 5 (29%) and 
7 (41%) of all hospitals. In 14 (82%) hospitals it had occurred that histological analysis 
of the resected specimen showed another diagnosis compared to the preoperative 
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diagnosis. Most of these cases were focal nodular hyperplasia. Five (29%) hospitals 
mentioned a few cases in which a HCC was diagnosed after resection.
follow-up
Patients who were managed by surveillance were followed for a median period of 4 
years (range 1–10) in all hospitals. In 14 (82%) of the 17 hospitals, radiological tools 
were used to monitor growth and malignant transformation. After surgical resection, in 
5 (29%) hospitals follow-up was not considered necessary. In the other cases, patients 
were followed for a median period of 2 years (range 1–5). Growth or residual lesions 
were monitored. Pregnancy was not discouraged in 15 hospitals, but in 11 (65%) of 
these, strictly defined conditions such as frequent follow-up (4 hospitals), a peripheral 
tumour localization that makes surgery easier if necessary (2 hospitals), a stable tumour 
size (2 hospitals), and a good informed consent about the risks in case of pregnancy (2 
hospitals) were noted. No restrictions in patients with HCA were imposed in 4 hospitals. 
In only 1 hospital, 1 patient was advised to postpone pregnancy until a surgical resec-
tion had been performed. Seven hospitals reported 1 or more patient(s) who presented 
with an adenoma during pregnancy; growth of the tumour occurred in 4 cases. Three of 
them fulfilled their pregnancy without complications. In 1 hospital, 1 patient underwent 
a surgical resection during the first trimester of pregnancy and another patient under-
went a premature caesarean section in the third trimester because of a rapidly growing 
adenoma.
imaginary cases
Clinical dilemmas on HCA were investigated on the basis of 5 imaginary cases (Table 
2). Small asymptomatic adenomas were managed by surveillance. In case of a large 
adenoma which was located centrally in the liver, the choice between surveillance and 
surgical resection was difficult to make and answers varied widely on this point. In 6 
hospitals an additional biopsy was preferred in case of multiple adenomas in order to 
exclude malignancy.
diScuSSion
Data obtained from this survey show that most Dutch specialists who responded to the 
questionnaire rely on multiphase contrast-enhanced CT or MRI series to confirm the 
diagnosis of HCA. Using these techniques it is usually possible to differentiate adenomas 
from other benign lesions such as focal nodular hyperplasia and haemangioma as well 
as from malignancies [10–12]. No strict consensus for the optimal imaging work-up of 
liver lesions was found. Most often, MRI was applied to characterize liver lesions by using 
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multiphase dynamic contrast-enhanced techniques. The availability of tissue-specific 
contrast media in MRI, e.g. gadobenate dimeglumine, which is one of the most recently 
used agents in hepatic imaging, permits lesion characterisation based on its cellular 
composition, enhancement pattern and morphological features [13]. The use of this 
highly advanced imaging modality during differential diagnosis of a focal liver lesion will 
prevent unnecessary liver biopsy or surgery. The role of ultrasound-guided percutane-
ous liver biopsy is debatable as various studies indicate that histology on needle biopsies 
may not be conclusive regarding HCA, focal nodular hyperplasia and well-differentiated 
HCC [14–16]. Only 2 hospitals in our questionnaire indicated that a biopsy was required 
to establish the diagnosis of HCA. Conservative management, including imaging sur-
veillance and discontinuation of OC, was the initial policy in all hospitals (Figure. 1). This 
strategy is in accordance with several studies advocating a conservative approach [14, 
15, 17, 18]. Some authors emphasize the possibility of malignant transformation in large 
lesions [17, 19, 20] and tend to resect HCAs >5 cm. The relationship between tumour size 
and bleeding risk is unclear. After rupture or bleeding of HCAs it is difficult to identify 
the size of the original tumour as a haematoma may disturb imaging reliability. While 
most patients with an adenoma are asymptomatic, up to 60% of those who present 
with symptoms do have signs of bleeding [15, 19, 21]. Although tumour size is the most 
table 2. Imaginary cases and answers of specialists from 17 hospitals with expertise in hepatobiliary 
surgery
Case Policy Hospitals, n
48-year-old female with a hilar-located 
adenoma of 8 cm and signs of intrahepatic 
bleeding
Resection if possible
Arterial embolisation
RFA
Observation
7 (41%)
4 (24%)
1 (6%)
5 (29%)
23-year-old female with an incidentally 
found adenoma located in the middle of 
the right lobe; she uses OC and has a clear 
wish for pregnancy in future
Surveillance
Surveillance, invasive treatment in case of 
growth or no regression
RFA
11 (65%)
4 (24%)
2 (12%)
40-year-old obese female diagnosed with 
4 lesions suspected for adenoma: 2 are 
located in the right liver (diameter 6 and 
2 cm) and two in the left (diameter 2 and 
3 cm)
Surveillance
Resection of largest one
Resection of largest adenoma and RFA of other 
lesions
RFA of largest lesion
7 (41%)
4 (24%)
5 (29%)
1 (6%)
Female patient with an adenoma of 8 cm; 
regression occurred after stopping OC; the 
tumour now measures 4 cm and she wants 
to become pregnant
Resection before pregnancy
RFA before pregnancy
Good informed consent and surveillance during 
pregnancy
10 (59%)
2 (12%)
5 (29%)
Female patient with an adenoma of 4 
cm, which did not show regression after 
stopping OC; she wants to be pregnant
Frequent surveillance during pregnancy
Resection or RFA before pregnancy
Informed consent; the patient has to decide for 
surveillance, surgery or RFA
8 (47%)
7 (41%)
2 (12%)
RFA = Radiofrequency ablation; OC = Oral contraceptives
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important factor to decide whether to manage by observation or to perform a surgical 
resection, abdominal pain was an equally important determinant. Surgical resection of 
HCA is described as an effective method to reduce complaints. However, various experts 
stress that it should be ascertained that symptoms are related to the HCA [15]. Abdomi-
nal pain often arises due to the sudden increase in volume of a haematoma. Bleeding 
can be managed conservatively and resorption of a haematoma can equally reduce 
symptoms. Many experts answered to favour a wait-and-see policy in dynamically 
stable patients [22]. The localization of a HCA and the surgical risks determine whether a 
surgical approach is feasible. If there are doubts about radiological diagnosis, specialists 
are more likely to favour surgical resection, i.e. to exclude HCC. Clinical dilemmas occur 
when multiple factors mentioned above are to be considered. In these situations it is 
complex to define an appropriate treatment strategy and comments varied consider-
ably between specialists. The use of imaging modalities is essential during follow-up of 
HCA, since there is a large discrepancy between clinical signs of patients and the size 
or growth of the adenoma. It has to be noted that it is a difficult decision to discour-
age pregnancy in otherwise healthy young women. Pregnancy was not discouraged in 
most of the clinics, but in most of the imaginary cases, a majority of experts wanted 
to exclude the risk of bleeding by resection before pregnancy. In a recently published 
review of 27 women who were pregnant with a HCA in situ, rupture occurred in 16 of 
them, leading to death of mother or child in 7 cases [5]. However, it has to be noted 
that all of these case reports were published in the 1970s or 1980s. In this period, the 
figure 1. Contrast-enhanced multiphase MRI series of patient with HCA: (a) T2-weighted, (b) arterial 
phase, (c) delayed phase during use of OC, (d) T2-weighted, (e) arterial phase, and (f) delayed phase after 
stopping use of OC.
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routine use of ultrasonography was less frequent and there might have been a delay in 
diagnosis because of confusion with other pregnancy-related diseases like preeclampsia 
or pulmonary embolism. When women are informed about the potential risks, it is safe 
to allow pregnancy, especially if the lesion is accessible for limited surgical resection. It 
seems unjustified to discourage all women with HCAs from pregnancy. In women with 
a clear diagnosis of a single HCA with a diameter <5 cm and without complaints, most 
experts advise a conservative policy. After discontinuation of OC, HCA does not seem to 
grow and the likelihood of bleeding decreases [23]. If the diagnosis of HCA is uncertain 
and the diagnosis HCC remains in differential diagnosis, radical resection of the tumour 
is recommended. At our centre, surgical treatment of solitary adenomas is restricted 
to patients having lesions that measure ≥5 cm, in those patients in which malignancy 
cannot be excluded and to lesions that do not show adequate regression after discon-
tinuation of OC, especially in case of women with a wish for pregnancy [9, 15]. However, 
due to the invasive nature of hepatic surgery and the risk of postoperative morbidity, 
other treatment strategies are needed. Several authors have described the successful 
application of minimal invasive strategies such as transarterial (chemo)embolization 
and radiofrequency ablation [24–28] . The role of these alternative treatments in case of 
HCA still needs to be established in clinical studies. Recent identification of gene muta-
tions, such as mutations in hepatocyte nuclear factor 1α and β-catenin that seem to be 
correlated to the phenotype of HCA, will create a basis for a new genotype/phenotype 
classification of HCAs. These developments will hopefully permit significant improve-
ments in liver biopsy interpretation, creating the possibility to predict the risk of bleed-
ing and malignant transformation and the ability to propose better guidelines in terms 
of surveillance and treatment [29, 30]. We conclude that the management of HCAs in the 
Netherlands is rather uniform. However, in complex situations where multiple factors 
may play a role in determining the management strategy, such as pregnancy or multiple 
adenomas, respondents’ opinions are very variable regarding treatment and follow-up. 
Because evidence-based data are scarce in the literature, it is recommended that Dutch 
specialists exchange knowledge and data of patients with HCA to develop the most 
adequate guidelines in complex situations, justifying a custom-made approach. This will 
prevent unnecessary surgery and may offer well-balanced advice on pregnancy in case 
of more complex cases.
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AbStrAct
background & Aims: A molecular and pathological classification system for hepatocel-
lular adenomas (HCA) was recently introduced and four major subgroups were iden-
tified. We aimed to validate this adenoma classification system and to determine the 
clinical relevance of the subtypes for surgical management.
Methods: Paraffin fixed liver tissue slides and resection specimens of patients radio-
logically diagnosed as HCA were retrieved from the department of pathology. Immu-
nostainings included liver-fatty acid binding protein (L-FABP), serum amyloid A (SAA), 
C-reactive protein (CRP), glutamine synthetase (GS) and β-catenin.
results: From 2000 to 2010, 58 cases (71 lesions) were surgically resected. Fourteen 
lesions were diagnosed as focal nodular hyperplasia with a characteristic map-like 
staining pattern of GS. Inflammatory HCA expressing CRP and SAA was documented in 
36 of 57 adenomas (63%). Three of these inflammatory adenomas were also β-catenin 
positive as well as GS positive and only one was CRP and SAA and GS positive. We identi-
fied eleven L-FABP-negative HCA (19%) and four β-catenin positive HCA (7%), without 
expression of CRP and SAA and with normal L-FABP staining, one of which was also GS 
positive. Six HCA were unclassifiable (11%). In three patients multiple adenomas of dif-
ferent subtypes were found.
conclusions: Morphology and additional immunohistochemical markers can discrimi-
nate between different types of HCA in >90% of cases and this classification, including 
the identification of β-catenin positive adenomas may have important implications 
in the decision for surveillance or treatment. Interpretation of nuclear staining for 
β-catenin can be difficult due to uneven staining distribution or focal nuclear staining 
and additional molecular biology may be required.
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introduction
Hepatocellular adenoma (HCA) is a rare benign tumor of the liver that occurs predomi-
nantly in women, in most cases within their reproductive years. The estimated incidence 
is about 1–1.3 per 1,000,000 in women who have never used oral contraceptives (OC), 
compared to a substantial higher incidence of 30–40 per 1,000,000 in long-term users 
[1,2]. These data refer to studies performed decades ago. Although to date the incidence 
may be lower due to reduced concentrations of OC, the detection rate may have in-
creased due to better and more frequently applied imaging techniques [3,4].
Recently, a new molecular and pathological classification of HCA was introduced by 
Bioulac-Sage and colleagues who suggested that the identification of subtypes might 
be of great clinical importance [5]. They divided HCAs in four subgroups, based on mor-
phological criteria, molecular characteristics and by the use of an immunohistochemical 
panel of markers. The first group, 35–40% of the HCA cases, was defined by the presence 
of mutations in the TCF1 gene that inactivate the hepatocyte nuclear factor 1α (HNF-
1α). The second group, 10–15% of cases, showed the presence of β-catenin activating 
mutations. The third group, 50% of cases, showed inflammatory and/or telangiectatic 
HCAs with serum amyloid A (SAA) and C-reactive protein (CRP) expression. This group 
was histomorphologically characterized by the presence, with variable intensity, of in-
flammatory infiltrates, thick walled arteries, sinusoidal dilatation and ductular reaction.
Finally, less than 10% of HCA are unclassified [6–8].
There are several interesting findings from this study. HNF-1α mutated HCA have a 
lack of liver-fatty acid binding protein (L-FABP) expression in the tumor and this subtype 
is most of the time highly steatotic, with steatosis grade 2 and 3 in 27% and 36%, respec-
tively [7,9]. Liver adenomatosis (HCA >10) is most often found in HNF-1α mutated HCA 
[6]. Another finding is that patients with a high body mass index (BMI) and excessive 
alcohol consumption were more frequently observed in the inflammatory group [10,11]. 
β-Catenin activated lesions seem to have a higher risk of malignant transformation in 
patients with HCA bigger than 4–5 cm [9,10]. Therefore identifying a β-catenin mutation 
is of major interest. It is well known that, it can be very difficult to differentiate HCA from 
a well-differentiated hepatocellular carcinoma (HCC), especially when some cytonuclear 
atypia is present. Additional markers may have great relevance in helping to discriminate 
these lesions. Glutamine synthetase (GS) is another useful marker in tumor liver pathol-
ogy. A strong and diffuse/homogeneous GS staining is shown in β-catenin mutated 
HCA. In focal nodular hyperplasia (FNH), a ‘map-like’ staining pattern is described [12].
The aim of this study was to validate the classification system and to determine the 
clinical relevance of the subtypes for surgical management.
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MAteriAlS And MetHodS
Patients
The Erasmus University Medical Centre Rotterdam in the Netherlands is a tertiary refer-
ral centre for focal liver lesions. From 2000 to 2010, 58 patients who were radiological 
diagnosed as HCA were treated by surgical resection. A total of 71 lesions were surgically 
excised. Clinical data for OC use, BMI and symptoms, radiological data for the number 
of lesions and follow-up data were retrospectively collected. The study was approved by 
the institutions review board.
Histopathological and immunohistochemical analysis
Paraffin fixed liver tissue slides were retrieved from the archives of the department of 
pathology, Erasmus University Medical Centre Rotterdam. For each lesion macroscopic 
characteristics (size, number of tumors) and microscopic features were noted by the 
liverpathologist. Non-tumoral liver tissue was evaluated for steatosis, sinusoidal dilata-
tion, inflammatory infiltrates and fibrosis according to the classification of the METAVIR 
group as follows: F0 (no fibrosis); F1 (portal fibrosis), F2 (few bridges), F3 (many bridges) 
and F4 (cirrhosis) [13]. Steatosis was graded according to Kleiner et al.: Grade 1 (5–33% 
of the hepatocytes), grade 2 (33–66% of the hepatocytes), grade 3 (more than 66% of 
the hepatocytes). Steatosis, if not observed or <5% was graded as grade 0 [14]. Lesions 
were evaluated for the presence and degree of dystrophic and solitary arteries, inflam-
matory infiltrates, sinusoidal dilatation, ductular reaction, haemorrhage, presence of a 
fibrous tumor capsule, presence of fibrous bands, steatosis (grade as mentioned above), 
cytonuclear atypia and the formation of pseudoglands. Sinusoidal dilatation was graded 
as follows: up to one third (grade 1), up to two thirds (grade 2), and more than two 
thirds of the sinusoids affected (grade 3). Absence of sinusoidal dilatation was graded 
as grade 0. Immunohistochemistry was performed on paraffin sections representative 
of the tumor. Immunostainings included L-FABP (polyclonal antibody, 1:100 dilution, 
Bio-Connect), SAA (monoclonal mouse antibody, 1:200 dilution, Dako), CRP (mouse 
monoclonal antibody, 1:1600 dilution, Bio-Connect), GS (monoclonal mouse antibody, 
1:3200 dilution, BD Biosciences) and β-catenin (monoclonal mouse antibody, 1:50 dilu-
tion, BD Biosciences). A nuclear staining for β-catenin, focal or diffuse, was considered 
positive. For each immunohistochemical staining a positive and negative control was 
used for quality control.
Statistical analysis
Continuous variables were summarized as mean and standard error in case of normal 
variances, or as the median with ranges in case of non-normal variances and categoric 
variables were summarized as frequency and percentages. Categorized variables were 
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compared with each other using the chi-square test or Fishers’ exact test. The nonpara-
metric Mann-Whitney test for unpaired data was used for continuous variables. All 
reported p values were based on 2-sided test of statistical significance. A p value of less 
than 0.05 was accepted as statistical significance.
reSultS
clinical and pathological features
From 2000 to 2010, in 58 patients, 71 lesions diagnosed as HCA by radiological imaging, 
were surgically resected. Fifty six patients (97%) were female using OC as documented 
in 50 women. The time of duration of OC use was known in 30 women, 27 women (90%) 
had been taking OC for ≥5 years. The median age at diagnosis was 36 years (range 15–64) 
and the median BMI was 26.6 (range 18.2–42.6). Acute abdominal pain was present in 30 
cases (53%), in 7 patients these symptoms were caused by bleeding. Eight cases (14%) 
presented with specific symptoms. The remaining cases were discovered as an incidental 
finding during radiological examination of the abdomen for unrelated reasons. Haemor-
rhage was seen in 31 of 57 lesions (54%) with a final diagnosis of HCA. No haemorrhagic 
component was seen in 14 lesions with a final diagnosis of FNH. We identified HCA in 47 
cases (57 lesions) and FNH in 11 cases (14 lesions), based on morphological criteria and 
with additional immunohistochemical analysis (see below).
Non-tumoral liver tissue was not available in three cases. Pathological analysis of the 
non-tumoral liver tissue showed steatosis grade 0 in 62% of cases, steatosis grade 1 or 
grade 2 in 33% of cases and steatosis grade 3 in 5% of cases. F0 was present in 78% 
of cases. All other patients presented F1 (20%) or F2 (2%). Forty-nine percent of cases 
presented with sinusoidal dilatation grade 1, 13% of cases presented with sinusoidal 
dilatation grade 2 and 2% of cases presented with sinusoidal dilatation grade 3. In 36% 
of cases there was no sinusoidal dilatation. Inflammatory infiltrates were present in 51% 
of cases. None of the patients had noted diseases known to be associated with HCA such 
as glycogenosis, familial adenomatous polyposis coli or aplastic anemia. Upon preopera-
tive imaging, 25 HCA patients were considered to have a single HCA in the liver. Multiple 
adenomas (2–9 nodules) were found in 18 patients and adenomatosis (≥10 nodules) 
was present in 4 cases. (Table 1) Two patients presented with a simultaneous occurrence 
of HCA and FNH. Follow-up data were available in 53 patients. Median follow-up was 35 
weeks (range 2–293 weeks). Two patients were followed elsewhere and three patients 
are still in follow-up (all <1 year). In 35 cases there was a complete resection of the le-
sions. In 23 patients there were nodules left in the surrounding liver (1–9 nodules), these 
nodules were stable in size during follow-up in 10 patients with a maximum diameter 
of 10–28 mm. In 9 patients regression of the lesions was observed; four patients were 
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treated with radiofrequency ablation. After surgery, five patients became pregnant with 
an uneventful outcome and stable tumor size in all cases. During follow-up there were 
no complications including bleeding or malignant transformation. None of the patients 
died during follow-up.
Analysis according to subgroups
The immunohistochemical analysis allowed us to classify the adenomas in 4 subgroups.
First, inflammatory HCA with expression of both CRP and SAA is the most frequent 
subgroup and was documented in 36 of 57 adenomas (63%). Among this subgroup, 3 
adenomas (8%) demonstrated focal positivity for β-catenin and demonstrated a diffuse 
and homogeneous staining pattern for GS (Figure 3) and one HCA (3%) demonstrated 
only a heterogeneous GS staining pattern (no nuclear β-catenin staining), involving a 
majority of hepatocytes and therefore considered as positive. Serum CRP levels before 
resection were available in 23 of 36 inflammatory adenomas. All patients, except two, 
table 1. Clinical and pathological characteristics
Characteristics Number (%) Median Range
Age, years 35.7 15-64
Sex
 Female 56 (96.6)
 Male 2 (3.4)
BMI, kg/m2 54 26.6 18.2-42.6
 < 25 24 (44.4)
 ≥ 25 30 (55.6)
 Missing 4
OC use (females) 50
 No OC use 1
 Missing 5
Number of HCA (radiological)
 Single 25 (53.2)
 > 1 to 10 18 (38.3)
 ≥ 10 4 (8.5)
Symptoms 57
 Acute abdominal pain 30 (52.6)
 Aspecific symptoms 8 (14.0)
 Symptom free 19 (32.8)
 Missing 1
Size (mm) resected HCA 68.5 5-200
Size (mm) resected FNH 70 10-90
Haemorrhagic HCA 31 (54.4)
Haemorrhagic FNH 0
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showed elevated serum CRP levels (range 11–523 mg/l). The two male patients were 
found in the inflammatory group; one showed expression of CRP, SAA and a heteroge-
neous staining pattern for GS as mentioned before. Second, a lack of L-FABP expression, 
compatible with HNF-1α mutation, was present in 11 adenomas (19%), with steatosis 
grade 3 in 64% of these adenomas (Figure 1). All other cases (3) with a lack of L-FABP, 
table 2. Clinical characteristics according to subtype classification of HCA and FNH
Characteristics Subtype classification of HCA (n = 57) FNH (n = 14)
L-FABP-negative (compatible 
with HNF-1α mutation)
Inflammatory 
type
β-catenin 
positive
Unclassified
Number of 
lesions
11 (19%) 36 (63%) 4 (7%) 6 (11%) 14
BMI, kg/m2
 < 25 6 11 4 1 7
 ≥ 25 5 22 0 5 5
 Missing 3 3
Size (mm)* 70 (5-165) 65 (9-200) 45 (20-90) 67.5 (30-100) 70 (10-90)
* median (range)
Figure 1. 
         
Liver-fatty acid binding protein (L-FABP) immunostaining in multiple steatotic HCA: lack of  
L-FABP expression in HCA in contrast with normal expression in non-tumoural liver 
 
figure 1. Liver-fatty acid binding protein (L-FABP) immunostaining in multiple steatotic HCA: lack of 
L-FABP expression in HCA in contrast with normal expression in non-tumoral liver.
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showed steatosis grade 1 or grade 2. No steatosis was present in one case. Third, (some) 
nuclear staining of β-catenin was observed in 3 HCA, without expression of CRP, SAA 
and GS and with normal L-FABP staining pattern. All these lesions had cytological ab-
normalities. Nuclear staining of β-catenin with concomitant diffuse and homogeneous 
GS staining positivity was observed in one HCA. None of these tumors had steatosis 
within the lesion. The fourth subgroup is formed by so-called unclassifiable adenomas: 
6 HCA were unclassifiable (11%) because they were CRP, SAA, β-catenin and GS nega-
tive, with a normal L-FABP staining pattern (Table 2). In three patients multiple resected 
adenomas (range 2–3) were of the same subtype: 3 steatotic adenomas in one patient 
and inflammatory adenomas in 2 patients (2 and 3, respectively). Two patients showed 
one unclassified and one inflammatory HCA, and another patient showed two β-catenin 
positive HCA and one unclassified HCA. As mentioned before, pathological signs of 
bleeding were seen in 31 of 57 HCA lesions (54%). Bleeding was more frequent in the 
L-FABP-negative group than in the inflammatory HCA group (73% vs. 50%, however the 
difference between the subgroups did not reach statistical significance). The median 
size of lesions, based on pathology, in the L-FABP-negative group was 70.0 mm (range 
5-165 mm) compared to a median size of 65.0 mm (range 9-200 mm) in the inflammatory 
group; the difference between the subgroups did not reach statistical significance. The 
Figure 2. 
 
          
 
Map-like staining pattern of glutamine synthetase (GS) in FNH    
 
figure 2. Map-like staining pattern of glutamine synthetase (GS) in FNH.
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frequency of multiple adenomas based on radiological imaging was almost equivalent 
in the L-FABP-negative group and the inflammatory group (44% vs. 42%). Patients with 
inflammatory HCA were more obese: median BMI 28.7 (range 18.6-42.6) compared to 
the L-FABP-negative group with a median BMI of 24.5 (range 22.3–40.8); however, the 
difference between the subgroups did not reach statistical significance. Subtype classifi-
cation was straightforward in more than 90% of HCA cases using immunohistochemical 
   
Figure 3.  
 
 
A. Homogeneous glutamine synthetase (GS) immunostaining pattern of HCA (left) and 
perivenular (zone 3) staining restricted to 2 or 3 plates of hepatocytes in non-tumoural liver 
(right) 
 
 
B. Area of GS positivity at the border of the tumour within a HCA (right). In this area, there 
was also nuclear positivity for -catenin  
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A. Homogeneous glutamine synthetase (GS) immunostaining pattern of HCA (left) and 
perivenular (zone 3) staining restricted to 2 or 3 plates of hepatocytes in non-tumoural liver 
(right) 
 
 
B. Area of GS positivity at the border of the tumour within a HCA (right). In this area, there 
was also nuclear positivity for -catenin  
(b)
figure 3. β-catenin positivity and glutamine synthetase (GS) positivity in two inflammatory HCAs. (a) 
Homogeneous GS immunostaining pattern of HCA (left) and perivenular (zone 3) staining restricted to 2 
or 3 plates of hepatocytes in non-tumoral liver (right) (b) Area of GS positivity at the border of the tumor 
within a HCA (right). In this area, there was also nuclear positivity for β-catenin.
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staining patterns and morphological criteria. In four cases the immunohistochemical 
markers were difficult to interpret. One case showed an inflammatory type HCA with a 
heterogeneous positivity of GS, which was not diffuse and not strong, except in some 
areas with a nuclear staining of β-catenin in these areas. In one case it was difficult to 
differentiate an area at the border of the tumor where cytonuclear atypia was seen 
within an adenoma, from a well-differentiated HCC. In this area β-catenin and GS were 
clearly positive (Figure 3). Additional staining with glypican-3 and HSP-70 could be of 
help in these situations [15]. Another inflammatory adenoma showed GS staining with a 
lot of background staining, however no nuclear staining of β-catenin was found. A third 
inflammatory HCA showed a heterogeneous GS staining and a doubtful nuclear staining 
of β-catenin. In these situations, molecular biology for the detection of β-catenin muta-
tions may be required.
Fourteen lesions, morphological compatible with FNH, showed a characteristic map-
like pattern of GS immunostaining (Figure 2). All FNH lesions were CRP, SAA and β-catenin 
negative, with a normal L-FABP staining. Microscopically all FNH lesions showed variable 
ductular reaction, fibrous septa, dystrophic arteries, intermingled with inflammatory 
cells. Haemorrhage and necrosis were not present.
diScuSSion
Currently, in our hospital all female patients with HCA are advised to stop the use of OC 
and other hormone medication including hormone replacement therapy, as regression 
of HCA may occur when estrogens are withdrawn [16–19]. Observation should be the 
first choice of treatment for most patients with HCA [20]. The management of solitary 
adenomas by conservative treatment or continuous surgical resection is still a matter of 
debate. Most authors believe that surgical resection is required if the diameter exceeds 
5 cm after 6 months of follow-up, if the lesion does not show adequate regression after 
discontinuation of OC or if bleeding occurs [21–24]. Surgical resection is also indicated 
if there is any suspicion on malignancy [25,26]. Immunohistochemical analysis may offer 
a helpful tool for HCA management strategy. The results of our series of 58 cases (71 le-
sions) are in accordance with data shown by Bioulage-Sage and colleagues and confirm 
that inflammatory HCA and L-FABP-negative HCA form the two main subgroups (83%) 
that differ on clinical and pathological grounds [6]. Morphology and immunohistochem-
istry allows subtyping of more than 90% of HCA. We observed 36 inflammatory HCA 
of which three demonstrated positivity for β-catenin and demonstrated a diffuse and 
homogeneous staining pattern for GS. Difficulties exist due to the fact that the number 
of β-catenin positive cells may be limited and staining may be focal (β-catenin expres-
sion was considered positive when the staining showed nuclear accumulation in the 
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neoplastic cells, sometimes with concomitant cytoplasmic staining). In our series, we did 
not find any patient with homogeneous nuclear staining of β-catenin throughout the 
lesion. The same counts for the subgroup that shows nuclear β-catenin staining without 
expression of CRP and SAA. These subgroups also showed focal β-catenin positivity and 
cytological atypia in all lesions. In agreement with the observations of Van der Borght et 
al., we noticed that β-catenin activated HCA had a complete absence of steatosis [27]. 
Inflammatory HCA occur more often in obese patients compared to the L-FABP-negative 
group. However, the difference between the subgroups did not reach statistical signifi-
cance. Bleeding was more frequently found in the L-FABP-negative group compared to 
the inflammatory group and the median size of lesions in the L-FABP-negative group was 
larger compared to the median size of adenomas in the inflammatory group. However, 
these data did not reach statistical significance, which may be due to the small group 
of 11 L-FABP-negative adenomas. In six patients multiple adenomas were resected and 
were of the same subtype in three patients. We observed that the other three patients 
showed adenomas of two different subtypes; always an unclassified HCA and one or 
more HCA of one other subtype. One might hypothesize that unclassified HCA may de-
velop with time into another subtype. On the other hand, it is conceivable that multiple 
adenomas of different subtypes may occur in the same patient.
HCA and FNH are the most frequent benign epithelial lesions of the liver observed 
in women during their reproductive years and are detected more frequent nowadays 
because of improvements in radiological modalities. Differentiation of HCA and FNH is 
important because FNH generally does not require treatment and follow-up, whereas 
HCA does. HCA can be complicated by life threatening rupture and bleeding or undergo 
malignant transformation necessitating treatment. In all our cases the morphological di-
agnosis of FNH was supported by the map-like staining pattern of GS [12]. When doubt 
remains about the diagnosis HCA (especially the inflammatory type that may contain 
inflammation as well as ductular reaction) or FNH, needle biopsy may be performed for 
the differential diagnosis and GS may be of help in this setting.
Whether the immunohistochemical markers will also be useful on biopsies from liver 
tumors, suspected of being HCA needs to be investigated. In most cases the identifica-
tion of L-FABP-negative and inflammatory type adenomas with positive CRP and SAA 
staining should be feasible on a biopsy, because of the more or less homogeneous 
staining pattern. However, the interpretation of β-catenin staining may be difficult 
because of the heterogeneous and sometimes focal nuclear staining pattern and addi-
tional molecular biology may be required, since close relationships were found between 
genetic data and immunohistochemical data [28–30]. This was already mentioned as a 
potential problem by Bioulac-Sage and colleagues and this is confirmed by our data [6]. 
A concomitant staining with GS is warranted to increase sensitivity to detect a β-catenin 
mutation, especially in the case of a biopsy. However, as mentioned before, no data are 
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available about the success rate of the immunohistochemical markers to classify sub-
groups on biopsies and our present experience suggest that sampling error will remain 
a problem in this situation. Besides, the amount of material obtained by biopsy could be 
insufficient to achieve a reliable diagnosis [22].
So far, management of HCA is defined by clinical parameters. All women with HCA 
should be advised to stop the use of OC’s and other hormone replacement therapy. 
Nodules >5 cm may be removed to avoid the risk of haemorrhage and the risk of ma-
lignant transformation. A decrease in size, documented by radiological imaging, after 
stopping OC may lead to a discharge or reduction in surveillance, particularly if no 
β-catenin mutation is detected. In the case of growth or β-catenin positivity, surgery 
may be required [6,8]. However, the possibility of immunohistochemical markers on 
biopsies needs to be investigated. To this date, the management of HCA requires a 
multidisciplinary approach.
concluSion
Morphology and immunohistochemical markers are useful in subtyping adenomas in 
more than 90% of cases and this classification, including the identification of β-catenin 
positive adenomas may have important implications in the decision for surveillance 
or treatment. However, in some patients, due to the low number of positive cells and 
focal positivity, the identification of nuclear staining for β-catenin still remains difficult. 
In this situation additional molecular biology for the detection of β-catenin mutation 
may be required. The consequence for treatment and follow-up of the subclassification 
remains to be determined. The low incidence of HCA and the absence of well defined 
information on the potential danger of malignant transformation of β-catenin positive 
lesions warrant a European multicenter study. This way, the classification system may be 
correlated with a legitimized clinical management.
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AbStrAct
Purpose: To investigate the correlation between magnetic resonance (MR) imaging 
findings and pathologic subtype classification of hepatocellular adenoma (HCA).
Materials and Methods: This retrospective study was approved by the institutional re-
view board, and the requirement for informed consent was waived. MR imaging studies 
of 61 lesions (48 patients; median age, 36 years) were available and were independently 
reviewed by two radiologists. Consensus readings on all morphologic and signal-inten-
sity imaging features were obtained. Previously, these lesions had been classified on the 
basis of pathologic findings and immunohistochemical analysis. Fisher exact and χ2 tests 
were performed to compare the results between the different subtypes. A Bonferroni 
correction was applied to correct for multiple testing (α < .0033).
results: MR imaging signs of diffuse intratumoral fat deposition were present in seven 
(78%) of nine liver-fatty acid binding protein (L-FABP)-negative HCAs compared with 
five (17%) of 29 inflammatory HCAs (P = .001). Steatosis within the nontumoral liver 
was present in 11 (38%) of 29 inflammatory HCAs compared with none of the L-FABP-
negative HCAs (P = .038). A characteristic atoll sign was only seen in the inflammatory 
group (P = .027). Presence of a typical vaguely defined type of scar was seen in five 
(71%) of seven β-catenin-positive HCAs (P = .003). No specific MR imaging features were 
identified for the unclassified cases.
conclusion: L-FABP-negative, inflammatory, and β-catenin-positive HCAs were related 
to MR imaging signs of diffuse intratumoral fat deposition, an atoll sign, and a typical 
vaguely defined scar, respectively. Since β-catenin-positive HCAs are considered prema-
lignant, closer follow-up with MR imaging or resection may be preferred.
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introduction
Hepatocellular adenoma (HCA) is an uncommon benign tumor of the liver that occurs 
particularly in young and middle-aged women (1). HCA can be complicated by life-
threatening rupture and bleeding or undergo malignant transformation (2,3). Manage-
ment of HCA frequently requires cessation of oral contraceptives, intermittent follow-up 
with radiologic imaging, and a recommendation to avoid pregnancy (4–6). Recently, 
the Bordeaux group established a new molecular and pathologic classification of HCA. 
They divided HCA into four different subgroups according to genotypic and phenotypic 
characteristics and clinical features (7–9). The first group, comprising 35%–40% of the 
HCA cases, was defined by the presence of mutations in the T-cell factor 1 gene that 
inactivate the hepatocyte nuclear factor 1α. Hepatocyte nuclear factor 1α-inactivated 
HCAs lack expression of liver-fatty acid binding protein (L-FABP) in the tumor. As a result, 
the majority of these tumors are highly steatotic (10). The second group, 10%–15% of 
cases, showed the presence of β-catenin-activating mutations. β-Catenin-activated le-
sions seem to have a higher risk of malignant transformation in patients with an HCA 
larger than 4–5 cm (7,8). The third group, 50% of cases, showed inflammatory HCAs with 
serum amyloid A (SAA) and C-reactive protein (CRP) expression. Finally, less than 10% 
of HCAs were unclassified (8,10). Glutamine synthetase (GS) is another useful marker 
in pathologic analysis of liver tumors. Strong, diffuse, and homogeneous GS staining 
has been shown in β-catenin-mutated HCA. This is in contrast to focal nodular hyper-
plasia (FNH), in which GS staining forms large hepatocyte areas that are organized in a 
characteristic map-like pattern, defined as positive GS staining in hepatocytes forming 
anastomosing areas, often surrounding venous structures (11). As previously described 
by Laumonier et al. (12), magnetic resonance (MR) imaging seems to be a useful tool for 
identifying the two major subtypes of HCA (ie, L-FABP-negative HCA and inflammatory 
HCA). The purpose of our study was to investigate the correlation between MR imaging 
findings and pathologic subtype classification of HCA.
MetHodS
Patients
This retrospective study was approved by the institutional ethical review board, and 
informed consent was waived. Between January 2000 and February 2010, a cohort of 
58 patients (71 lesions) who were radiologically diagnosed with an HCA were treated 
with surgical resection. The lesions were previously reviewed and classified on the basis 
of pathologic and immunohistochemical analysis (13). Among these 58 patients, we 
identified 50 patients in whom liver MR imaging had been performed. Two patients 
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were excluded from the study owing to a lack of adequate MR imaging pulse sequences 
to allow evaluation. A total of 48 patients (median age, 36 years) were included in the 
study. Among this group, a total of 61 lesions were surgically excised.
Histopathologic and immunohistochemical analysis
Immunohistochemical staining was performed on paraffin sections representative of the 
tumor and included L-FABP (polyclonal antibody, 1:100 dilution; Bio-Connect, Huissen, 
the Netherlands), SAA (monoclonal mouse antibody, 1:200 dilution; Dako, Heverlee, Bel-
gium), CRP (mouse monoclonal antibody, 1:1600 dilution; Bio-Connect), GS (monoclonal 
mouse antibody, 1:3200 dilution; BD Biosciences, Breda, the Netherlands), and β-catenin 
(monoclonal mouse antibody, 1:50 dilution; BD Biosciences), as previously described 
(13). For each immunohistochemical stain, positive and negative controls were used for 
quality control. The immunohistochemical analysis allowed us to classify the adenomas 
into four subgroups, and subtype classification was straightforward in more than 90% 
of HCA cases. A lack of L-FABP expression, compatible with hepatocyte nuclear factor 
1α mutation, was present in nine HCA lesions. Four lesions were positive for β-catenin 
without expression of CRP and SAA. Nuclear staining of β-catenin with a concomitant 
diffuse and homogeneous staining pattern for GS was observed in one of these four 
β-catenin-positive HCAs. All lesions in this subgroup showed cytologic atypia. The larg-
est group consisted of 30 inflammatory HCAs with expression of both CRP and SAA. 
Additional β-catenin activation with a concomitant diffuse and homogeneous staining 
pattern for GS was demonstrated in three inflammatory HCAs. One inflammatory HCA 
demonstrated a heterogeneous staining pattern of GS without nuclear β-catenin stain-
ing positivity. Five HCAs remained unclassified because they were negative for CRP, SAA, 
β-catenin, and GS, with a normal L-FABP staining pattern. Thirteen lesions that were 
morphologically compatible with FNH showed a characteristic map-like pattern of GS 
immunostaining; were negative for CRP, SAA, and β-catenin; and had normal L-FABP 
staining.
Mr imaging technique and analysis
Forty-one patients were imaged at our institution. All these patients underwent MR im-
aging on one of two 1.5-T units (Philips Medical Systems, Best, the Netherlands; or Signa, 
GE, Milwaukee, Wisconsin, USA) with the same protocol. A fourchannel phased-array 
body coil was used. In each patient, a single-shot fast spin-echo sequence (repetition 
time msec/echo time msec, 832/80–120; flip angle, 90°) with varying echo times (short 
and long echo times of 80 and 120 msec, respectively), a fat-suppressed T2-weighted 
fast spinecho sequence (3000/80; flip angle, 90°), and T1-weighted in- and opposed-
phase gradient-echo sequences (echo times, 4.6 and 2.3 msec, respectively; flip angle, 
80°) were used. In addition, fat-suppressed dynamic gadolinium-enhanced T1-weighted 
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imaging was performed in at least four phases precontrast, arterial, portal, and delayed) 
after administration of an intravenous bolus of 30 mL of non-liver-specific gadolinium 
chelate (gadopentetate dimeglumine, Magnevist; Schering, Berlin, Germany). The 
optimal arterial phase was based on bolus tracking. The portal and delayed phases 
were acquired at 45 and 120 seconds, respectively, after the acquisition of the arterial 
phase. Delayed-phase three-dimensional T1-weighted gradient-echo imaging was also 
performed at least 4 minutes after contrast material injection. A section thickness of 5-7 
mm was used in all sequences. Seven patients were imaged at collaborating hospitals, 
and their studies were reviewed at our institution. Minimal prerequisites for inclusion 
of these studies were the availability of T1- and T2-weighted images of the whole liver. 
T1- and T2-weighted images were available for all seven MR imaging studies performed 
at collaborative hospitals. In six of the seven studies, in- and opposed-phase images and 
dynamic contrast material-enhanced images were available. In one MR imaging study 
obtained at a collaborating hospital, only uniphase contrast-enhanced images in the ve-
nous phase were available. T1- and T2-weighted, in- and opposed-phase, and dynamic 
contrast-enhanced images were available for all MR imaging studies performed at our 
hospital. Two readers (M.G.J.T. and R.S.D., both with 7 years experience in abdominal im-
aging) reviewed the MR images independently while blinded to the clinical history and 
pathologic diagnosis. Thereafter, consensus on all imaging features was obtained. For all 
lesions, the following image features were noted by the radiologist: number of nodules, 
presence of steatosis in the nontumoral liver (absence, mild, moderate, or severe), loca-
tion of resected lesion according to the Couinaud numbering system (14), maximum size 
of resected lesion, contour (regular or lobulated), overall aspect on T2-weighted images 
(homogeneous or heterogeneous), presence of macroscopic hemorrhagic component 
(defined as focal T1-weighted hyperintense area), presence of necrotic or cystic compo-
nent (defined as pronounced hyperintense signal on T2-weighted images), presence of 
central scar (defined as T2-hyperintense lines enhancing in the late venous phase), pres-
ence and percentage of region of steatosis within the lesion (absence [0%], mild [<33%], 
moderate [33%–66%], or severe [>66%]) (empirically), presence of tumor capsule (low 
signal intensity on T2-weighted images and delayed phase enhancement) or pseudo-
capsule (high signal intensity on T2-weighted images and delayed phase enhancement) 
(15), signal intensity on T1- and T2-weighted images (slightly hypointense, markedly 
hypointense, isointense, slightly hyperintense, or markedly hyperintense), predominant 
phase of enhancement (arterial, portal, or venous; homogeneous, heterogeneous, or 
two phases), and intensity of enhancement (slight, moderate, or marked). Finally, on the 
basis of the images evaluated, each radiologist was asked to make a diagnosis for each 
lesion detected. Differentiation between HCA and FNH was based on typical features for 
both lesions, as previously published (16–19).
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Statistical analysis
Categorical variables were summarized as frequency and percentages. Categorized vari-
ables were compared with each other by using the χ2 or Fisher exact test. All reported 
P values were based on two-sided tests of significance. A Bonferroni correction was ap-
plied to correct for multiple testing (15 categorical variables). A P value of less than .0033 
was considered to indicate a significant difference. Because the β-catenin-activated and 
unclassifiable groups were quite small, the statistical analysis was mainly focused on the 
inflammatory and L-FABP-negative groups. Interobserver agreement was calculated by 
using Cohen κ statistics (≤0.20, poor agreement; 0.21–0.40, fair agreement; 0.41–0.60, 
moderate agreement; 0.61-0.80, good agreement; and 0.81–1.00, very good agreement) 
(20).
reSultS
clinical and general pathologic and imaging features
We identified HCA in 38 patients (48 lesions) and FNH in 10 patients (13 lesions) on the 
basis of morphologic criteria and immunohistochemical analysis (Figure 1). Forty-six 
(96%) of forty-eight patients were women (median age, 36 years; range, 15–64 years). 
The two male patients were both diagnosed with HCA (median age, 35 years; range, 
31–39 years). The median age at diagnosis for all individuals was 36 years (range, 
15–64 years). Oral contraceptive use was documented in 40 women. The duration of 
oral contraceptive use was known in 27 women: 24 women (89%) had been taking 
61 lesions 
9 L-FABP negative 
48 HCA  
30 Inflammatory 4 -catenin positive 5 Unclassified 
• 7 severe steatosis within 
lesion  
• 13 atoll sign • 3 typical vaguely 
defined scar 
• 3 poorly delimited high 
intensity areas 
• 5 no specific MR 
features 
13 FNH 
figure 1. Flowchart shows specific MR imaging features according to pathologic subtype classification of 
HCA.
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oral contraceptives for at least 5 years. Acute abdominal pain was the main reason for 
diagnostic imaging in 25 patients (52%), including bleeding of the lesion in six patients. 
Nonspecific symptoms were the reason for diagnostic imaging in seven cases, and the 
remaining cases were discovered as an incidental finding during radiologic examina-
tion of the abdomen for unrelated reasons. At MR imaging, 18 patients with HCA were 
considered to have a single lesion in the liver. Multiple adenomas (2-9 nodules) were 
found in 15 patients, and adenomatosis (≥10 nodules) was present in five patients. In 
three patients, multiple resected HCAs were of the same subtype (one patient with three 
L-FABP-negative HCAs; two patients with inflammatory HCAs [two or three lesions]). Two 
patients had one unclassified and one inflammatory HCA, and another patient had two 
β-catenin–positive HCAs and one unclassified HCA. At MR imaging (Table 1), 40 (85%) 
of 47 HCAs (one was not interpretable) were isointense to slightly hyperintense on T1-
weighted images. On T2-weighted images, most HCAs were slightly hyperintense (37 
of 48, 77%). No FNH lesions were hyperintense on T1-weighted images or contained 
intratumoral fat. On T2-weighted images, the signal was slightly hyperintense in eight 
(62%) of 13 FNH lesions. A central scar was seen in 10 (77%) of 13 FNH lesions, compared 
with 10 (21%) of 47 HCAs (one was doubtful) (P = .001). Markedly intense homogeneous 
enhancement in the arterial phase was seen in eight (62%) of 13 FNH lesions, compared 
table 1. MR imaging characteristics of HCA and FNH
Characteristics HCA (n = 48) FNH (n = 13)
Contour
 Regular 27 (56) 2 (15)
 Lobulated 21 (44) 11 (85)
Aspect
 Homogeneous 17 (35) 6 (46)
 Heterogeneous 31 (65) 7 (54)
Hemorrhagic component 10 (21) 0
Necrotic or cystic component
 Present 7 (15) 0
 Doubtful 1 0
Central scar
 Present 10 (21)* 10 (77)*
 Doubtful 1 0
Lesion Steatosis†
 Absent 35 (74) 13 (100)
 Mild 4 (9) 0
 Moderate 1 (2) 0
 Severe 7 (15) 0
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table 1. (continued)
Characteristics HCA (n = 48) FNH (n = 13)
 Not interpretable 1 0
Capsule 0 0
Pseudocapsule 14 (29) 5 (38)
T1-weighted signal intensity
 Slightly hypointense 5 (11) 8 (62)
 Markedly hypointense 1 (2) 5 (38)
 Isointense 29 (62) 0
 Slightly hyperintense 11 (23) 0
 Markedly hyperintense 1 (2) 0
 Not interpretable 1 0
T2-weighted signal intensity
 Slightly hypointense 3 (6) 2 (15)
 Markedly hypointense 0 0
 Isointense 7 (15) 3 (23)
 Slightly hyperintense 37 (77) 8 (62)
 Markedly hyperintense 1 (2) 0
 Not interpretable 0 0
Enhancement phase
 Arterial 47 (100) 13 (100)
 Portal 0 0
 Venous 0 0
 Not interpretable 1 0
Enhancement
 Homogeneous 26 (57) 8 (62)
         Heterogeneous 14 (30) 5 (38)
 Two phases 6 (13) 0
 Not interpretable 2 0
Intensity of enhancement
 Slightly 5 (11) 0
 Moderate 24 (51) 2 (15)
 Markedly 18 (38) 11 (85)
 Not interpretable 1 0
Atoll sign
 Present 13 (27) 0
 Doubtful 6 (13) 1 (8)
Note – Data are numbers of lesions, with percentages of lesions with interpretable results for that 
characteristic in parentheses.
* P = .001 for difference between HCA and FNH.
† Absent = 0%, mild = <33%, moderate = 33%-66%, severe = >66%
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with 12 (26%) of 46 HCAs (two were not interpretable). On T2-weighted images, a char-
acteristic hyperintense rim-like band in the periphery of the lesion (like an atoll) that was 
isointense to surrounding liver in the center of the lesion (like the surrounding sea) was 
seen in 13 (27%) of 42 (doubtful in six) of HCAs and in no FNH lesions. We termed this 
the atoll sign (Figures 2, 3). Interobserver agreement for the final diagnosis of each lesion 
was moderate (κ= 0.484).
figure 2. (a) Arterial- and (b) late vascular–phase dynamic contrast-enhanced T1-weighted transverse MR 
images. (c) T2-weighted MR image shows characteristic atoll sign of an inflammatory HCA in segment 6/7, 
which includes a T2-hyperintense signal band in the periphery of the lesion (like an atoll) with a center that 
is isointense to surrounding liver (like the surrounding sea). T2-hyperintense region typically enhances in 
the (b) late vascular phase, possibly corresponding to dilated sinusoids within inflammatory HCA.
figure 3. Satellite image of southern part of Tikehau Atoll. (Image courtesy of National Aeronautics and 
Space Administration Earth Observatory; http://earthobservatory.nasa.gov/IOTD/view.php?id=39329.)
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Mr image analysis by subgroup
L-FABP-negative HCAs
Decreased signal intensity on T1-weighted opposed-phase images owing to intratumor-
al fat deposition was present in seven (78%) of nine L-FABP-negative HCAs, measured 
as a region of severe and diffuse steatosis within the lesion (Table 2) (Figure 4). None of 
the other subtypes had diffuse steatosis within the lesion. Five (17%) of 29 inflammatory 
HCAs (one was not interpretable) showed only focal steatosis within the lesion (P = .001). 
All L-FABP-negative HCAs were slightly hyperintense on T2-weighted images.
table 2. MR imaging characteristics of HCA by subtype
Characteristics L-FABP-negative
(n = 9)
Inflammatory
(n = 30)
Β-catenin-positive
(n = 4)
Unclassified
(n = 5)
Size (mm)* 75 (28-124) 77 (15-184) 51 (25-80) 51 (42-110)
Nontumoral liver steatosis
 Absent 9 (100) 18 (62) 4 (100) 3 (60)
 Mild 0 2 (7) 0 1 (20)
 Moderate 0 2 (7) 0 0
 Severe 0 7 (24) 0 1 (20)
 Not interpretable 0 1 0 0
Contour
 Regular 4 (44) 18 (60) 3 (75) 2 (40)
 Lobulated 5 (56) 12 (40) 1 (25) 3 (60)
Aspect
 Homogeneous 4 (44) 10 (33) 2 (50) 1 (20)
 Heterogeneous 5 (56) 20 (67) 2 (50) 4 (80)
Hemorrhagic component 2 (22) 4 (13) 1 (25) 3 (60)
Necrotic or cystic component
 Present 2 (22) 2 (7) 2 (50) 1 (20)
 Doubtful 0 1 0 0
Central scar
 Present 1 (11) 5 (17) 3 (75) 1 (20)
 Doubtful 0 1 0 0
Lesion Steatosis†
 Absent 2 (22) 24 (83) 4 (100) 5 (100)
 Mild 0 4 (14) 0 0
 Moderate 0 1 (3) 0 0
 Severe 7 (78) 0 0 0
 Not interpretable 0 1 0 0
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table 2. (continued)
Characteristics L-FABP-negative
(n = 9)
Inflammatory
(n = 30)
Β-catenin-positive
(n = 4)
Unclassified
(n = 5)
Capsule 0 0 0 0
Pseudocapsule 2 (22) 7 (23) 3 (75) 2 (40)
T1-weighted signal intensity
 Slightly hypointense 1 (13) 4 (13) 0 0
 Markedly hypointense 0 1 (13) 0 0
 Isointense 6 (75) 16 (53) 4 (100) 3 (60)
 Slightly hyperintense 1 (13) 8 (27) 0 2 (40)
 Markedly hyperintense 0 1 (3) 0 0
 Not interpretable 1 0 0 0
T2-weighted signal intensity
 Slightly hypointense 0 2 (7) 0 1 (20)
 Markedly hypointense 0 0 0 0
 Isointense 0 3 (10) 2 (50) 2 (40)
 Slightly hyperintense 9 (100) 24 (80) 2 (50) 2 (40)
 Markedly hyperintense 0 1 (3) 0 0
 Not interpretable 0 0 0 0
Enhancement phase
 Arterial 9 (100) 29 (100) 4 (100) 5 (100)
 Portal 0 0 0 0
 Venous 0 0 0 0
 Not interpretable 0 1 0 0
Enhancement
 Homogeneous 6 (67) 16 (57) 2 (50) 2 (40)
         Heterogeneous 3 (33) 8 (29) 2 (50) 1 (20)
 Two phases 0 4 (14) 0 2 (40)
 Not interpretable 0 2 0 0
Intensity of enhancement
 Slightly 3 (33) 1 (3) 1 (25) 4 (80)
 Moderate 3 (33) 14 (48) 3 (75) 0
 Markedly 3 (33) 14 (48) 0 1 (20)
 Not interpretable 0 1 0 0
Atoll sign
 Present 0 13 (43) 0 0
 Doubtful 2 (22) 4 (13) 0 0
Note – Unless otherwise specified, data are numbers of lesions, with percentages of lesions with 
interpretable results for that characteristic in parentheses.
* Data are medians, with ranges in parentheses.
† Absent = 0%, mild = <33%, moderate = 33%-66%, severe = >66%.
P = .001 for L-FABP-negative vs inflammatory HCAs.
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β-catenin–positive HCAs
Nuclear staining of β-catenin (without expression of CRP and SAA) was observed in four 
HCAs. On MR images, three (75%) of these nodules demonstrated a scar and poorly 
delimited high-signal-intensity areas (Figure 5). A pseudocapsule was present in three 
(75%) of the four β-catenin-positive HCAs, whereas none of these had a fibrous tumor 
capsule. One lesion had a hemorrhagic component.
Inflammatory HCAs
Twenty-four (80%) of 30 inflammatory HCAs appeared isointense to slightly hyperintense 
to the surrounding liver on T1-weighted images and appeared slightly hyperintense on 
T2-weighted images. Steatosis within the nontumoral liver was present in 11 (38%) of 29 
inflammatory HCAs (one was not interpretable), whereas none of the L-FABP-negative 
HCAs showed steatosis within the nontumoral liver (P = .038). The characteristic atoll 
sign was seen in 13 (43%) of 26 inflammatory HCAs, and a doubtful atoll sign was noted 
in four lesions. No clear cases with an atoll sign were seen in the L-FABP-negative group 
(P = .027) or other subgroups. Focal positivity for β-catenin with a concomitant diffuse 
and homogeneous staining pattern of GS was seen in three inflammatory HCAs. None 
of these β-catenin-positive inflammatory HCAs showed steatosis within the nontumoral 
liver, and only one lesion showed mild steatosis within the lesion. These lesions ap-
peared heterogeneous on images obtained with each sequence. These lesions appeared 
isointense to slightly hyperintense to the surrounding liver on T1-weighted images and 
appeared slightly hyperintense on T2-weighted images. In accordance with β-catenin-
positive HCAs without expression of CRP and SAA (see above), two β-catenin-positive 
figure 4. Transverse (a) opposed-phase, (b) in-phase, and (c) contrast-enhanced venous-phase T1-
weighted MR images show an L-FABP-negative HCA in segment 5/6, which shows a strong homogeneous 
drop in signal intensity on a and slight enhancement on c.
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figure 5. Transverse (a) arterial- and (b) late vascular–phase T1-weighted dynamic contrast-enhanced 
and (c) T2-weighted fat-saturated MR images show a β-catenin-positive HCA located in segment 4, with 
poorly delineated areas of increased signal intensity and a hyperintense scar on c. Lesion enhances 
irregularly on b.
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inflammatory HCAs showed a central scar. None of the β-catenin-positive inflammatory 
HCAs had a hemorrhagic component. One inflammatory HCA demonstrated a hetero-
geneous staining pattern of GS without nuclear β-catenin staining. This lesion was 
heterogeneous on all MR images. On T1- and T2-weighted images, this lesion appeared 
slightly hyperintense to the surrounding liver. This lesion also had a central scar.
Unclassified HCAs
A small group of five HCAs remained unclassified with immunohistochemical analysis. 
In this group, no characteristic features were seen on MR images. None of these lesions 
showed steatosis within the lesion. Hemorrhagic components were seen in three (60%) 
of the five unclassifiable lesions.
Central scar in β -catenin- and GS-positive lesions
Ten (77%) of 13 FNH lesions had a typical scar revealing hyperintense lines on T2-
weighted images, which enhanced in the portovenous phase. Ten (21%) of 47 HCAs had 
a central scar, and one HCA had a central scar that both readers interpreted as doubtful. 
Three of four β-catenin-positive HCAs (without expression of CRP and SAA) showed 
poorly delimited high-signal-intensity areas on T2-weighted images as hyperintense 
scar regions, which enhanced late during the porto-venous phase. These regions were 
revealed as a spotty less-demarcated pattern of enhancement (Figure 5). Three inflam-
matory HCAs showed a central scar, which was revealed as hypointense thin lines on 
T2-weighted images. Two inflammatory HCAs with nuclear positivity for β-catenin and 
a homogeneous GS staining pattern also showed a scar. Signs of a scar were present in 
one L-FABP-negative HCA and in one unclassified HCA. β-Catenin positivity in HCA and 
GS positivity in HCA and FNH were significantly associated with the presence of a central 
scar. Presence of a central scar was seen in five (71%) of seven β-catenin-positive HCAs 
compared with five (13%) of 40 β-catenin-negative HCAs (P = .003) (one was doubtful). 
HCA and FNH showed the presence of a central scar in 14 (78%) of 18 GS-positive lesions 
compared with six (14%) of 42 GS-negative lesions (one was doubtful) (P < .001). The 
final diagnosis of the pathologist was compared with the final consensus interpretation 
of the two abdominal radiologists. In six cases, the diagnosis differed: Two of 48 HCAs 
were mistaken for FNH, and four of 13 FNH lesions were mistaken for HCA. Both false-
negative HCAs showed presence of scar regions.
Two of the four missed FNH lesions showed no scar, and one missed FNH was wrongly 
diagnosed owing to multiple smaller liver lesions reminiscent of multiple adenomas. All 
false-negative FNH lesions showed a homogeneous isointense or slightly hyperintense 
signal on T2-weighted images.
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diScuSSion
The main goal of our study was to investigate the correlation between MR imaging find-
ings and pathologic subtype classification since state-of-the-art MR imaging provides 
the most comprehensive and noninvasive imaging work-up of patients suspected of 
having HCAs (15). We were able to confirm specific MR imaging features that can be used 
to identify different subgroups of HCA, especially inflammatory and L-FABP-negative 
HCAs, as previously described by Laumonier et al. (12). L-FABP-negative HCA can be 
recognized with high reliability and is seen as a diffuse decrease in signal intensity on 
opposed-phase images because of the presence of intratumoral fat in the lesion. MR 
imaging was used to detect L-FABP-negative HCA in 78% of L-FABP-negative adenomas 
in which marked intratumoral steatosis was present. Only 17% of inflammatory HCAs 
showed steatosis within the lesion (P = .001); however, this subgroup showed only mild 
to moderate steatosis, which was distributed focally. All L-FABP-negative HCAs showed 
slightly hyperintense signal on T2-weighted images, possibly owing to the intratumoral 
T2 effect of fat (J-coupling effect) (21). In almost half of the inflammatory HCAs, we found 
a typical atoll sign on MR images, which is characterized by a hyperintense signal band 
in the periphery of the lesion (like an atoll) and isointensity of the center of the lesion 
with respect to the surrounding liver (like the surrounding sea) on T2-weighted images. 
No clear cases with an atoll sign were seen in the L-FABP-negative or other subgroups; 
however, the difference did not reach significance since a Bonferroni correction was 
applied to correct for multiple testing. In 10 (77%) of 13 inflammatory HCAs with a 
characteristic atoll sign, T2-hyperintense islands were visible in the center portion of the 
lesion. The T2-hyperintense regions (signal band and center islands) typically enhance 
in the late vascular phase. This characteristic atoll sign is possibly due to sinusoidal 
dilatation within inflammatory HCA. These areas of sinusoidal dilatation enhance in the 
venous phase, whereas the rest of the tumor enhances in the arterial phase. Those areas 
are hyperintense on T2-weighted images, which is probably reflective of the high water 
content in these bloodfilled regions.
The presence of a vaguely demarcated scar in HCA was significantly associated with 
nuclear staining of β-catenin (P = .003). At microscopic examination of the available 
slides from the tumor, two of five β-catenin-positive HCAs with presence of a vaguely 
demarcated scar showed pathologic areas and septa of fibrosis. The remaining β-catenin-
positive HCAs with presence of a scar did not show areas of fibrosis, which may be owing 
to sampling error because of the large size (29, 70, and 100 mm) and limited sampling of 
these lesions. Presence of a scar in HCA and FNH was significantly associated with a dif-
fuse and homogeneous GS staining pattern (P < .001). However, three lesions presented 
a central scar without positive β-catenin and GS findings. All β-catenin-positive HCAs 
showed features of slight to moderate enhancement compared with FNH, which showed 
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marked enhancement in most cases. We did not observe β-catenin or GS positivity in 
L-FABP-negative lesions. Therefore, by combining the atoll sign with the presence of a 
scar, we may be able to differentiate between β-catenin-positive inflammatory HCA and 
β-catenin-negative inflammatory HCA. Typical poorly delimited high-signal-intensity ar-
eas on T2-weighted images may be another characteristic MR imaging feature observed 
in β-catenin-positive HCAs, since this was also described by Laumonier et al. (12). No 
specific MR imaging features were identified for the unclassified group of HCA.
In most cases in our study, a clear diagnosis of HCA or FNH could be made. However, 
two (4%) of 48 HCAs were mistaken for FNH, and four (31%) of 13 FNH lesions were 
mistaken for HCA. The high percentage of FNH lesions that were mistaken for HCAs 
may be owing to a verification bias since the FNH lesions included were diagnosed as 
HCAs at the time of resection. It is likely that more atypical FNH lesions were included 
in our study. The verification bias may also be a reason for the low percentage (62%) of 
FNH lesions showing intense homogeneous enhancement. The moderate interobserver 
agreement, mainly owing to the verification bias of atypical FNH lesions, may suggest 
that the identification of imaging features of benign hepatic lesions such as HCA and 
FNH may be quite challenging at times.
The question is: How can we differentiate HCA from FNH with more certainty? It is 
probably that accurate differentiation requires the combination of different features. 
Hyperintensity on both in- and opposed-phase T1-weighted images (owing to intratu-
moral blood degradation products) is often seen in HCA and has rarely been noted in 
FNH lesions (22). Intratumoral fat deposition is a typical feature in HCA and is seldom 
seen in FNH. While slight enhancement in the arterial phase can be seen in HCA, typical 
FNH lesions have more pronounced enhancement. Moreover, the presence of a scar in 
the lesion is not solely found in FNH lesions but may also be seen in HCAs. In all HCA 
cases in our study where there was a misdiagnosis (probably owing to the internal scar), 
the slight degree of enhancement of the lesion should have alerted us that the lesion 
could be HCA instead of FNH.
We suggest classifying HCA by using state-of-the-art MR imaging and following the 
Bordeaux criteria. Specific subgroups of patients with HCA could be counseled ap-
propriately. In women with a clear diagnosis of HCA lesions at least 5 cm in diameter 
that do not show adequate regression after discontinuation of oral contraceptives, we 
recommend surgical resection. Steatotic HCAs smaller than 5 cm may be observed, and 
follow-up may be stopped when the lesion remains stable or shows reduction in size 
after 6 months of follow-up, since we did not observe β-catenin positivity in L-FABP-
negative HCAs. HCAs that present with a central scar and without other signs of FNH 
require a more aggressive approach because of the risk of malignant transformation. 
Close follow-up or resection may be advised in these cases (Figure 6). No published 
data are available on the success rate of using immunohistochemical markers to classify 
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subgroups at biopsy. The interpretation of β-catenin staining on biopsies may be dif-
ficult because of the heterogeneous and sometimes focal nuclear staining pattern, and 
our previous experience suggests that sampling error will remain a problem in this 
situation (13).
The major limitation of our study was the small number of β-catenin-positive HCAs 
(four lesions of the β-catenin subtype and three β-catenin-positive inflammatory le-
sions) we were able to include. The identification of inflammatory β-catenin-positive 
HCA remains a crucial issue owing to the risk of malignant transformation. Therefore, 
the poorly delimited high-signal-intensity areas observed in β-catenin-positive HCAs 
deserve additional investigation. Multicenter studies will be required to improve the 
identification of HCA subgroups and to investigate the consequences for clinical man-
agement.
MR imaging may improve the subtype classification of HCA, especially in cases of 
inflammatory and L-FABP-negative HCAs. MR imaging findings of a vaguely demarcated 
scar and poorly delimited high-signal-intensity areas on T2-weighted images in HCA 
seem to be related to β-catenin positivity. Since β-catenin-positive lesions seem to 
have a higher risk of malignant transformation, surgical resection or close follow-up is 
advocated in patients presenting with these lesions.
  
MR imaging: HCA lesion 
≥ 5 cm < 5 cm 
Resection  
Increased signal intensity:  
Steatotic HCA 
Atoll-sign without scar 
Scar and high-intensity areas:  
β-catenin HCA 
Other 
Follow-up 
Follow-up 
Resection / close follow-up 
Follow-up 
figure 6. Flowchart shows suggested surgical management of HCA on the basis of MR imaging findings.
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AbStrAct
background & Aims: Hepatocellular adenoma in pregnant women requires special 
considerations because of the risk of hormone induced growth and rupture. To prevent 
these potential lethal complications, pregnancy is either often discouraged or the surgi-
cal resection of large adenomas is recommended. It may be questioned whether it is 
justified to deny a young woman a pregnancy, as the biological behaviour of hepatocel-
lular adenoma may be less threatening than presumed. In this study we establish the 
management of hepatocellular adenoma during pregnancy based on our own experi-
ence and literature.
Methods: Twelve women with documented hepatocellular adenoma were closely 
monitored during a total of 17 pregnancies between 2000 and 2009. Their files were 
reviewed.
results: In four cases, hepatocellular adenomas grew during pregnancy, requiring a 
Caesarean section in one patient (two pregnancies) at 36 and 34 weeks because of an 
assumed high risk of rupture. In one case radiofrequency ablation therapy was applied 
in the first trimester to treat a hormone sensitive hepatocellular adenoma, thereby 
excluding potential growth later in pregnancy. No intervention was performed in the 
other 14 cases and all pregnancies had an uneventful course with a successful maternal 
and fetal outcome.
conclusions: A ‘‘wait and see’’ management may be advocated in pregnant women 
presenting with a hepatocellular adenoma. In women with large tumours or in whom 
hepatocellular adenoma had complicated previous pregnancies, surgical resection may 
be recommended. In women with smaller adenomas it may no longer be necessary to 
discourage pregnancy.
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introduction
Hepatocellular adenoma (HCA) is an uncommon benign tumour of the liver that occurs 
particularly in women during their reproductive years. The annual incidence rate of HCA 
is approximately 1-1.3 per 1,000,000 in women who have never used oral contracep-
tives (OC), compared to 30-40 per million in long-term users [1,2]. Thus, most HCAs are 
associated with the use of OC [3–5], an association which was first described in 1973 [3]. 
Other conditions associated with the presence of HCA have been described, including 
anabolic steroids, glycogen storage disease I and III and pregnancy [6–13]. Most likely 
the association of HCA and pregnancy is due to the increased levels of steroid hormones 
[14,15]. The presence of HCA can be complicated by hormone induced growth and sub-
sequently, spontaneous haemorrhagic rupture that may threaten the life of both mother 
and child. A growing or bleeding adenoma may present with persistent or acute severe 
pain localized in the upper right quadrant and in the epigastric region. Its presentation 
can be difficult to differentiate from more common aetiologies of abdominal pain in 
pregnancy, like preeclampsia, Haemolysis Elevated Liver enzymes and Low Platelets 
(HELLP) syndrome or non-obstetric pathology like appendicitis, gallbladder disease, 
biliary pancreatitis, or pulmonary embolism [16]. This differential diagnosis may lead to 
a diagnostic delay. Early detection of HCA and a correct management of these patients 
are highly important, since several manuscripts documented high maternal and fetal 
risks in case of a ruptured HCA during pregnancy with a reported maternal and fetal 
mortality rate of 44% and 38%, espectively [17]. In the last decennium, the introduction 
and widespread use of highly advanced image modalities have probably decreased the 
doctors’ delay in the diagnosis of HCA and the associated maternal and fetal mortality 
risk might be reduced significantly. No ruptures associated with gestation were reported 
in tumours less than 6.5 cm in size [17]. In non pregnant women haemorrhage has been 
documented in a tumour of 4.5 cm in size but is most commonly seen in tumours greater 
than 10 cm [17]. The risk of rupture is highest during the third trimester, most likely due 
to the accumulating level of estrogens and an increase in hyperdynamic circulation com-
bined with an increase in vascularity of the liver with growth of the adenoma [17]. In the 
postpartum period, the risk of bleeding seems to be high as well; this can be explained 
by the sudden withdrawal of estrogens after delivery that may cause a sudden massive 
regression of the tumour leading to haemorrhage [17]. Because of the unpredictable 
behaviour of HCA and high maternal and fetal mortality of a ruptured HCA during preg-
nancy women with a large HCA or a growing and hormone sensitive HCA are advised 
to avoid pregnancy by most experts (either incidental findings previous to a pregnancy 
or women who experienced complications of an adenoma during pregnancy) [2,15]. 
In addition, pregnancy itself limits the diagnostic modalities and interventions may be 
associated with greater risks in case of large adenomas [17]. At our centre, HCAs with a 
66 Chapter 4.1
diameter of 5 cm or larger that do not show adequate regression after discontinuation 
of the use of OC are considered for invasive treatment before pregnancy [15]. We were 
able to study 12 patients from a prospectively acquired database who sustained HCAs 
of different sizes during a total number of 17 pregnancies.
PAtientS And MetHodS
The Erasmus Medical Centre is a tertiary referral centre for focal liver lesions with an area 
of adherence of approximately 4 million people. From 2000 to 2009 all data of patients 
with HCA were recorded prospectively in a weekly multidisciplinary meeting attended 
by a radiologist, hepatologist, pathologist, and surgeon specialized in solid liver tu-
mours. At the time of diagnosis every HCA patient was advised to discontinue the use 
of OC and to prevent pregnancy. If pregnancy would nevertheless occur, patients were 
strongly advised to contact our centre to evaluate growth of the tumour by the surgeon 
or hepatologist. Follow-up of the fetus was carried out by the gynaecologist on a regular 
basis. A gynaecologist was consulted only in those cases where a significant growth of 
the adenoma was observed and its management could influence pregnancy. The pa-
tients described (12 of 183 patients with HCA) were diagnosed by contrast enhanced CT 
or MR imaging between January 2000 and December 2009. Until 2008 Gadolinium was 
the contrast agent of choice for MR imaging. In some cases, Gadolinium was followed 
by Resovist contrast for increased diagnostic certainty. After 2008, MultiHance was the 
contrast agent of choice for MR imaging. During their pregnancy they were closely 
monitored by means of repetitive ultrasound and/or MR imaging. The frequencies of 
the measurements had no fixed time schedule and depend on the size and changes 
in the characteristics of the lesion. Their files were reviewed to evaluate presentation 
and time of presentation, use of OC, size and growth before and during pregnancy and 
postpartum, complications and management during pregnancy, gestation time and 
way of delivery, maternal and fetal outcome, and complications and management after 
delivery.
reSultS
Nearly all women (11 of 12) were diagnosed with HCA prior to their pregnancy. In one 
patient, HCA was diagnosed during pregnancy (Table 1). Eleven patients were using OC 
at the time of diagnosis, or had used OC in the past. In four patients there had been a 
regression of HCAs after discontinuation of OC. One patient became pregnant before 
it was possible to evaluate her hormone sensitivity for the HCA. Another two patients 
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table 1. Patient characteristics, diagnosis and management
Case 
no.
Age Presentation before 
pregnancy
OC Diagnosis Management before 
pregnancy
Course of HCA after 
discontinuation OC
1 29 Symptomatic 
(bleeding, 
haemodynamically 
stable)
Yes 3 HCAs, all < 5,0 cm Elective surgery; 
laparoscopic segment 
2/3 resection. 
Discontinuation OC
No regression or 
growth of lesions
2 37 No complaints; 
incidental finding 
on US
Yes 1 HCA, < 5,0 cm Conservative. 
Discontinuation OC
Regression of lesion
3 30 Symptomatic 
(bleeding, 
haemodynamically 
stable)
Yes Multiple HCAs, one > 
5,0 cm
Conservative. 
Discontinuation OC
Unknown; stopped 
OC before HCA was 
diagnosed
4 28 Unspecific 
complaints; 
incidental finding 
on US
Yes Multiple HCAs, all < 
5,0 cm
Conservative. 
Discontinuation OC.
Weight reduction
Regression of 
lesions
5 25 Unspecific 
complaints; 
incidental finding 
on US
Yes 3 lesions, atypical 
FNH/ adenoma, all < 
5,0 cm
Conservative. 
Discontinuation OC
Unknown
6 41 No complaints; 
incidental finding 
on US
Yes 3 HCAs, one > 5,0 cm Elective surgery, 
segment 4 resection
No regression or 
growth of lesions
7 33 Presentation 
during pregnancy; 
symptomatic (pain 
right flank)
Yes 1 HCA, < 5,0 cm Before 2nd pregnancy 
RFA; segment 4a.
Discontinuation OC
Unknown; stop of 
OC before HCA was 
diagnosed
8 23 Unspecific 
complaints 
(abdominal pain); 
diagnosis elsewhere
Yes 2 HCAs, one > 5,0 cm Elective embolisation.
Discontinuation OC
Growth of lesions
9 31 Unspecific 
complaints; 
incidental findings 
on US
No Multiple HCAs, one > 
5,0 cm
Conservative. -
10 35 Symptomatic 
(bleeding, 
haemodynamically 
stable)
Yes Multiple HCAs, all < 
5,0 cm
Elective surgery; 
segment 3/6 resection.
Discontinuation OC
No regression or 
growth of lesions
11 36 Unspecific 
complaints; 
incidental findings 
on CT
Yes 1 HCA, < 5,0 cm Conservative. 
Discontinuation OC
Regression of lesion
12 28 Unspecific 
complaints; 
incidental findings 
on US
Yes 2 HCAs, one > 5,0 cm Conservative. 
Discontinuation OC
Regression of 
lesions
US = ultrasound
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stopped OC before HCA was diagnosed. In one patient there was growth of the HCA two 
and a half years after discontinuation of OC. No regression or growth of the HCA was 
noticed in three patients. Ten patients presented in the first trimester of pregnancy for 
monitoring of the HCA (Table 2). In one patient with multiple HCAs (case No. 3) there 
was serious concern about the risk of rupture of these lesions. One year before preg-
nancy she presented with an acute sensation of upper right quadrant pain, based on an 
table 2. Details of HCA with concern to pregnancy and follow-up after delivery
Case 
no.
Pregnancy 
no.
Growth Interventions 
during pregnancy
Follow-up after 
delivery
Course of HCAs during follow-
up
1 1 No None Follow-up elsewhere
2 1 No None 10 months Regression, HCA hardly visible 
on last US
2 No None 8 months Regression of lesion
3 1 Yes: > 5cm C-section and 
administration 
on IC-unit after 
delivery.
17 months Some regression of 3 HCAs, 
remaining HCAs status quo. No 
evidence of rupture.
2 Yes: > 5cm, 
in two 
tumours
C-section Ongoing Some regression of HCAs on 
CT,
No evidence of rupture
4 1 No None None Unknown
5 1 Yes, but < 
5cm
None 24 months Regression of lesion
2 No None Ongoing Unknown
6 1 No None 3 months On US no evidence of focal liver 
lesions
7 1 Yes: > 5 cm None Follow up elsewhere Regression of lesion
2 No: no 
tumour after 
RFA
None 5 months On US no evidence of focal 
liver lesion
8 1 No None 10 months 1 HCA regression, 1 HCA status 
quo ante
2 No None Ongoing Unknown
9 1 No RFA 1st trimester; 
segment 6
48 months 1 HCA regression after RFA, 
remaining HCAs status quo 
ante
10 1 2nd trimester 
minimal 
regression
C-section 16 months Regression, HCA hardly visible 
on last MRI
11 * 1 Unknown None 8 months Regression of lesion
12 1 No None Ongoing Unknown
US = ultrasound
* In case no. 11 there was no monitoring of HCA in our hospital.
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intracapsular haemorrhage of an HCA. She withdrew from medical attention during the 
first trimester of her first pregnancy, but presented at the gynaecologist at 33 weeks ges-
tation because of diabetes gravidarum. Until then, the patient was under surveillance 
at her general practitioner. At 33 weeks gestation, MR imaging, after ultrasound was 
performed, revealed a significant growth of the largest lesion from 32 to 75 mm (Figure 
1). Another lesion showed signs of haemorrhage that had been noticed 2 years ago. At 
that time the lesion was measured 60 mm. This lesion measured 40 mm during her 33 
weeks of gestation. To exclude any further risks, it was decided to deliver the child by 
means of a Caesarean section (C-section) at 36 weeks with close postpartum monitoring 
of the mother at the Intensive Care Unit for several days because of an increased risk of 
haemorrhage. Despite our advice to prevent further pregnancies, this patient became 
pregnant a second time. In between her first and second pregnancy, there was a regres-
sion of the lesion from 75 to 40 mm demonstrated by MR imaging. During her second 
pregnancy, marked growth of the HCAs was noticed again, resulting in a C-section at 
33 weeks. Both children were born healthy. Two patients (case Nos. 5 and 7) showed 
growth in association with pregnancy and regression of the tumour postpartum (Fig-
ures 2 and 3). In one patient (case No. 9), who wanted to keep her pregnancy, the tumour 
was treated with radiofrequency ablation (RFA) during the first trimester of her second 
pregnancy. The HCA showed regression during her pregnancy from 43 x 35 mm to 27 x 
19 mm. Maternal and fetal outcomes were excellent in all cases and none of the HCAs 
resulted in complications during pregnancy or after delivery.
figure 1. MR-images of one of the adenomas (segment 2/3) of patient no. 3, nine months after diagnosis 
and discontinuation of OC’s and in the 34th week of pregnancy. Due to pregnancy and the volume of the 
abdomen, the tumour was displaced in segment 2 and 3 cranially. The tumour shows significant growth.
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diScuSSion
The diagnosis of HCA may severely impact the life of a young fertile woman, in particular 
because of the overall agreed advice to avoid pregnancy. Literature on the course of HCA 
during pregnancy and recommended management is scarce. Some authors advocate 
that women with HCA should not get pregnant [2,15]. As to date we cannot identify pre-
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figure 2. Growth of the largest adenoma during pregnancy.
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figure 3. Regression of the largest adenoma postpartum.
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cisely those at risk of complications. It is likely that only a small subgroup of patients may 
experience complications. We provide a small but unique series of women who were 
monitored meticulously during pregnancy. Most cases of HCA related to pregnancy de-
scribed in the literature were presented during pregnancy or shortly postpartum. From 
the international literature between 1966 and 2003, Cobey et al. retrieved 26 cases of 
women presenting with HCA during pregnancy or early postpartum and proposed an 
algorithm for their diagnosis and management [17]. Presentation was acute and often 
dramatic with rupture of the adenoma in 16 women, and frequently with a delay in 
establishing the correct diagnosis, with high maternal and fetal mortality. An aggressive 
approach towards resection of HCA was advocated, especially for those greater than 
5 cm, based upon the high maternal and fetal mortality (44% and 38%, respectively) 
for women presenting with HCA during pregnancy. Small adenomas were supposed to 
be managed by observation [17]. We have previously reported that more than half of 
the HCAs are discovered after the patient has sustained at least one pregnancy [18]. 
None of these patients have reported problems during their pregnancies. In the current 
small series, just one patient presented with a tumour growth of real concern and that 
demanded an invasive intervention during pregnancy. In addition, rupture or other 
complications of solitary or multiple HCAs did not occur during intensive follow-up. 
Based on these data we believe that a plea for a less aggressive surgical approach to-
wards HCA in pregnant women may be justified. Especially in small tumours (<5 cm) we 
propose close monitoring and we believe it can be safe to allow pregnancy. However, in 
some women in whom the growth of the HCA is substantial there is reason for concern. 
Some authors suggest a C-section for HCA given the tendency to rupture at term [17]. 
In our study three C-sections (two patients) were performed, without complications. In 
one case (No. 3) the C-section was performed in consultation with the patient because 
of marked growth and an unknown risk of rupture of the HCAs. In the other patient (case 
No. 10) C-section was due to decelerations on the cardiotocography. All other patients 
had a normal delivery which was never complicated by the rupture of an HCA. Therefore, 
in our opinion, patients with HCA may deliver vaginally if there are no complicating 
factors, like perinatal problems. Prognostic factors on rupture and malignant degenera-
tion during pregnancy remain unknown until this moment. Women with HCAs must be 
informed about the possible risks before pregnancy. The literature on the management 
of HCAs during pregnancy is scarce due to the low incidence of HCAs in general [2,15], 
and the low number of HCAs detected during pregnancy in particular. Growth of HCA in 
pregnant women requires special considerations for contemplating and timing possible 
interventions.
In the cases where an intervention is indicated, surgical resection as well as a minimal 
invasive approach may be considered, especially in smaller lesions. An intervention is 
safest in the 2nd trimester [14]. RFA is a minimally invasive technique, which is widely 
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used for the treatment of patients with primary and secondary malignant tumours 
especially when resection is not an option. RFA is believed to be a relatively safe pro-
cedure in experienced hands with low mortality and morbidity [19–22]. In 2006, Fujita 
et al. reported a pregnant patient with a HCA that was treated by RFA during her 18th 
gestational week [23]. In our centre RFA is occasionally used as an alternative treatment 
in women with HCA. A disadvantage of RFA is that after ablation of the tumour there 
is no material for pathological analysis. When there is any doubt about the diagnosis, 
especially about the benign character of the tumour, the diagnosis should be confirmed 
first. If malignancy cannot be excluded, surgical resection is preferred. Selective arterial 
embolization can be used both as an elective treatment to reduce the size of the HCA as 
well as the initial emergency treatment in case of active bleeding of the HCA [24–26]. It 
is a minimally invasive and safe procedure compared to laparotomy and complications 
are rare. There are no large patient series, and especially in pregnant women with HCA 
there is little experience with the use of arterial embolization, although some authors 
suggest that it is a safe and effective treatment for HCA [27,28]. Since the risk of radiation 
exposure [29,30] to the fetus is increased, especially before 26 weeks of gestation, we 
feel that selective arterial embolization should only be used as an emergency treatment 
when RFA or surgery are not a favourable option, for instance for more centrally located 
tumours that are hardly accessible by RFA.
In conclusion, based on our small but unique prospective series we propose to not 
discourage all women with HCAs from pregnancy. We hypothesize that pregnancy may 
be allowed in case of a known HCA under certain conditions such as size and after dis-
cussing the risk-benefit ratio with the patient. Women should be aware of the potential 
risks as an intervention may still be indicated during pregnancy, especially if the lesion is 
accessible for limited surgical resection or a percutaneous RFA. Close monitoring by liver 
ultrasound every 6 weeks may offer adequate information for surveillance of the hepatic 
lesion. In women who have large tumours or who have experienced complications of 
HCA in previous pregnancies, a negative advice against pregnancy is justified because 
of an increased risk of complications. In that case, surgical resection should be recom-
mended before pregnancy. HCA in pregnant women implies special considerations, 
therefore, additional data from different centres for the risk of hormone induced growth 
and rupture of the adenoma during pregnancy are needed.
Management of HCA during pregnancy 73
Chapter
4.1
referenceS
 1. Reddy KR, Schiff ER. Approach to a liver mass. Semin Liver Dis 1993; 13: 423-435.
 2. Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW, Jr. Epidemiology of hepa-
tocellular adenoma. The role of oral contraceptive use. Jama 1979; 242: 644-648.
 3. Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and 
oral contraceptives. Lancet 1973; 2: 926-929.
 4. Berg JW, Ketalaar RJ, Rose EF, Vernon RG. Letter: Hepatomas and oral contraceptives. Lancet 1974; 
2: 349-350.
 5. Stenwig AE, Solgaard T. Ruptured benign hepatoma associated with an oral contraceptive. A case 
report. Virchows Arch A Pathol Anat Histol 1975; 367: 337-343.
 6. Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993; 152 Suppl 1: 
S63-70.
 7. Carrasco D, Prieto M, Pallardo L, Moll JL, Cruz JM, Munoz C, Berenguer J. Multiple hepatic ad-
enomas after long-term therapy with testosterone enanthate. Review of the literature. J Hepatol 
1985; 1: 573-578.
 8. Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroen-
terol 2005; 39: 401-412.
 9. Giannitrapani L, Soresi M, La Spada E, Cervello M, D’Alessandro N, Montalto G. Sex hormones and 
risk of liver tumor. Ann N Y Acad Sci 2006; 1089: 228-236.
 10. Hussain SM, van den Bos IC, Dwarkasing RS, Kuiper JW, den Hollander J. Hepatocellular adenoma: 
findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography 
and pathologic analysis. Eur Radiol 2006; 16: 1873-1886.
 11. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen 
storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastro-
enterol Nutr 1997; 24: 276-279.
 12. Santambrogio R, Marconi AM, Ceretti AP, Costa M, Rossi G, Opocher E. Liver transplantation for 
spontaneous intrapartum rupture of a hepatic adenoma. Obstet Gynecol 2009; 113: 508-510.
 13. van Aalten SM, Terkivatan T, de Man RA, van der Windt DJ, Kok NF, Dwarkasing R, Ijzermans JN. 
Diagnosis and treatment of hepatocellular adenoma in the Netherlands: similarities and differ-
ences. Dig Surg 2010; 27: 61-67.
 14. Parangi S, Levine D, Henry A, Isakovich N, Pories S. Surgical gastrointestinal disorders during 
pregnancy. Am J Surg 2007; 193: 223-232.
 15. Terkivatan T, de Wilt JH, de Man RA, Ijzermans JN. Management of hepatocellular adenoma dur-
ing pregnancy. Liver 2000; 20: 186-187.
 16. Angelini DJ. Obstetric triage revisited: update on non-obstetric surgical conditions in pregnancy. 
J Midwifery Womens Health 2003; 48: 111-118.
 17. Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their 
diagnosis and management. Am J Surg 2004; 187: 181-191.
 18. van der Windt DJ, Kok NF, Hussain SM, Zondervan PE, Alwayn IP, de Man RA, JN IJ. Case-orientated 
approach to the management of hepatocellular adenoma. Br J Surg 2006; 93: 1495-1502.
 19. Atwell TD, Brandhagen DJ, Charboneau JW, Nagorney DM, Callstrom MR, Farrell MA. Successful 
treatment of hepatocellular adenoma with percutaneous radiofrequency ablation. AJR Am J 
Roentgenol 2005; 184: 828-831.
 20. Garrean S, Hering J, Helton WS, Espat NJ. A primer on transarterial, chemical, and thermal ablative 
therapies for hepatic tumors. Am J Surg 2007; 194: 79-88.
74 Chapter 4.1
 21. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. 
Radiology 2000; 217: 633-646.
 22. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver 
tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter 
study. Radiology 2003; 226: 441-451.
 23. Fujita S, Kushihata F, Herrmann GE, Mergo PJ, Liu C, Nelson D, Fujikawa T, et al. Combined hepatic 
resection and radiofrequency ablation for multiple hepatic adenomas. J Gastroenterol Hepatol 
2006; 21: 1351-1354.
 24. Erdogan D, van Delden OM, Busch OR, Gouma DJ, van Gulik TM. Selective transcatheter arterial 
embolization for treatment of bleeding complications or reduction of tumor mass of hepatocel-
lular adenomas. Cardiovasc Intervent Radiol 2007; 30: 1252-1258.
 25. Huurman VA, Stoot JH, van der Linden E, Terpstra OT, Schaapherder AF. Necrosis of a large hepatic 
tumor after hemorrhage and subsequent selective arterial embolization. World J Gastroenterol 
2006; 12: 6059-6061.
 26. Stoot JH, van der Linden E, Terpstra OT, Schaapherder AF. Life-saving therapy for haemorrhaging 
liver adenomas using selective arterial embolization. Br J Surg 2007; 94: 1249-1253.
 27. Stoot JH, van Roosmalen J, Terpstra OT, Schaapherder AF. Life-threatening hemorrhage from 
adenomas in the liver during pregnancy. Dig Surg 2006; 23: 155.
 28. Stain SC, Woodburn DA, Stephens AL, Katz M, Wagner WH, Donovan AJ. Spontaneous hepatic 
hemorrhage associated with pregnancy. Treatment by hepatic arterial interruption. Ann Surg 
1996; 224: 72-78.
 29. Kal HB, Struikmans H. [Pregnancy and medical irradiation; summary and conclusions from the 
International Commission on Radiological Protection, Publication 84] Zwangerschap en straling; 
samenvatting en conclusies van Publicatie 84 van de International Commission on Radiological 
Protection. Ned Tijdschr Geneeskd 2002; 146: 299-303.
 30. Menias CO, Elsayes KM, Peterson CM, Huete A, Gratz BI, Bhalla S. CT of pregnancy-related compli-
cations. Emerg Radiol 2007; 13: 299-306.


chapter 4.2
Pregnancy And Liver adenoma 
Management – PALM study
Submitted
Susanna M. van Aalten
Mirelle E.E. Bröker
Türkan Terkivatan
Jan J. van Busschbach
Harry J. de Koning
Ewout W. Steyerberg
Eric A.P. Steegers
Robert A. de Man
Jan N.M. IJzermans
78 Chapter 4.2
AbStrAct
background: Hepatocellular adenoma (HCA) in pregnant women requires special con-
siderations because of the risk of hormone induced growth and spontaneous rupture, 
which may threaten the life of both mother and child. Due to scarcity of cases there is 
no evidence-based algorithm for the evaluation and management of HCA during preg-
nancy. Most experts advocate that women with HCA should not get pregnant or advise 
surgical resection before pregnancy. Whether it is justified to deny a young woman a 
pregnancy, as the biological behaviour may be less threatening than presumed depends 
on the incidence of HCA growth and the subsequent clinical events during pregnancy.
We aim to investigate the management and outcome of HCA during pregnancy and 
labor based on a prospectively acquired online database in the Netherlands.
Methods & design: The Pregnancy And Liver adenoma Management (PALM) - study 
is a multicentre prospective study in three cohorts of pregnant patients. In total 100 
pregnant patients, ≥ 18 years of age with a radiologically and/or histologically proven 
diagnosis of HCA will be included in the study. Radiological diagnosis of HCA will be 
based on contrast enhanced MRI. Lesions at inclusion must not exceed 5 cm. The study 
group will be compared to a healthy control group of 63 pregnant patients and a group 
of 63 pregnant patients with diabetes mellitus without HCA. During their pregnancy 
HCA patients will be closely monitored by means of repetitive ultrasound (US) at 14, 20, 
26, 32 and 38 weeks of gestation and 6 and 12 weeks postpartum. Both control groups 
will undergo US of the liver at 14 weeks of gestation to exclude HCA lesions in the liver. 
All groups will be asked to fill out quality of life related questionnaires.
discussion: The study will obtain information about the behaviour of HCA during 
pregnancy, the clinical consequences for mother and child and the impact of having a 
HCA during pregnancy on the health related quality of life of these young women. As 
a result of this study we will propose a decision-making model for the management of 
HCA during pregnancy.
trial registration: Dutch trial register: NTR3034
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introduction
Hepatocellular adenoma (HCA) is rare benign tumor of the liver that occurs particularly 
in women during their reproductive years. The incidence is not exactly known. Stud-
ies performed years ago show an estimate incidence of 1-1.3 per 1,000,000 in women 
who have never used oral contraceptives (OC), compared to 30-40 per 1,000,000 in 
long-term users [1-2]. The association of HCA with the use of OC was first described 
in 1973 [3]. In subsequent years many authors have supported the hypothesis of an 
association between OC and HCA [4-8]. The mechanism by which estrogen or other 
steroids contributes to the development of HCA is still not understood and studies are 
rare. Symptomatic patients with HCA present with right upper quadrant abdominal pain 
or discomfort secondary to bleeding within the HCA, elevated liver enzymes and symp-
toms of life treating hemorrhage into the peritoneal cavity. However, most patients with 
HCA are asymptomatic and present as an incidental finding during ultrasonographic 
examination of the abdomen for unrelated reasons or are noted during laparoscopic 
cholecystectomy. Despite its benign nature, the diagnosis of HCA has a great impact of 
the lives of these, mostly, young women because HCA can be complicated by hormone 
induces growth and rupture. Besides that malignant transformation of HCA into hepato-
cellular carcinoma has been reported with an overall frequency of 4.2% [9].
Regardless of the exact etiology and risk factors all female patients should be advised 
to stop OC’s and other hormone medication such as hormone replacement therapy, 
since regression of HCA may occur when steroids are withdrawn [10-13] and observa-
tion should be the first choice of treatment for most patients with HCA. Because of the 
risk for spontaneous rupture most authors believe that surgical resection is required 
if the diameter exceeds 5 cm after 6 months of follow-up without OC use, if the lesion 
does not show adequate regression after discontinuation of OC or if rebleeding occurs 
[14-17]. Surgical resection is also indicated if there is diagnostic doubt e.g. whether a 
tumor is malignant [18-19].
HCA in pregnant women requires special considerations because of the risk of hormone 
induced growth and spontaneous rupture, due to increased levels of steroid hormones 
during pregnancy that may threaten the life of both mother and child. Most experts ad-
vocate that women with HCA should not get pregnant or advise surgical resection before 
pregnancy [2, 18]. Cobey et al. reported a maternal and fetal mortality risk of ruptured 
HCA during pregnancy of 44% and 38%, respectively [20]. However, all these cases were 
published in the 1970s and 1980s and nowadays the introduction and widespread use 
of highly advantage imaging modalities have probably decreased the doctors’ delay in 
the diagnosis of HCA. We recently proposed not to discourage all women with HCA from 
pregnancy, based on a study in which we monitored twelve women with documented 
HCA during a total of 17 pregnancies. In 4 cases HCA’s grew during pregnancy, requiring 
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a Caesarean section in 1 patient (2 pregnancies) and radiofrequency ablation (RFA) in 1 
case during the first trimester of pregnancy. All pregnancies had an uneventful course 
with a successful maternal and fetal outcome [21]. However, there is no evidence-based 
algorithm for the evaluation and management of HCA during pregnancy and labor, due 
to scarcity of cases. The conclusion not to discourage all women with HCA from preg-
nancy has, however, to be proven in a large multicentre study in which we will closely 
monitor pregnant patient with a HCA in a prospectively acquired database to give more 
insight in the behaviour of HCA during pregnancy.
MetHodS & deSign
Study objective
In this study we will investigate the management and outcome of HCA during preg-
nancy and labor based on a prospectively acquired online database in the Netherlands.
Main objective of the PALM-study
• To investigate the incidence of HCA growth during pregnancy and labor.
Secondary objectives of the PALM-study
• To investigate in which trimester of pregnancy growth of HCA occurs;
• To investigate the degree of growth of HCA during pregnancy;
• To investigate whether there is regression of HCA postpartum;
• To investigate the HCA-related interventions during pregnancy and labor;
• To investigate the incidence of bleeding of HCA during pregnancy and labor;
• To investigate liver-related clinical signs during pregnancy;
• To investigate elevated liver enzymes during pregnancy;
• To evaluate the health related quality of life of pregnant patients with HCA;
• To investigate whether there is a difference between health related quality of life 
of pregnant patients with HCA and pregnant patients with other co-morbidity that 
have an indication for pregnancy care at the obstetrician in secondary care and 
healthy pregnant patients.
Study design
The PALM-study is a multi-centre prospective study in three cohorts of pregnant 
women. The study starts on November 1 2011 and inclusion of patients will be a period 
of minimal 3 to maximal 5 years. In total 100 pregnant patients with HCA < 5 cm will 
be included in the study. These patients will be compared to a healthy control group 
consisting of 63 pregnant patients without HCA and a group consisting of 63 pregnant 
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patients with diabetes mellitus (DM). The exact sample size will be 226 patients. Ap-
proval of the medical ethical committee was obtained.
Patient selection
Study group
Properly Dutch speaking, pregnant patients, 18 years of age or older with a radiologically 
and/or histologically proven diagnosis of HCA can be included in the study. Radiologi-
cal diagnosis of HCA will be based on contrast enhanced magnetic resonance imaging 
(MRI) and if available in combination with (contrast enhanced) ultrasonography (US). 
Lesions must not exceed 5 cm. In the first weeks of pregnancy patients will be referred 
to the obstetrician for pregnancy care. Baseline starts at 14 (+/- 3) weeks of gestation. At 
this day and every 6 weeks patients will undergo US of the HCA lesion at the radiologist. 
Before US of the HCA lesions patients will be asked to fill out generic health related qual-
ity of life questionnaires (12-item Short Form SF 12 and EuroQol questionnaire EQ-5d), 
a generic anxiety questionnaire (State-Trait Anxiety Inventory STAI-6) and the Impact of 
Event Scale (IES) questionnaire for thoughts and feelings about HCA around the US. One 
week afterwards the study group will be asked to fill out the STAI-6 en IES again. At 14 
and 32 weeks of pregnancy patients will undergo venapunction.
Control group 1 (healthy pregnant patients without HCA)
Properly Dutch speaking, healthy pregnant patients, 18 years of age or older without 
HCA. In the Netherlands, pregnant women will start pregnancy care with an indepen-
dently practicing midwife early in pregnancy at the primary care level [22]. The midwife 
is responsible for the pregnant women as long as the pregnancy, labor or postpartum 
period is normal [23]. In case of complication, the midwife will refer the women to the 
obstetrician in secondary care [22-23]. Women with a high risk profile based on their 
medical or obstetric history will be cared for the obstetrician from the start of pregnancy 
[22-23]. Patients presenting at the practicing midwife will be asked to participate in the 
study. Thereafter, the patients will be included in the study by the study investigator. 
Patients will undergo US of the liver at 14 (+/-3) weeks of gestation to exclude HCA le-
sions in the liver. At this day and every other 6 weeks patients will be asked to fill out the 
SF-12 and EQ-5d questionnaire. At 14 and 32 weeks of pregnancy patients will undergo 
venapunction. In case of an uncomplicated pregnancy, the patient remains under the 
care of her practicing midwife during her pregnancy and postpartum.
Control group 2 (pregnant patients with Diabetes Mellitus)
Properly Dutch speaking, pregnant patients, 18 years of age or older with Diabetes Mel-
litus, can be included in the study. These patients have an indication for pregnancy care 
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at the obstetrician in secondary care. Patients will undergo US of the liver at 14 (+/-3) 
weeks of gestation to exclude HCA lesions in the liver. At this day and every other 6 
weeks patients will be asked to fill out the SF-12 and EQ-5d questionnaire. At 14 and 32 
weeks of pregnancy patients will undergo venapunction.
For all groups informed consent is mandatory. A patient can always withdraw her con-
sent at anytime during the study where after she is referred for the present standard of 
care.
Hypothesis
Pregnancy may be allowed in case of one or more known HCA < 5 cm (without previous 
intervention), because a HCA < 5 cm will not disturb the course of pregnancy.
Disrupted course of pregnancy:
• Interventions during pregnancy (radiological and/or surgical intervention).
• Decreased quality of life and/or anxiety in patients during pregnancy related to the 
presence of HCA in the liver and possible growth during pregnancy.
retrospective cohort study
We have previously reported that more than half of the HCA are discovered after the 
patient has sustained at least one pregnancy and none of these patients have reported 
problems during their pregnancies [19]. As mentioned above, recently we described a 
small but unique series of 12 women with documented HCA who were closely moni-
tored during a total of 17 pregnancies between 2000 and 2009. In 4 cases HCA’s grew 
during pregnancy, requiring a Caesarean section in 1 patient (2 pregnancies) and RFA in 
1 case during the first trimester of pregnancy to treat a hormone sensitive HCA, thereby 
excluding potential growth later on in pregnancy. No intervention was performed in the 
other 14 cases. All pregnancies had an uneventful course with a successful maternal and 
fetal outcome and we concluded that a “wait and see” management may be advocated 
in pregnant women presenting with HCA. In women with large tumours or in whom 
HCA had complicated previous pregnancies, surgical resection may be recommend [21]. 
However, additional data from different centres for the risk of hormone induces growth 
and rupture of HCA during pregnancy is needed.
interventions
During their pregnancy HCA patients will be closely monitored by means of repetitive 
US (and MRI in case of growth of the lesion) at 14 (+/- 3) and 20 and 26 and 32 and 
38 weeks of gestation and 6 and 12 weeks postpartum. At the same days both control 
groups will be asked to fill out the SF-12 and EQ-5d questionnaire at 14 (+/- 3) and 20 
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and 26 and 32 and 38 weeks of gestation and at 6 and 12 weeks postpartum. (Figure 1) 
The study group will be asked to fill out the SF-12, EQ-5d, STAI-6 and IES questionnaires 
before and one week after US of the HCA lesion(s). Both control groups will undergo US 
of the liver at 14 (+/- 3) weeks of gestation to exclude HCA lesions in the liver. At 14 and 
32 weeks of pregnancy all patient groups will undergo venapunction.
Pregnancy
Weeks ultrasonography Venapunction Questionnaires
14 S, C1, C2 S, C1, C2 S, C1, C2 *
20 S S, C1, C2 *
26 S S, C1, C2 *
32 S S, C1, C2 S, C1, C2 *
38 S S, C1, C2 *
Post-partum
Weeks ultrasonography Venapunction Questionnaires
6 S S, C1, C2 *
12 S S, C1, C2 *
S, study group; C1, control group 1 (healthy pregnant patients without HCA); C2, control group 2 
(pregnant patients with Diabetes Mellitus).
* The study group will be asked to fill out the SF-12, EQ-5d, STAI-6 and IES questionnaires before and 
one week after US of the HCA lesion(s). Both control groups will be asked to fill out the SF-12 and EQ-5d 
questionnaire.
figure 1. Study protocol.
online database
We established a website which allows hepatologists, surgeons and gyneacologists to 
submit clinical data in an online database. Each centre will have a code to log in and 
patients will be consecutively assessed a unique number. Registration of a new patient 
includes entry of the following data: date of birth, weight, height, date of hospital ad-
mission, symptoms at presentation, known risk factors for HCA such as glycogenosis 
and familial polyposis, [24] previous pregnancies, previous use of OC or other hormone 
medication including hormone replacement therapy, course of HCA after discontinu-
ation of OC, size of HCA before pregnancy, size of HCA during pregnancy (14 (+/− 3) 
and 20 and 26 and 32 and 38 weeks), course of HCA postpartum (6 and 12 weeks 
postpartum), complications and management during pregnancy, gestation time, way 
of delivery (vaginally, Caesarean section), maternal and fetal outcome, complications 
and management after delivery. Only authorized users can gain action to the online 
database of his or her patients. The database offers excess to the registered data on 
anytime and anywhere. The coordinating investigator will monitor whether all required 
fields are completed.
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follow-up
Follow-up of patients takes place at 6 and 12 weeks postpartum postpartum by means 
of US (and MRI in case of growth) to document the size of HCA postpartum. Both control 
groups will be asked to fill out the SF-12 and EQ-5d questionnaires at these days. The 
study group will be asked to fill out the SF-12, EQ-5d, STAI-6 and IES questionnaires 
before and one week after US of the HCA lesion(s).
outcome measures
Primary outcome: Biological behaviour and clinical consequences of HCA < 5 cm during 
pregnancy. Growth is measured by repetitive US (and MRI in case of growth) at 14 (+/- 3) 
and 20 and 26 and 32 and 38 weeks of gestation. Secondary outcome: General health 
and pain scales as a measure for quality of life and anxiety related questionnaires for 
thoughts and feelings of adenomas around US. Other secondary outcomes are com-
plications due to growth of the HCA during pregnancy possibly followed by interven-
tions during pregnancy, incidence of hemorrhage and rupture of the HCA, incidence of 
liver-related clinical signs during pregnancy (itch, icterus), incidence of elevated liver 
enzymes during pregnancy.
Power calculation
In our previous study we measured growth of HCA in 4 out of 17 pregnancies (24%) or 
in 3 out of 12 women (25%). On a yearly basis approximately 50 new patients with HCA 
are seen at the outpatient clinic of the Erasmus University Medical Centre. The expecta-
tion is that 10% (5) of these women get pregnant. The expectation is that a total of 100 
pregnant HCA patients from different tertiary referral centres in the Netherlands can 
be included in the study during a period of 3 to maximum 5 years. For an expected 
incidence of 25% of HCA growth during pregnancy we calculated a 95% confidence 
interval of +/− 8.5% [16.5 - 33.5%], which we consider sufficiently small.
A difference of 0.5 Cohen’s D in health-related quality of life is a relevant difference 
[25]. We calculated that for this purpose 63 patients in both control groups have to be 
enrolled. A two-sample t test was performed with a two-sided significant level of 0.05 
and a power of 0.80.
Access to personal data
Medical data with which the identity of a patient could be traced will be replaced by 
a code number. The coordinating investigator is the only one who has the key to the 
code numbers and knows which code number stands for which patient. The principal 
investigator has only access to the coding system of his or her patients and will never 
be able to open the database from other centres. Only members of the investigating 
team and members of the medical ethical committee of the participating centres will 
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have access to the medical data. All data will be collected in a prospectively acquired 
database by the principal investigators and managed by the coordinating investigator.
diScuSSion
Once the diagnosis of HCA has been established, patients will be advised to discontinue 
OC. Expert opinions are very variable regarding treatment and follow up in complex 
situations were multiple factors play a role in determining the management strategy, 
like pregnancy [18]. As to date there are limited data about the behavior of HCA during 
pregnancy and labor and therefore we cannot identify precisely those at risk for complica-
tions. However, in 2006 we reported a series of 48 patients of which in 44% HCA were 
discovered after the patient had sustained at least one pregnancy [19]. None of these 
patients have reported problems during their pregnancies. Likely, only a small subgroup 
of patients may experience complications and to date pregnancy might be discouraged 
in too many patients caused by unnecessary intervention before pregnancy. We hypoth-
esize that pregnancy may be allowed in case of one or more known HCA < 5 cm (without 
previous intervention), because HCA < 5 cm will not disturb the course of pregnancy. 
Close monitoring during pregnancy by means of repetitive US (and MRI in case of growth) 
should be carried out to rule out rapid growth of the lesion. The risk of rupture seems the 
highest during the third trimester of pregnancy [20]. Most likely due to the cumulating 
level of estrogens and an increase in hyperdynamic circulation combined with an increase 
in vascularity of the liver with growth of the adenoma [20]. Symptoms and the level of liver 
enzymes will be registered to find out if there is a relation between symptoms, elevated 
liver enzymes and growth of the HCA during pregnancy. Patients will be followed-up 
postpartum to investigate if there is a risk of HCA complications after delivery.
    The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) provided 
guidelines for diagnosis, treatment, and use of laparoscopy for surgical problems during 
pregnancy [26]. However, these guidelines are mostly based on case reports and retro-
spective studies and therefore graded at a low level of evidence. The SAGES suggest that 
MRI without the use of intraveneous gadolinium, and US is considered safe and can be 
used at any stage of pregnancy (Level IIIB and Level IIA respectively) [26]. Data regarding 
safety of CEUS during pregnancy is scare and yet uncertain. However, Hua et al. reported 
an animal study in which SonoVue may affect the placenta [27]. Therefore, we will not 
use CEUS for patient follow-up during pregnancy.
One should be aware of the potential risks as an intervention may still be indicated 
during pregnancy. In approximately one in 635 pregnancies a non-obstetric operation 
during pregnancy is required, especially appendectomy, cholecystectomy and adnexal 
procedures [28]. However, it is conceivable that more non-obstetric operations might be 
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required due to the risk of hormone induced growth and spontaneous rupture of HCA 
during pregnancy. Despite maternal and fetal outcomes following abdominal disease 
and surgery in pregnancy improved over the past years, the exact risk of HCA-related 
interventions during pregnancy to both mother and fetus is unknown [29]. We do know 
that changes in physiology and abdominal anatomy characteristics of pregnancy make 
abdominal surgery more difficult [29]. The least risk of general anaesthesia is in the 2nd 
trimester of pregnancy [30].
Based on a systematic review of the literature, Wilson et al. suggested angio-em-
bolisation and formal resection in case of haemorrhage of HCA during pregnancy and 
suggested this strategy to be safe for both the mother and the fetus with good clinical 
outcomes [31]. The role of RFA during pregnancy is not well studied. In our previous 
study we described a RFA procedure during the first trimester of pregnancy [21] and 
Fujita et al. reported a pregnant patient with a HCA that was treated by RFA during her 
second trimester of pregnancy (18th week of gestation) [32].
   The influence on the course of pregnancy, since a woman is aware of having a HCA, 
is also unknown. Patients can get horrified when confronted with the new diagnosis of 
a hepatic mass [20] and it is conceivable that women can be anxiety during pregnancy 
due to the presence of HCA in the liver and the possible growth during pregnancy. 
Therefore, quality of life will be an important measurement for future management of 
HCA during pregnancy. It is conceivable that frequent monitoring by means of US may 
comfort the patients or can be frightening. All patient groups will be asked to fill out the 
SF-12 and EQ-5d questionnaires every 6 weeks. HCA patients will be asked to fill out the 
STAI-6 and IES questionnaires before the US of the liver lesions and one week after US to 
investigate anxiety related to HCA and US during pregnancy.
   Our main point of interest is whether it is justified to deny a young woman with a HCA 
< 5 cm a pregnancy. With this study we hope to obtain information about the behaviour 
of HCA during pregnancy and the impact of HCA during pregnancy on the life of these 
young women. Furthermore we hope to propose a decision-making model for the man-
agement of HCA during pregnancy.
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AbStrAct
Purpose: To investigate the safety and efficacy of radiofrequency (RF) ablation for the 
treatment of hepatocellular adenoma (HCA).
Materials and Methods: From 2000 to 2009, 170 patients with HCA were referred to a 
single tertiary hepatobiliary center. Medical records of 18 patients treated with RF abla-
tion were retrospectively analyzed.
results: All patients were female, and the majority had a history of hormonal contracep-
tive use. Ten patients (56%) had multiple HCAs, with a median number of two lesions 
(range, one to 12) per patient. Median size of HCA at the time of RF ablation was 3.0 cm 
(range, 0.8 -7.3 cm). A total of 45 HCAs were ablated in 32 sessions (open, n = 4; percuta-
neous, n = 28). RF ablation was complete after the first session in 26 HCAs (57.8%), and 
the majority of patients underwent multiple RF ablation sessions to fully ablate all HCAs. 
Major complications developed in two patients.
conclusions: RF ablation can be used effectively in the treatment of HCA. However, 
multiple sessions are often required, and signs of residual adenoma might persist in 
some patients despite repetitive treatment. RF ablation might be especially beneficial in 
cases not amenable to surgery or in patients who would require major hepatic resection 
otherwise.
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introduction
Hepatocellular adenoma (HCA) is an uncommon benign tumor of the liver that is most 
often diagnosed in young women in the second or third decade of life (1). Although the 
development of HCA has traditionally been associated with long-term use of hormonal 
oral contraceptive agents, an association with pregnancy has also been reported (2) in 
which existing or newfound HCA tumors tend to grow under the influence of increased 
serum estrogen levels. Although benign itself, HCA has a potential for malignant degen-
eration or spontaneous rupture, with potentially life-threatening hemorrhage. Therefore 
treatment is indicated in selected patients (3,4). Historically, surgical resection has been 
the treatment of choice for the management of HCA, but in some cases, these young and 
otherwise healthy patients would require large hepatic resections for centrally located 
or bilaterally distributed HCA, with associated morbidity and costs (5–7). Several authors 
have, therefore, described the successful application of minimally invasive strategies 
such as transarterial embolization and radiofrequency (RF) ablation, although we are 
aware of no published series larger than 10 patients (8–13). Here we describe our experi-
ence with RF ablation for the treatment of HCA in 18 patients. Institutional review board 
approval is not required at our institution for retrospective studies such as this one.
MAteriAlS And MetHodS
Between 2000 and 2009, a total of 170 consecutive patients with the diagnosis of HCA 
were referred to Erasmus Medical Center in Rotterdam, The Netherlands. Sixty-two 
patients (36%) underwent invasive treatment, and in 18 patients (11%), this treatment 
involved open or percutaneous RF ablation of one or more HCAs. In addition, in 39 
patients (23%), surgical resection of one or more HCAs was the treatment of choice. 
Another five patients (3%) underwent transarterial embolization of their HCA. The medi-
cal records of 18 patients treated with RF ablation were retrospectively analyzed.
Patient characteristics
The median age of the 18 patients who underwent RF ablation for one or more HCAs was 
29.5 years (range, 21-37 y), and all patients were female. The median body mass index 
was 26 kg/m2 (range, 18-44 kg/m2), and all but one patient had a history of hormonal 
oral contraceptive agent use. None of the patients had a history of viral hepatitis or 
liver cirrhosis. In the majority of patients, HCAs were asymptomatic and were detected 
incidentally on imaging studies obtained for other purposes. Two patients presented 
with acute bleeding from a previously unknown HCA (patients 6 and 10), one of whom 
required transarterial embolization to control bleeding 2 years before the final RF abla-
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tion treatment. RF ablation treatment of the residual HCA tissue was initiated in these 
two patients because both had an active desire to become pregnant. Treatment of HCA 
was believed to be indicated because of an active pregnancy wish in 13 patients with 
proven hormone-sensitive HCA (72%), growth of HCA lesions in two patients (12%; 
one during pregnancy), HCA exceeding 5 cm in size in one patient (6%), and a lifelong 
dependence on hormone-substitution therapy in two patients (12%).
diagnosis and workup
Initial treatment was usually conservative, consisting of discontinuation of oral contra-
ceptive agents for at least 6 months and radiologic follow-up with computed tomogra-
phy (CT) or magnetic resonance (MR) imaging every 3-6 months to monitor growth or 
regression of HCA. Patients were offered invasive treatment when (i) lesions remained 
larger than 5 cm or did not stop growing after cessation of oral contraceptive treatment, 
(ii) malignancy could not be excluded, or (iii) the patient expressed a desire for pregnancy 
in the presence of a hormone-sensitive HCA tumor larger than 3 cm. RF ablation was the 
treatment of choice for cases not amenable to surgery in view of the location or number of 
HCAs or if resection was considered potentially harmful as a result of insufficient volume 
of the future liver remnant (< 25% of total liver volume). If uncertainty existed regarding 
the diagnosis based on radiologic examinations, surgical resection was the treatment of 
choice and RF ablation was not considered. Diagnostic imaging included a triphasic CT 
scan in all patients and dynamic four-phase contrast-enhanced MR scan in 17 patients. 
Histologic specimens for biopsy were not obtained in any patient included in the study.
Procedures
RF ablation was performed by using a 480-kHz RF Cool-tip RF system (Radionics, Burl-
ington, Massachusetts) with a single 3-cm needle (if HCA was < 3 cm) or three clustered 
3-cm needles (for larger lesions) or a 250-W RITA RF generator with a Starburst RF abla-
tor (AngioDynamics, Queensbury, New York). The procedures were carried out under 
general anesthesia by an experienced interventional radiologist (all > 50 cases). For the 
open approach, a right subcostal incision was made to gain access to the abdominal 
cavity, and the liver was mobilized for optimal exposure. In each case, RF electrodes 
were introduced into the lesion under contrast-enhanced CT or ultrasound (US) guid-
ance. Lesions were ablated for 5-15 minutes after target temperatures were reached 
(100°C) until the ablation zone was believed to encompass the entire tumor based on 
US and CT images. Ablation of approximately 0.5 cm of healthy liver tissue surrounding 
the lesion was attempted in all cases. In the majority of cases, efficacy of treatment and 
the presence of complications (eg, pneumothorax) was estimated based on contrast-
enhanced CT images obtained directly after ablation. Because of a lack of availability of 
intraoperative CT scanning, open ablations were performed under US guidance.
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Assessment of response and follow-up
All patients underwent triphasic contrast-enhanced CT scanning at 4-6 weeks after the 
RF ablation procedures to asses any residual disease (Figure 1). When no signs of residual 
disease were found, follow-up scans were obtained every 3-6 months for the first year 
after RF ablation treatment.
figure 1. (a) Arterial-phase CT image of a large HCA (arrow) in the posterior segment of the liver in a 
22-year-old woman. (b) Contrast-enhanced MR image of the same HCA (arrow) 8 months after cessation 
of oral contraceptive treatment. (c) Arterial-phase CT image of HCA after incomplete percutaneous 
RF ablation. Hyperattenuating residual HCA tissue (arrow) is observed at the posterior border of 
the hypoattenuating RF ablation zone. (d) Arterial-phase CT image of HCA after successful repeat 
percutaneous ablation. No residual HCA tissue is observed (arrow).
Statistical analysis
Data are expressed as medians and ranges or means ± SD for continuous variables and 
as proportions (in percent) for binary variables. Differences between groups were in-
vestigated by using the Student t test for continuous variables and the χ2 test for binary 
variables. All statistical analysis were performed by using SPSS software (version 16.0; 
SPSS, Chicago, Illinois).
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reSultS
A total of 76 HCAs were diagnosed in the 18 patients included in the study, ranging 
in size from 1.0 cm to 14 cm at the time of diagnosis. The median number of HCAs per 
patient was two (range, one to 12). Multiple HCAs (two to nine nodules) were found in 
seven patients, and liver adenomatosis (ie, ≥ 10 nodules) was present in three cases. 
After various durations of conservative management, including cessation of oral con-
traceptive treatment and serial imaging, the median diameter of the largest HCA at the 
time of treatment was 3.8 cm (range, 1.5-7.3 cm; mean ± SD, 3.9 cm ±1.2).
treatment
The Table shows the clinical and treatment-related characteristics of the 18 patients 
with HCAs treated with RF ablation. In these 18 patients, a total of 45 HCA lesions were 
ablated in 32 RF ablation sessions. The median number of HCAs ablated per patient 
was one (range, one to nine; mean ± SD, 2.8 ± 3.2), with a median size of 3 cm (range, 
0.8 -7.3 cm; mean ± SD, 2.9 cm ± 1.2). The median number of RF ablation sessions per 
patient was two (range, one to four). Although the majority of patients were treated with 
only percutaneous RF ablation, an open approach was applied in three patients that 
combined RF ablation with resection of one or more HCAs (n = 5). One of these patients 
underwent additional percutaneous treatment of two HCAs after incomplete ablation 
of these lesions. In addition, in one patient with liver adenomatosis (ie, ≥ 10 nodules) 
located in both lobes of the liver, a staged procedure was attempted, with complete 
resection and ablation of all left-sided lesions during a first stage that also included right 
portal vein embolization to obtain adequate volume of the left lobe to allow for a later 
right hepatectomy. However, during the second stage of the operation, it was believed 
that the quality of the left lobe was insufficient to withstand a right hepatectomy and it 
was decided instead to ablate all HCAs in the right liver lobe 2 months after right portal 
vein embolization. In addition, in another patient with two HCAs, one lesion was treated 
with percutaneous RF ablation and another HCA was treated with percutaneous ethanol 
injection, as this lesion was not considered to be eligible for RF ablation because of its 
proximity to the gallbladder in segment 5. Finally, a total of 25 small HCAs were left 
untreated in six patients with multiple adenomas (all < 1.5 cm in diameter).
outcome
Eight patients (44%) required one session of RF ablation each, seven (39%) required two 
sessions each, and two (11%) required more than two RF ablation sessions to obtain a 
satisfactory treatment of all HCAs (with no need for further treatment). In one patient 
(6%) with extensive adenomatosis (ie, ≥ 10 HCAs), four dominant lesions were success-
fully treated in two percutaneous RF ablation sessions, but one lesion (4.5 cm) in the left 
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lateral segment was situated superior to the stomach and could not be reached percu-
taneously during either session. Despite a clinically satisfactory result, minimal residual 
disease (< 1 cm) was observed around one ablated HCA after one or more subsequent 
sessions of RF ablation in five patients. However, no further treatment was offered in 
these cases, and it was decided to follow these patients radiologically. Three of these 
patients also had several small HCA lesions (< 1 cm) in the remainder of the liver that we 
chose not to treat.
When analyzed per lesion, 26 of 45 HCAs (58%) were successfully ablated at the first 
attempt, and nine HCAs (20%) were successfully ablated in a second session. Three HCAs 
required three (n = 2) or four (n = 1) RF ablation sessions to achieve complete ablation 
(Figure 2). Seven HCAs (in five patients) still show evidence of minimal residual HCA tis-
sue adjacent to the ablation zone at the time of the present manuscript submission. No 
difference was observed in the mean size of HCAs with residual disease after one RF ab-
lation session (2.9 cm) versus that of HCAs that showed a complete radiologic response 
after one session (3.1 cm; P = .73, Student t test). However, open RF ablation of HCA was 
successful on the first attempt significantly more often (15 of 19 HCAs; 79%) compared 
with percutaneous ablation (11 of 26 HCAs; 31%; P = .013). The median follow-up of all 
lesions was 440 days (range, 41-1,351 d).
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figure 2. The rate of success after ablation of HCA per lesion. The y-axis shows the number of lesions that 
were ablated in one, two, three, or more sessions, respectively, as indicated on the x-axis.
98 Chapter 5.1
ta
bl
e 
1.
 C
lin
ic
al
 c
ha
ra
ct
er
is
tic
s 
an
d 
tr
ea
tm
en
t o
ut
co
m
es
 o
f t
he
 1
8 
pa
tie
nt
s 
w
ith
 H
CA
s 
tr
ea
te
d 
w
ith
 R
F 
ab
la
tio
n
Pt
. 
no
A
ge
 
(y
)
bM
i
tu
m
or
s
la
rg
es
t 
(m
m
)
Se
gm
en
t
co
ur
se
 *
in
di
ca
ti
on
tr
ea
tm
en
t (
no
.)
co
m
pl
ic
at
io
ns
o
ut
co
m
e
d
ia
gn
os
ed
A
bl
at
ed
1
32
26
1
1
38
4
U
nk
no
w
n
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (1
)
-
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
2
36
22
12
9
73
3,
 5
-8
Re
gr
es
si
on
 o
f 
le
si
on
s
Pr
eg
na
nc
y 
w
is
h
O
pe
n 
RF
/r
es
ec
tio
n 
(1
); 
pe
rc
ut
an
eo
us
 
RF
H
em
at
om
a 
in
 
ab
do
m
in
al
 w
al
l, 
no
 
in
te
rv
en
tio
n
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
3
34
18
1
1
30
5
N
A
H
or
m
on
e 
de
pe
nd
en
cy
Pe
rc
ut
an
eo
us
 
RF
 (2
)
-
M
in
im
al
 re
si
du
al
 
H
CA
4
31
23
1
1
44
4
U
nk
no
w
n
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (3
)
-
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
5
32
27
10
9
61
1-
4,
 7
, 8
U
nk
no
w
n
Si
ze
 >
 5
 c
m
O
pe
n 
RF
/r
es
ec
tio
n 
(1
); 
pe
rc
ut
an
eo
us
 
RF
 (3
)
Bl
ee
di
ng
 (r
ig
ht
 
he
pa
tic
 a
rt
er
y)
, n
o 
in
te
rv
en
tio
n
M
in
im
al
 re
si
du
al
 
H
CA
6
23
24
1
1
38
5
U
nk
no
w
n
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (2
)
-
M
in
im
al
 re
si
du
al
 
H
CA
7
23
29
1
1
42
7
Re
gr
es
si
on
 o
f 
le
si
on
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (2
)
-
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
8
21
20
1
1
32
2
N
A
H
or
m
on
e 
D
ep
en
de
nc
y
Pe
rc
ut
an
eo
us
 
RF
 (2
)
-
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
9
26
20
6
2
35
5,
 6
Re
gr
es
si
on
 o
f 
le
si
on
s
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (2
)
Bl
ee
di
ng
 (l
iv
er
 
pa
re
nc
hy
m
a)
, n
o 
in
te
rv
en
tio
n
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
10
22
23
1
1
15
6
Re
gr
es
si
on
 o
f 
le
si
on
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 R
F
-
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
11
30
32
2
2
40
2,
 6
Re
gr
es
si
on
 o
f 
le
si
on
s
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (1
)
-
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
Radiofrequency ablation for HCA 99
Chapter
5.1
Pt
. 
no
A
ge
 
(y
)
bM
i
tu
m
or
s
la
rg
es
t 
(m
m
)
Se
gm
en
t
co
ur
se
 *
in
di
ca
ti
on
tr
ea
tm
en
t (
no
.)
co
m
pl
ic
at
io
ns
o
ut
co
m
e
d
ia
gn
os
ed
A
bl
at
ed
12
37
29
7
2
35
2,
 4
U
nk
no
w
n
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (2
)
-
M
in
im
al
 re
si
du
al
 
H
CA
13
27
41
1
1
36
4
U
nk
no
w
n
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 R
F
-
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
14
32
44
9
5
45
3-
8
Re
gr
es
si
on
 o
f 
le
si
on
s
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (3
)
-
O
ne
 u
nt
re
at
ed
 
H
CA
15
33
26
4
3
36
5-
8
Re
gr
es
si
on
 o
f 
le
si
on
s
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (1
)
-
N
o 
ev
id
en
ce
 o
f 
di
se
as
e
16
28
35
2
1
28
7
G
ro
w
th
 o
f 
le
si
on
s
Pr
eg
na
nc
y 
w
is
h
Pe
rc
ut
an
eo
us
 
RF
 (1
)
Li
ve
r a
bc
es
s, 
pe
rc
ut
an
eo
us
 
dr
ai
na
ge
N
o 
fo
llo
w
-u
p 
av
ai
la
bl
e
17
25
33
6
3
37
2,
 3
, 5
U
nk
no
w
n
G
ro
w
th
O
pe
n 
RF
/r
es
ec
tio
n 
(1
)
-
M
in
im
al
 re
si
du
al
 
H
CA
18
29
24
10
1
43
6
N
o 
O
C 
us
e
G
ro
w
th
 d
ur
in
g 
pr
eg
na
nc
y
Pe
rc
ut
an
eo
us
 
RF
 (1
)
CV
A
, n
o 
in
te
rv
en
tio
n
M
in
im
al
 re
si
du
al
 
H
CA
N
ot
e 
- B
M
I =
 b
od
y 
m
as
s 
in
de
x;
 C
VA
 =
 c
er
eb
ro
va
sc
ul
ar
 a
cc
id
en
t; 
H
CA
 =
 h
ep
at
oc
el
lu
la
r a
de
no
m
a;
 O
C 
= 
or
al
 c
on
tr
ac
ep
tiv
es
; R
F 
= 
ra
di
of
re
qu
en
cy
.
Co
ur
se
 o
f H
CA
 a
ft
er
 d
is
co
nt
in
ua
tio
n 
of
 o
ra
l c
on
tr
ac
ep
tio
n.
100 Chapter 5.1
coMPlicAtionS
There were two major procedure-related complications (Society of Interventional Ra-
diology [SIR] class D [14]). One patient who underwent open RF ablation of two lesions 
and a right posterior segmentectomy for a third HCA developed cerebral ischemia with 
concomitant temporary paresis of the left arm caused by severe intraoperative bleeding. 
However, complete neurologic recovery was observed 3 months after surgery. Further 
cardiologic workup revealed a persistent foramen ovale, which likely contributed to the 
development of this serious complication. Another patient who underwent concomitant 
percutaneous ethanol injection of one HCA developed a hepatic abscess at the site of 
ethanol injection that required prolonged percutaneous drainage. Minor complications 
(SIR class A and B) included minor bleeding in three patients that required no further 
intervention (14).
diScuSSion
The diagnosis of HCA in young women often raises dilemmas for the treating physician. 
A conservative approach consisting of discontinuation of oral contraceptive treatment, 
radiologic follow-up, and negative advice regarding pregnancy would be preferable for 
many patients. However, the risk of life-threatening hemorrhage or malignant degen-
eration as well as the need for lifelong radiologic follow-up or a desire to have children 
has often led to a preference for active treatment. In patients with centrally located HCA 
or multiple HCA tumors in both lobes of the liver, complete resection of all lesions would 
necessitate a large liver resection, which would rather be avoided in this young and 
otherwise healthy population. In addition, hepatic adenomatosis is frequently associ-
ated with moderate to severe steatosis, precluding major hepatic resection (15).
Previously, we reported on the cost effectiveness of various treatment strategies for 
HCA, showing that RF ablation was the least expensive treatment with the most gained 
quality-adjusted life years (16); however, no data were provided on the efficacy of RF 
ablation for HCA. Limited data from other centers (9–13) shows that, with the avail-
ability of minimally invasive techniques such as RF ablation, HCA can be treated with 
low morbidity and high satisfaction. However, these data were largely anecdotal. One 
larger series of 10 patients described the successful application of RF ablation for the 
management of one or two HCA tumors. All patients tolerated the procedure well and 
no cases of local failure were reported (13). The present data suggest that RF ablation 
of HCA can lead to complete the destruction of all viable HCA tissue with no signs of 
residual or recurrent HCA on follow-up imaging in some patients, thereby “saving” these 
patients from hepatic resection. Nonetheless, residual HCA tissue adjacent to the zone 
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of ablation was often observed on follow-up imaging, resulting in repeat RF ablation 
sessions in many patients. In selected patients, we chose not to treat this residual HCA 
tissue, especially when other small (< 1 cm) HCAs were also present. We hypothesize 
that a small amount of remaining HCA tissue will behave similarly to a small HCA tumor. 
Even though some growth might occur, the chance the HCA will reach dimensions that 
pose a risk for rupture remains unlikely (17). The fact that no residual lesions in the pres-
ent study have shown growth or other changes visible on CT or MR imaging during 
follow-up supports this strategy. Clearly, the rate of local technical failure is relatively 
high in the present series, with many HCAs requiring multiple sessions of RF ablation 
treatment. This is somewhat surprising given the efficacy of RF ablation reported in 
the treatment of hepatocellular carcinoma, which is similar to HCA in many ways (18). 
However, the absence of liver cirrhosis and a capsule around the tumor might limit 
the efficacy of RF ablation when applied to HCA compared with HCC. Also, more than 
half of the treated HCAs in the present study were larger than 3 cm, which could have 
contributed to the failure of this technique. In addition, several other factors might have 
contributed to the failure of RF ablation in these patients, including difficulties with 
three-dimensional probe positioning and decreased target visualization as a result of 
steatosis and patients’ central adiposity. The fact that open ablation resulted in a higher 
rate of complete ablations in the first attempt supports this, as targeting is often easier 
in an open setting. Also, the inability to accurately monitor the effect of thermal ablation 
in these lesions might have partly contributed to the high local failure rate (19). In all 
patients with residual HCA tissue on follow-up images, there was discordance between 
the immediate postprocedural CT scan (showing complete ablation) and the 4–6-week 
follow-up scan (showing residual HCA tissue). Also, in several cases, US showed hardly 
any tissue-specific changes resulting from ablation, making it particularly difficult to 
assess the success of this treatment in real time. Supposedly, these limitations can be 
addressed in the future with the availability of new ablation methods such as micro-
wave ablation, more sophisticated image guidance platforms, and novel techniques to 
monitor thermal ablation such as MR thermography or US elasticity imaging (20,21). 
In the cohort of patients presented here, the diagnosis of HCA was made exclusively 
based on radiologic studies, including contrast-enhanced MR imaging and multipha-
sic CT imaging. On both modalities, HCAs typically show early homogeneous arterial 
enhancement without signs of washout or capsular enhancement and are usually well 
differentiated from hepatocellular carcinoma or focal nodular hyperplasia lesions (22). 
Tissue biopsy was not performed routinely given the high specificity of cross-sectional 
imaging and the associated risk of tumor seeding and sampling error. Rather, resec-
tion was the treatment of choice for lesions that raised concern for malignancy. Which 
patients should undergo surgical treatment for HCA and which patients should not 
remains a topic largely open for debate. Some data show that the risk of bleeding and 
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malignant degeneration is particularly increased in large or growing HCA tumors. A 
recent large retrospective multicenter study (4) in 124 patients showed that malignant 
degeneration and bleeding occurred only in patients with very large HCAs (> 8 cm and 
> 7 cm, respectively), and most would agree that HCAs of this size range require surgical 
intervention in most cases (4). Moreover, a recent systematic review (23) incorporating 
all known reports on malignant degeneration in HCA showed an overall risk of 4.2% 
of malignant degeneration in HCA, of which only 4% occurred in lesions smaller than 
5 cm. However, a selection bias should be acknowledged based on the fact that these 
reports include only patients who underwent surgical intervention and do not include 
those patients who underwent conservative management. Taking these data into con-
sideration, it might be controversial to treat lesions smaller than the threshold of 5 cm. 
However, in our opinion, young women with one or more HCAs smaller than 5 cm and 
an active pregnancy wish constitute a special patient group. When these HCAs have 
been shown to be hormone-sensitive (eg, shrank after cessation of oral contraceptive 
treatment), one might anticipate them to grow during pregnancy. Given the increased 
risk of bleeding and its associated morbidity and mortality in growing adenomas, as well 
as the possibility of these lesions reaching a size too large to treat with local ablative 
therapies and therefore requiring liver resection, we have often considered early treat-
ment of these relatively small lesions (17).
The present study might offer some guidance to the clinician to define the position of 
RF ablation in the treatment of HCA. Satisfactory results were obtained in most patients, 
and the postprocedural course was mild in the majority of patients. We suggest that RF 
ablation could be applied selectively for the treatment of HCA, especially in patients 
who would require large liver resections otherwise or in whom resection is not possible 
in view of bilateral spread of HCA. However, even percutaneous RF ablation can be as-
sociated with severe complications (although both patients with major complications 
in the present study underwent other concomitant procedures), and many patients 
required multiple sessions of RF ablation, increasing the costs and use of resources sig-
nificantly for these patients. Therefore, future research should focus on the comparison 
of different treatment modalities for the treatment of HCA, including laparoscopic liver 
resection, alternative ablative therapies, and transarterial embolization.
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AbStrAct
Traditionally, surgical resection has been the treatment of choice in many patients with 
hepatocellular adenoma because of the risk of rupture, hemorrhage and malignant 
transformation. However, some patients are not amenable for surgery due to the exten-
sive involvement of the liver, as in patients with liver adenomatosis. We report 2 cases 
with liver adenomatosis in which we combined surgery with open and percutaneous 
radiofrequency ablation for lesions located in both lobes of the liver. Minimal invasive 
treatment including radiofrequency ablation may offer new perspectives in the treat-
ment of patients with liver adenomatosis.
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introduction
Hepatocellular adenoma (HCA) is a rare benign tumor of the liver, occurring mostly in 
young women in their reproductive years and is associated with long-term exposure 
to estrogens, mostly oral contraceptives (OC). In the last decennium, the introduction 
and widespread use of highly advanced image modalities has increased the number of 
incidental HCA findings [1,2]. HCA can be complicated by life-threatening complications 
such as malignant transformation, rupture and hemorrhage [3,4]. There is an ongoing 
debate on the management of hepatic adenomas, regarding surveillance, surgical 
resection and other less invasive treatments, such as radiofrequency ablation (RFA) and 
transarterial embolization. In most cases the discussion is focused on the management 
of solitary adenomas. The management might even become more complex when pa-
tients present with multiple adenomas as is the case of liver adenomatosis (LA). Here, we 
report the treatment of 2 female patients with bilobar liver adenomatosis in whom we 
combined surgical resection with RFA.
cASe 1
A 35-year-old woman presented at a neurological outpatient clinic because of restless 
legs. Abnormal liver enzymes were discovered by routine laboratory work-up. The patient 
had no abdominal complaints and had used OC for 20 years. Her γ-glutamyltransferase 
level was 183 U/l (normal 0-34 U/l) and her alkaline phosphatase level was 286 U/l (nor-
mal: 0-119 U/l). Laboratory values of aspartate aminotransferase, alanine aminotrans-
ferase, total bilirubin and coagulation tests were within the normal range. Additional 
analysis by abdominal ultrasound showed a large hyperechoic lesion with a diameter of 
approximately 10 cm situated in the right lobe and multiple smaller hyperechoic lesions 
in both lobes of the liver. A magnetic resonance (MR) imaging scan of the abdomen 
revealed multiple lesions in both lobes of the liver and a well-defined lesion in segment 
VIII of the liver measuring 12.0 cm x 7.8 cm in size. On T1-weighted MR imaging, all tu-
mors were isointense compared to the surrounding liver. T2-weighted imaging showed 
hyperintense lesions compared to the surrounding liver and diffuse homogeneous 
signal intensity after contrast administration. In the delayed phase, the lesions remained 
slightly hyperintense to the surrounding liver. The MR imaging findings were consistent 
with LA. A needle biopsy of the largest lesion, which was performed elsewhere, was 
revised in our clinic and confirmed the diagnosis. First, cessation of OC was advised 
and regression of most lesions was seen after 6 months (Table 1; Figure 1). However, no 
further regression was seen 8 months later. Because of the size of the adenomas, our 
multidisciplinary team decided to remove the adenomas in several steps. Three small 
110 Chapter 5.2
table 1. Size of HCA lesions 6 months after discontinuation of OC
HCA segment HCA size during OC use, cm HCA size 5 months after 
discontinuation of OC, cm
VIII 12.0 x 8.7 6.7 x 7.7
VII 6.1 x 5.5 5.7 x 4.5
II 3.4 x 3.0 2.8 x 2.0
III 3.0 2.3
III 3.2 2.4
V/VI 5.2 x 3.8 3.8 x 3.0
V 3.4 x 2.2 3.1 x 1.8
VI 5.9 x 4.0 4.7 x 3.1
IVa/IVb/VI/VII/VIII some small lesions < 2.6 no difference
Fig. 1 
 
 
 
 
MR image of biggest HCA in segment VIII of the liver at presentation (a) and after 6 
months of oral contraceptive cessation (b) 
 
a
b 
figure 1. MR image of the biggest HCA in segment VIII of the liver at presentation (a) and after 6 months 
of OC cessatio  (b).
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superficial adenomas in the left lobe were resected and 5 adenomas in segment II, III and 
IVa of the liver were treated with open RFA during the same session. RFA was performed 
using a 480-kHz radiofrequency (RF) generator with a Cool-Tip RF System and Switching 
Controller (Valleylab, Covedien, Burlington, Mass., USA). The RFA procedure was carried 
out under general anesthesia by an experienced interventional radiologist. For the open 
approach, the patient was positioned in a supine position. The liver was mobilized for 
optimal exposure. After lesion identification, a RF electrode was placed in the lesion of 
interest under ultrasound guidance. Lesions were ablated for 5-15 min or until target 
temperatures were achieved in 1 or more sessions. Ablation of approximately 0.5 cm 
of healthy liver tissue surrounding the lesion was attempted. Histological examination 
of the resected lesions showed inflammatory adenomas, expressing serum amyloid A 
and C-reactive protein. Recent studies have shown that tumors with homogeneous 
glutamine synthetase staining and β-catenin positivity have a higher risk of malignant 
transformation of HCA into hepatocellular carcinoma [5,6] . However, in these lesions 
glutamine synthetase and β-catenin stainings were negative. In preparation of a right-
sided extended hemihepatectomy, right portal embolization was performed 16 weeks 
later to induce an atrophy of the embolized lobe to be resected, with a compensatory 
hypertrophy of the counter lobe to be preserved. However, resection was considered 
potentially harmful for the patient as there was a lack of hypertrophy of the left lobe 
which would lead to not having enough residual liver volume after surgery. It was 
decided to perform open RFA of the 9 remaining lesions, including the largest one in 
segment VIII of the liver which measured 73.0 mm x 63.0 mm in size 10 weeks before 
right portal embolization. Follow-up multiphasic computed tomographic (CT) scans 
performed 2, 8 and 16 months later showed adequate ablation of all lesions (Figure 2 ). 
After follow-up of 34 months, there was no evidence of recurrent liver lesions.
cASe 2
A 32-year-old woman was referred to our hospital for evaluation of multiple liver lesions. 
Her complaints consisted of abdominal discomfort, feeling of cramps, bloated abdomen 
and irregular bowel movement. Physical examination revealed normal signs, except 
obesity with a BMI of 27.5. Laboratory values of aspartate aminotransferase, alanine ami-
notransferase, alkaline phosphatase, total bilirubin and coagulation tests were within 
the normal range. Her γ-glutamyltransferase level was 75 U/l (normal 0-34 U/l). Work-up 
by her general practitioner involved an abdominal ultrasound, which showed multiple 
liver lesions. She had used OC up to half a year ago for a long period and after which 
she switched to an intrauterine device, NuvaRing, which locally releases a continuous 
low-dose of estrogen and progestin. She had a wish for pregnancy in the near future. 
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She denied a history of alcohol or intravenous drug abuse. The patient underwent a 
multiphasic CT scan that revealed a 5.9 cm x 6.2 cm lesion in segment V, 2 lesions of 
3.0 cm and at least 10 multiple smaller lesions in each the right and left lobes of the 
liver, all compatible with the diagnosis of HCA. Radiological follow-up with a CT scan 3 
months later did not show any regression of the lesions despite withdrawal of OC. The 
patient was discussed in our weekly multidisciplinary meeting and because of the size of 
the largest adenoma and a wish for pregnancy, surgery on the largest adenoma and an 
Fig. 2 
 
 
 
 
 
 
CT image 3 days (a) and 2 months (b) and 16 months after RFA (c). There is no 
enhancing tissue observed around the zone of thermal ablation, indicating adequate 
treatment effect 
 
 
c 
b 
a 
figure 2. CT image 3 days (a), 2 months (b) and 16 months (c) after RFA. There is no enhancing tissue 
observed around the zone of thermal ablation, indicating adequate treatment effect.
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open RFA of the smaller lesions was advised (Figure 3). Histological examination [includ-
ing glutamine synthetase as a useful immunohistochemical marker in the diagnosis of 
focal nodular hyperplasie (FNH)] of the resected lesion showed FNH [7]. Because of this 
unexpected finding of a FNH, a radiological re-evaluation of the residual lesions was 
performed and the residual lesions were still regarded to be adenomas. A CT scan was 
performed 3 months postoperatively, and showed 7 adenomas successfully ablated at 
the first attempt, 1 hypervascular zone adjacent to one of the ablation fields being suspi-
cious for vital HCA tissue, incorrect placement of the RFA needle in 1 adenoma, and 2 
vital adenomas not treated with RFA and not visible at first CT scan. Because this patient 
had a clear pregnancy wish, percutaneous RFA of the 4 remaining lesions was advised 
and again performed. The MR scan which was performed 6 weeks post-RFA showed 2 
adenomas that were ablated successfully and again 2 zones suspicious for residual HCA 
tissue. Twelve and 31 weeks after the first percutaneous RFA session, a 3rd and 4th ses-
sion of percutaneous RFA was performed for the remaining 2 residual HCA tissue zones. 
Again a CT scan was performed, which showed adequate ablation of all lesions.
Fig. 3  
 
 
 
CT image of multiple HCA lesions 6 months before (a) and 2 weeks after (b) 1st  RFA 
 
a 
b 
figure 3. CT image of multiple HCA lesions 6 months before (a) and 2 weeks after (b) first RFA.
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diScuSSion
In 1985, Flejou et al. [8] described a series of LA defined as the presence of ≥ 10 adenomas 
in an otherwise normal liver parenchyma. The diagnosis of HCA has a great impact on 
the lives of young women, especially if they have a wish for pregnancy. HCA in pregnant 
women requires special considerations because of the risk of hormone-induced growth 
and rupture due to the increased levels of steroid hormones during pregnancy that may 
threaten the life of both mother and child [9]. Historically, surgical resection of HCAs 
has been the treatment of choice if the tumor diameter exceeds 5 cm after 6 months of 
follow-up after cessation of OCs, because of the risk of hemorrhage or malignant degen-
eration [2,10–12]. Although tumor size is one of the main factors in deciding whether to 
manage HCA by observation or to perform a surgical resection, we advise a conservative 
policy if the tumor still shows adequate regression after 6 months of cessation of OC. 
We consider surgery in lesions ≥ 5 cm in size that show no more decrease in size after 6 
months of cessation of OC. However, some patients are not amenable for surgery due 
to centrally located tumors or due to the extensive involvement of the liver in LA. In 
such cases, an alternative minimal invasive treatment like RFA may be the treatment of 
choice. RFA can be performed percutaneously or in an open setting [13]. Moreover, RFA 
procedures can be electively performed and carefully planned.
RFA destroys tissue by application of interstitial hyperthermia resulting in coagulative 
necrosis, and is a safe and successful treatment for adenomas, especially those with a 
diameter of < 4 cm. However, limited data are available on this topic [13–17]. The largest 
series was described by Rhim et al. [15], who performed percutaneous RFA in 10 patients 
with 12 pathologically proven HCAs. Adequate ablation was found in all adenomas and 
all patients tolerated the procedure well. Fujita et al. [13] reported a combined hepatic 
resection and open RFA for 3 patients with multiple HCAs, with a maximum of 3 ablated 
adenomas per case.
We report 2 cases with LA in which we combined surgery with open and percutaneous 
RFA for lesions in both the right and left liver lobe. Although multiple sessions were 
required, a follow-up CT scan showed adequate ablation of all the lesions at the end. 
There is still the question, however, as to which patients should be selected for RFA only 
and which patients should undergo surgical treatment followed by RFA. In patients with 
multiple bilateral or right-sided lesions warranting large resections, the choice for RFA 
seems apparent. Patients with smaller lesions or left-sided lesions, which can be easily 
resected using a small laparotomy or even using laparoscopic techniques, might pose a 
larger dilemma. This choice is not as clear given the fact that multiple RFA sessions might 
be needed for the treatment of 1 lesion, which could be resected in a single surgical 
session. In these cases the anatomical location of the lesion within the liver parenchyma 
may influence the preferred treatment.
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Although HCA is a benign disease, malignant transformation of HCA to hepatocellular 
carcinoma has been described in the literature, especially in large lesions. Moreover, a 
recent systematic review incorporating all reports on malignant degeneration in HCA 
showed an overall risk of 4.2% of malignant transformation of HCA into hepatocellular 
carcinoma, of which only 4.4% occurred in lesions smaller than 5 cm [18]. Therefore in 
patients with multiple HCAs or LA, one should strictly consider a surgical resection of 
adenomas ≥ 5 cm in diameter or adenomas with radiological signs of malignancy. The 
surgical procedure may be combined with open RFA for the remaining smaller lesions, 
and can be considered a safe and effective treatment option because of the low mortal-
ity and morbidity rates of this procedure [17]. Furthermore, in small tumors RFA is the 
preferred treatment because of the short hospital stay, low cost and the best gain in 
quality-adjusted life years [17]. The low costs are due to low procedural costs, the rela-
tively low complication rate and the absence of a long follow-up period for patients with 
no residual tumor [17]. Transcatheter arterial embolization followed by RFA could be an 
alternative and effective treatment strategy for LA to prevent rupture and hemorrhage 
in large tumors when it is difficult to perform a hepatectomy [19].
In case 2 there was a simultaneous occurrence of LA and FNH in the liver. Discrimina-
tion between HCA and FNH can be difficult on radiological imaging and alternation of 
these diagnoses may be harmful because HCA has an increased risk of hemorrhage, 
rupture and malignant transformation, while FNH does not. Little literature is available 
on the simultaneous occurrence of HCA and FNH and the simultaneous occurrence 
of multiple HCAs or LA and FNH [20]. Laurent et al. [20] described 5 out of 30 cases 
of multiple benign hepatic nodules in which HCA was found together with FNH. This 
association could be coincidental or secondary to shared causal mechanisms like angio-
genic abnormalities induced by OC, tumor-induced growth factors or thrombosis, and 
local arteriovenous shunting [20]. Although the association of FNH and HCA could be 
coincidental, it seems that the presence of FNH is higher than expected in adenomatosis 
and multiple inflammatory HCAs [20]. In conclusion, minimal invasive treatment like RFA 
might be helpful in the treatment of patients with LA or multiple HCAs located in both 
lobes of the liver. Although LA can be regarded as a benign liver disease, proper control 
of multiple lesions may be indicated in selected patients.
A balanced approach using surgery and RFA is advocated in the management of this 
complex disease.
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AbStrAct
background: Although benign in itself, hepatocellular adenoma (HCA) can be compli-
cated by hormone induced growth and subsequently hemorrhage and rupture. How-
ever, the true risk of hemorrhage and rupture is not exactly known. A systematic review 
of literature was performed to make a risk estimate for hemorrhage and rupture in HCA.
Methods: A systematic literature search of the PubMed and Embase databases was 
performed for all articles published from 1969 till March 2011, relevant to hemorrhage 
and/or rupture of HCA.
results: Twenty-eight articles were selected containing a total of 1 176 patients. Hemor-
rhage was reported with an overall frequency in 27.2% of cases, and in 15.8% of the total 
number of HCA lesions. Rupture and intraperitoneal bleeding were reported in 17.5% of 
cases. Acute symptoms of hemorrhage prior to the diagnosis HCA were present in 86.4% 
of patients. Six out of 13 articles in which the size of HCA lesions in which hemorrhage 
occurred was noted, reported hemorrhage in HCA < 5 cm.
conclusion: Hemorrhage and rupture is a common complication in patients with HCA 
with an overall frequency of hemorrhage in 27.2% of cases. To identify those patients 
who require aggressive treatment prospective multicentre studies are warranted to 
establish the incidence of hemorrhage and rupture for small HCA.
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introduction
Hepatocellular adenoma (HCA) is a rare benign tumor of the liver that occurs particu-
larly in women during their reproductive years1. Although benign in itself, the diagnosis 
of HCA has a great impact on the lives of these, mostly, young women. Malignant 
transformation of HCA into hepatocellular carcinoma has been reported in literature. 
Besides that, the presence of HCA can be complicated by hormone induced growth and 
subsequently, rupture and bleeding, which is usually the cause of right upper quadrant 
abdominal pain. HCA in pregnant women requires special considerations because of 
the risk of hormone-induced growth and rupture due to the increased levels of steroid 
hormones during pregnancy that may threaten the life of both mother and child2. 
Because of the risk of hemorrhage, rupture and malignant transformation surgical 
resection is the preferred treatment in patients with HCA > 5 cm3-6. A recent systematic 
review incorporating all reports on malignant degeneration showed an overall risk of 
4.2% on malignant transformation of HCA into hepatocellular carcinoma, of which only 
4.4% occurred in lesions smaller than 5 cm in diameter7. However, the true incidence 
of hemorrhage and rupture is not exactly known and the reported rate of hemorrhage 
and rupture in literature varies from 11% to 49%3,8. The aim of this systematic review is 
to make a risk estimate for hemorrhage and rupture in HCA as reported in the literature.
MetHodS
literature search strategy
A systematic literature search of the PubMed and Embase databases was performed for 
all articles published from 1969 till March 2011, relevant to rupture and/or hemorrhage 
figure 1. Search terms used in PubMed and Embase databases.
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of HCA. There was no literature available prior to 1969 in either databases. Search terms 
used in different databases are shown in Figure 1. All titles and abstracts were screened 
and relevant articles were selected.
literature screening
Studies were evaluated for inclusion by two independent researchers (SMA, TT) for 
relevance to the subject. A random check was performed by a supervisor (JNMIJ). Study 
selection was accomplished through three levels of study screening (Figure 2). Articles 
were included if they described a series of patients with HCA seen in a particular time 
period. Studies which described only patients with liver adenomatosis were excluded. 
At level 1, duplicate articles found in both databases were excluded. At level 2, titles 
and abstracts of all articles were screened for relevance. Irrelevant articles, case reports, 
review articles and abstracts presented at scientific meetings were excluded. At level 3, 
a full text review was conducted for final inclusion. In case of overlapping series, only 
the most recent publication was included to avoid double counting of patients with 
HCA. Irrelevant articles were those articles that did not describe a series of patients in 
a particular time period, articles that gave only a summary of current knowledge of 
HCA, articles focusing on focal nodular hyperplasia or articles that did not answer the 
research question.
figure 2. Flow diagram showing selection of articles. HCA: hepatocellular adenoma.
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data extraction
For all articles data regarding the number of cases with HCA, the total number of HCA 
lesions, the number of cases who underwent surgical resection for HCA, the number 
of female cases, mean age at presentation, OC use, number of HCA lesions with hem-
orrhage, number of cases in which hemorrhage and intraperitoneal rupture occurred 
and the diameter of HCA lesions in case of hemorrhage were assessed. Hemorrhage 
was defined as macroscopic signs of hemorrhage at pathological examination and/or 
hemorrhage identified by radiologic imaging.
Statistical analysis
Data were presented in a table and were presented as mean and percentages. Numera-
tor and denominator were noted for number of hemorrhage and rupture.
reSultS
At level 1 selection, a total of 790 articles were identified by the initial search through 
PubMed (n = 330) and Embase (n = 460) databases. A total of 261 duplicate articles 
were excluded. At level 2 selection 485 articles were excluded of which 353 irrelevant 
articles, 117 case reports, 11 review articles and 4 abstracts presented at scientific meet-
ings. Forty-five articles were selected for full text review (level 3 selection). Because of 
overlapping data 9 articles were excluded as well as another 8 irrelevant articles which 
did not answer the research question. In total 28 articles describing a series of patients 
with HCA seen in a particular time period and reporting the total number of HCA (cases) 
in which hemorrhage and rupture occurred were included in the analysis3-6,8-31.
general analysis
27 out of 28 articles included in the study contained a total of 1176 patients with one 
or more HCA (Table 1). One series described by Mathieu et al. did not indicate the total 
number of patients. In this study only the total number of HCA diagnosed by magnetic 
resonance imaging, all of which were histologically proven, were noted. 1073 out of 1176 
(91.2%) patients with HCA underwent surgical resection of HCA. In 24 articles (972 patients) 
the male/female ratio was available, included were 880 women (91.0%) and 92 (9%) men.
Analysis of hemorrhage and rupture
As shown in table 1, information about the total number of HCA lesions with hemorrhage 
was available in 748 lesions. 118 out of 748 HCA lesions (15.8%) presented with hemor-
rhage. Information about the total number of cases showing hemorrhage was available 
in 1160 cases, with hemorrhage noted in 315 cases (27.2%). When studies were excluded 
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that describe patient series before the introduction of second and third generation OC, 
which contained much lower hormone levels, a comparable risk of hemorrhage in 192 
out of 755 cases (25.4%) was found3-4,6,9,11-15,18-20,22-23,25-27,29,31-32.
table 2. Overview of patients presented acutely with symptoms of hemorrhage prior to the diagnosis 
hepatocellular adenoma(s)
reference Year Patients (n) resected 
cases (n)
initial presentation with 
hemorrhage (n cases)
Edmondson et al. 9 1976 42 41 10/10
Rooks et al. 8 1979 85 84 3/42
Vana et al. 10 1979 96 70 11/11
Nime et al. 11 1979 37 37 -
Barrows et al. 12 1983 71 71 -
Thompson et al. 13 1983 5 5 2/2
Gonzalez et al. 14 1985 12 12 2/3 a
Mathieu et al. 15 1986 27 27 4/4
Leese et al. 16 1988 24 21 11/11 b
Paulson et al. 17 1994 14 7 -
Chung et al. 18 1995 16 15 -
Ault et al. 19 1996 12 5 4/4
Mathieu et al. 20 1997 - - 3/3
Ribeiro et al. 21 1998 27 27 10/10
Closset et al. 22 2000 16 16 5/7 c
Ichikawa et al. 23 2000 25 14 -
Ji et al. 24 2000 4 4 -
Weimann et al. 25 2000 77 77 7/12 d
Reddy et al. 26 2001 25 25 3/3
Hung et al. 27 2001 12 12 1/4
Terkivatan et al. 5 2001 33 19 12/12
Toso et al. 28 2005 25 25 10/10
van der Windt et al. 6 2006 48 16 13/21
Chaib et al. 29 2007 28 28 3/3
Cho et al. 3 2008 41 41 12/12
Bioulac-Sage et al. 30 2009 128 128 -
Deneve et al. 31 2009 124 124 -
Dokmak et al. 4 2009 122 122 -
total 1176 1073 159/184 (86.4%)
-: no data available or no data reported
a one of which had sustained abdominal trauma; b one of which had sustained abdominal trauma; c 
five patients presented acutely and two patients presented with chronic pain and had evidence of 
rupture; d two patients presented with a ruptured adenoma during pregnancy and one patient revealed 
intratumoural hemorrhage one week after caesarean section.
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A total of 114 out of 652 cases (17.5%) presented with rupture and intraperitoneal 
bleeding. In 12 out of 28 articles the size of HCA after hemorrhage was noted. HCA in 
which hemorrhage occurred with a diameter of < 5 cm was shown in 6 articles (number 
of HCA unknown). The smallest reported HCA in this systematic review in which hemor-
rhage occurred was in a lesion of 1 cm. 159 out of 184 (86.4%) patients presented acutely 
with symptoms of hemorrhage prior to the diagnosis HCA. Hemorrhage and rupture due 
to abdominal trauma was described in 2 series17,21. (Table 2) Pregnancy related complica-
tions were described in one study and noted in three patients; two patients presented 
with a ruptured HCA during pregnancy and one patient revealed intratumoral hemor-
rhage one week after caesarean section31.
diScuSSion
Hemorrhage can be explained by the histological characteristics of HCA being a highly 
vascular tumour with multiple thin-walled sinusoids, feeding arteries, and poor con-
nective tissue support21,33-34. Hemorrhage can easily spread into the liver or abdominal 
cavity, because HCA commonly lack a true, fibrous tumour capsule35. This systematic 
review shows that hemorrhage and rupture as described in literature is a common com-
plication in patients with HCA with an overall frequency of hemorrhage in 27.2% of 
cases. Rooks et al. described a mortality rate of 21% (6 out of 29 patients) after rupture 
and intraperitoneal bleeding8. However, none of the other articles described mortality 
asscociated with the tumour and important is that the article described by Rooks et al. 
was published in the end seventies, a period in which experts were less familiar with the 
disease entity. Moreover, highly advanced image modalities were introduced in the last 
decennium and were not available in the end seventies.
The incidence and pathogenesis of HCA are not exactly known. The association of HCA 
with the widespread use of OC since the commercial introduction in the 1960s was first 
described by Baum et al. in 197336. It should be noted that data regarding the incidence 
of HCA refer to studies performed decades ago. Nowadays benign liver tumours are 
detected more frequently as an incidental finding due to the increased routine use of 
abdominal imaging as part of a screening in case of a known extrahepatic malignancy 
or medical check-up. On the other hand, the incidence of HCA is reported to be lower by 
the introduction of new second and third generation OC during the mid seventies and 
eighties, respectively, which contain much lower hormone levels37-38. However, when 
studies were analysed which described patient series from the eighties and beyond, a 
comparable risk of hemorrhage in 25.4% of cases was found.
   Many authors advocate surgical resection if the diameter of the lesion exceeds 5 cm 
because of the increased risk of hemorrhage and malignant transformation. Six out of 
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13 manuscripts that are included in this review and that do describe the size of the 
lesions in which hemorrhage occurred, reported hemorrhage in HCA smaller than 5 cm. 
Cho et al. reported hemorrhage in one lesion of 1 cm3. It may be difficult to measure the 
size of HCA after hemorrhage, related to the hematoma around the lesion39. While on 
the one hand, the size of the lesion may be overestimated, on the other hand lesions 
may be estimated smaller because of the difficulty to distinguish vital HCA tissue from 
destructed parts of the lesion. Although hemorrhage is noted in very small tumours, the 
risk of hemorrhage and rupture seems to be very small. Three studies investigated the 
association between number of tumours and the risk of hemorrhage and rupture and 
showed that the risk of hemorrhage and rupture did not differ between patients with 
single or multiple HCA4,15,29.
Recently the Bordeaux group established a molecular and pathological subtype clas-
sification of HCA. They divided HCA in four different subgroups based on morphological 
criteria, molecular characteristics and by the use of an immunohistochemical panel of 
markers; Hepatocyte nuclear factor 1α-inactivated HCA (H-HCA) which have a lack of 
liver-fatty acid binding protein expression in the tumour; β-catenin mutated HCA; in-
flammatory HCA with serum amyloid A and C-reactive protein expression; less that 10% 
remain unclassified40-41. Despite the expectation that the inflammatory subgroup has a 
higher risk of hemorrhage and rupture, due to the histomorphological characteristics 
of thick walled arteries, sinusoidal dilatation, inflammatory infiltrates and ductular reac-
tion, there is no difference in the risk of bleeding for inflammatory HCA and the H-HCA 
subgroup of HCA11,41. Inflammatory HCA and H-HCA are the two major subgroups of 
HCA, however the numbers described in literature are small. A prospective multicentre 
study is warranted to establish the incidence of hemorrhage and rupture for small HCA 
and to establish the actual risk of hemorrhage and rupture for each subgroup to identify 
those patients who require aggressive treatment.
One of the limitations of this systematic review is that most articles reported their 
data on resected HCA, which could have led to an overestimation of the true risk of 
hemorrhage and rupture because small lesions were not detected, not reported or 
were treated conservatively and discharged from follow-up. In addition, in most articles 
published in the 70s, 80s and 90s most patients were advised to undergo resection of 
HCA to prevent a later presentation of malignant transformation and hemorrhage and 
rupture of the lesion.
   The current systematic review reports on 1176 patients with HCA and shows that 
hemorrhage and rupture is a common complication in patients with HCA with an overall 
frequency of 27.2% of cases and in 15.8% of the total number of HCA lesions. Rupture 
and intraperitoneal bleeding were reported in 17.5% of cases. However, the risk of hem-
orrhage and rupture in HCA < 5 cm seems small. To identify those patients who require 
aggressive treatment multicentre studies are warranted to establish the actual risk of 
Hemorrhage and rupture of HCA 129
Chapter
6
hemorrhage and rupture for each subgroup of HCA following the Bordeaux criteria. So 
far, surgical resection of HCA ≥ 5 cm seems justified. The decisions on the management 
of smaller HCA should be based on symptoms, patient characteristics, a wish for preg-
nancy and the available expertise.
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AbStrAct
During recent years, there was a great development in the area of hepatocellular ade-
nomas (HCA), especially regarding the pathological subtype classification, radiological 
imaging and management during pregnancy. This review discusses the current know-
ledge about diagnosis and treatment modalities of HCA and proposes a decision-making 
model for HCA. A Medline search of studies relevant to epidemiology, histopathology, 
complications, imaging and management of HCA lesions was undertaken. References 
from identified articles were hand-searched for further relevant articles.
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introduction
Radiological, as well as histological differentiation of hepatocellular adenoma (HCA) 
from other benign or malignant liver tumours, such as focal nodular hyperplasia (FNH) 
or hepatocellular carcinoma (HCC) might be difficult. However, once the diagnosis of 
HCA has been established, defining the right management strategy may be challeng-
ing as well. There are no randomized controlled studies available that depict a clear 
decision-making for the treatment of HCA in various conditions, and the management 
of individual patients depends mainly on the physicians or surgeons insight. The need 
for a clear decision-making is obvious as, for example, in case of young women in her 
childbearing age with multiple, bilateral or centrally located lesions and a need for 
pregnancy. As new imaging and treatment modalities have been developed during the 
last years, management of HCA has also developed sufficiently to warrant an update. 
In this manuscript, we review the current knowledge about diagnosis and treatment 
modalities of HCA, based on our own experience and literature reports, and we define 
evidence-based management. A Medline search of studies relevant to epidemiology, 
histopathology, complications, imaging and management of HCA lesions was undertak-
en. References from identified articles were hand-searched for further relevant articles.
ePideMiologY
HCA is a rare benign tumour of the liver that occurs more frequently in women within 
their reproductive years. The estimated incidence is about 1-1.3 per 1,000,000 in women, 
who have never used oral contraceptives (OC) compared to a substantial higher risk of 
30-40 per 1,000,000 in long-term users (1, 2). It should be noted that these data refer to 
studies performed decades ago. Although the incidence of HCA is reported to be prob-
ably lower by introduction of new generation OC with much lower hormonal levels (3), 
nowadays benign liver tumours are detected more frequently as an incidental finding as 
a result of the increased routine use of abdominal imaging as part of a screening in case 
of a known extrahepatic malignancy or medical check-up.
HiStoPAtHologY
Macroscopy and microscopy
Macroscopically, an HCA lesion is smooth and soft on palpation and occurs as a solitary 
tumour, as well as multiple lesions. We reviewed our series of 221 patients with a clear 
diagnosis of HCA referred to our hospital between 2000 and 2009 and report HCA to 
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be solitary in 32% of the patients. Ninety-nine patients (45%) presented with multiple 
adenomas (2-9 HCA lesions) and 23% presented with hepatic adenomatosis, defined as 
the presence of ≥ 10 HCA (4). Microscopic examination shows cords of hepatocytes hav-
ing a glycogen and lipid content and abnormal parenchymal architecture with absence 
of portal tracts and hepatic veins is seen. The hepatic plate can be two or more cells 
thick, separated by dilated sinusoids. Bile ducts are absent, a key histological feature 
that helps to distinguish it from FNH (5, 6). The cut surface of the adenoma has a charac-
teristic yellow appearance, which comes from the lipid accumulation.
classification
Recently, the Bordeaux group established a new molecular and pathological classifica-
tion system for HCA (7). The classification described by Bioulac-Sage et al. is of great 
clinical importance. They divided HCAs in four different subgroups using an immunohis-
tochemical panel of markers. These markers were defined by the presence of mutations 
in TCF1 gene, inactivating the hepatocyte nuclear factor 1 (HNF-1α) in 35-50% of the 
HCA patients; presence of β-catenin activating mutations was observed in 15-18% of pa-
tients; serum amyloid A (SAA) and C-reactive protein (CRP) expression in inflammatory 
HCA was found in 40–55% of patients, histomorphologically characterised by inflamma-
tory infiltrates, thick walled arteries, sinusoidal dilatation and ductular reaction; less than 
10% of HCA could not be classified (8, 9). There are several interesting findings from this 
study. The HNF-1α-mutated HCAs were most of the time highly steatotic, with a lack of 
expression of liver-fatty acid binding protein (L-FABP) in immunohistochemistry analysis 
(9). Liver adenomatosis (LA; HCA ≥ 10) was most often found in L-FABP-negative HCA (8) 
and germline HNF-1α mutations cause LA in addition to diabetes (MODY3) (10). Patients 
with a high body mass index and excessive alcohol consumption were more frequently 
observed in the inflammatory group (7, 11), whereas β-catenin-activated lesions seem 
to have a higher risk of malignant transformation in HCC in patients with HCA larger 
than 4-5 cm (7, 12). As previously described, it might be very difficult to distinguish 
HCA from a well-differentiated HCC. Identifying β-catenin-positive HCA is therefore of 
major interest. However, the risk of HCC in patients without β-catenin mutation is an 
unanswered question (9). Results of our series of 58 surgically resected HCA lesions were 
in accordance with data reported by Bioulac-Sage et al., confirming that inflammatory 
HCA and steatotic-type L-FABP-negative HCA to be the two main subgroups. They differ 
on clinical and pathological grounds showing the features as mentioned above (13). 
Morphology and immunohistochemistry allow subtyping of more than 90% of HCA (13) 
(Figures 1-3). Interpretation of immunohistochemistry needs adequate techniques and 
training, particularly for the interpretation of β-catenin and glutamine synthetase (GS). 
The identification of nuclear staining for β-catenin can be very difficult, because the 
number of β-catenin-positive cells may be limited. Moreover, interpretation of β-catenin 
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may be difficult because of the heterogeneous and sometimes, focal nuclear staining 
pattern. Subtyping the lesion as β-catenin-positive HCA is straightforward when there is 
a strong and homogeneous GS staining pattern, and accompanied by nuclear β-catenin 
expression. However, if the GS over expression is heterogeneous, the interpretation 
becomes more difficult (13, 14). Paradis et al. described a variant of FNH, the so called 
telangiectatic FNH, which has a molecular pattern closer to HCA than to FNH. These 
figure 1. Inflammatory hepatocellular adenoma (HCA). (a) Macroscopic view of an inflammatory HCA 
of 9 cm in largest diameter. At cut section, the lesion has a red-brown aspect with areas of intratumoural 
fat and sinusoidal dilatation (*). (b) Paraffin section, haematoxylin and eosin stain. Sinusoidal dilatation 
(*), mild ductular reaction and inflammatory reaction. (c,d) Serum amyloid A (SAA) immunostaining 
expression and C-reactive protein (CRP) immunostaining expression in HCA in contrast with non-tumoural 
liver (NTL).
figure 2. ‘Steatotic’ hepatocellular adenoma (HCA). (a) Paraffin section, haematoxylin and eosin stain. 
Marked steatosis in adenomatosis (arrows). (b) Liver-fatty acid binding protein immunostaining (L-FABP) in 
multiple steatotic HCA: lack of L-FABP in HCA in contrast with normal expression in non-tumoural liver (NTL).
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lesions would be more accurately referred to as ‘telangiectatic hepatocellular adenomas’ 
(15, 16). The Bordeaux group delivers more evidence that these telangiectatic lesions 
are defined by specific morphological characteristics, i.e. partially preserved lobulation, 
presence of portal tract-like structures with dystrophic arteries and ductular reaction 
(15). These lesions are frequently subject to bleeding because of the areas of sinusoidal 
dilatation and peliosis (17). The Bordeaux group demonstrated a common molecular 
link between telangiectatic FNH and inflammatory HCA and established that the so 
called telangiectatic FNH is part of the inflammatory subtype of HCA with telangiectatic 
features (7).
coMPlicAtionS
Haemorrhage
The presence of HCA can be complicated by hormone-induced growth and subse-
quently, rupture and bleeding, which is usually the cause of right upper quadrant 
abdominal pain in symptomatic patients. Haemorrhage can be explained by the histo-
logical characteristics of HCA being a highly vascular tumour with multiple thin-walled 
sinusoids, feeding arteries and poor connective tissue support (5, 6, 18). Haemorrhage 
will spread into the liver or abdominal cavity, because HCA commonly lack a true, fibrous 
tumour capsule (19). Deneve et al. analysed data from five academic medical centres 
and searched for factors that were associated with rupture of HCA. One hundred and 
nineteen patients were included in this study; a total of 31 patients (25%) had evidence 
of rupture. They concluded that patients with ruptured HCAs were more likely to have 
a history of recent use of OC compared to patients with a non-ruptured HCA (58% vs. 
25%) (20). Whether rupture and bleeding will occur seems also be correlated with the 
size of the HCA. Deneve et al. reported that no tumour < 5 cm in largest diameter had 
evidence of rupture (20). Dokmak et al. described that a risk of haemorrhage was almost 
exclusively observed in HCA > 5 cm in diameter, and less than 1% of HCA < 5 cm had 
macroscopic haemorrhagic stigmata (21). In addition, the risk of rupture is believed to 
figure 3. β-catenin activate hepatocellular adenoma (HCA). (a) Paraffin section, haematoxylin and eosin 
stain. Formation of pseudoglands (*) (b) Homogeneous glutamine synthetase immunostaining (GS) of 
HCA in contrast with non-tumoural liver (NTL). (c) Nuclear positivity of β-catenin immunostaining.
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increase during pregnancy because of the increased hormone levels (22). Haemorrhage 
of HCA is seldom caused by external trauma (23). Risk of rupture seems not to be as-
sociated with tumour number (20, 21). In our experience, in a series of 221 patients, 45 
HCA patients (20%) presented with radiological evidence of haemorrhage. All patients 
in whom haemorrhage occurred were female with a median age of 38 years (range 
21–66). Thirty-nine patients (87%) were using OC at the time of diagnosis, with data 
missing from five patients. Nine of 45 patients presented with an active bleeding during 
diagnosis. The initial management in four of them included haemodynamic support 
with suppletion of blood products and coagulants. In two of these patients, selective 
transcatheter arterial embolization (TAE) followed. In total, six of nine patients presented 
with an active bleeding were treated with TAE to stop the bleeding. The remaining 36 
patients were stable. All patients are still alive. In four patients, haemorrhage of the HCA 
occurred after biopsy of the lesion. After rupture, the size of the HCA and the rate of 
regression of its diameter during follow-up may be difficult to measure as lesions tend 
to be estimated larger after rupture, related to the haematoma around the lesion (24). 
In our series, all lesions showed tumour regression or even disappearance of the lesion 
after rupture. This might be caused by devascularisation and shrinkage of the adenoma 
as a result of the bleeding, or regression of the lesion is due to withdrawn of OC use. The 
risk of rupture of other HCA lesions in the liver remains unknown.
Malignant transformation
Malignant transformation of HCA into HCC has been reported, although it is considered 
to occur rarely (25, 26). The reported proportion of malignant degeneration in HCAs 
vary from 4 to 18% (20, 25-27). Recently, Stoot et al. reported an overall frequency of 
malignant transformation of HCA of 4.2% (28). The HCA nodules with aberrant nuclear 
β-catenin expression (β-catenin-mutated adenomas) are of high risk of developing HCC 
out of HCA (see phenotype classification). The β-catenin-mutated subgroup seems over-
represented in male patients and specific risk factors, such as male hormone administra-
tion, are associated with their development (9). Some authors suggest the association 
of HCC with the simultaneous occurrence of HCA and glycogen storage disease type Ia 
(GSD Ia) (29–32). Kishnani et al. described the possibility that HCA associated with GSD 
Ia is to be related to HCC transformation because it is likely that cooperative activation 
of multiple oncogenes on 6p and inactivation of multiple tumour suppressor genes on 
6q contribute to the development of HCAs in GSD Ia patients. Gain of 6p and loss of 6q 
are frequently indentified in HCC (31). However, the exact pathogenesis of malignant 
transformation of HCA remains unknown. Little literature is available about size as risk 
factor for malignant transformation of HCA. Micchelli et al. reported malignant transfor-
mation in HCA greater than 4 cm (25). It should be kept in mind that multiple HCA of 
different subtypes can occur in the same patients (33). Therefore, resection of an HCA 
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without malignant characteristics in a patient with multiple adenomas does not exclude 
possible malignant transformation of the remaining liver lesions.
bioPSY
Liver biopsy can be used if imaging cannot firmly establish the diagnosis of a liver 
nodule. Whether the immunohistochemistry markers, as mentioned above, will also be 
accurate on biopsies of liver lesions suspected of being HCA needs to be questioned. 
Using the genotype/phenotype classification might allow the identification of patients 
at risk of rupture or malignant transformation. This information could, theoretically, be 
used to direct management. However, needle biopsies may lead to sampling error, and 
moreover, it may be associated with haemorrhage or needle-track tumour seeding in 
case of a malignant lesion (34). In addition, the amount of material obtained by biopsy 
is often insufficient to achieve a reliable diagnosis. In most cases, the identification of 
L-FABP-negative and inflammatory-type HCA with positive CRP and SAA staining should 
be feasible on a biopsy, because of more or less homogeneous staining pattern (33). 
However, the interpretation of β-catenin staining may be difficult because of the het-
erogeneous and sometimes focal nuclear staining pattern, and additional molecular 
biology may be required, as close relationships were found between genetic data and 
immunohistochemical data (33, 35–37). A concomitant staining with GS is warranted 
to increase sensitivity to detect a β-catenin mutation, especially in the case of a biopsy 
(33). Recent immunohistochemical data obtained on biopsies are very encouraging al-
lowing the identification of subtypes in more than 80% of cases [abstract 1710 AASLD 
2010, (38)] The role of needle biopsy or aspiration of focal liver lesions remains much 
debated. Although histological examination is still considered to be the gold standard in 
the diagnosis of benign and malignant liver tumours, the availability of highly advanced 
radiological techniques provides a noninvasive diagnostic tool that is being used 
frequently. Besides, radiological examination, especially magnetic resonance imaging 
(MRI), has a high accuracy rate for HCA (6, 8). This may have consequences for the role 
of histology during work-up of a focal liver lesion, which has its own diagnostic pitfalls.
iMAging
On unenhanced computed tomography (CT) scans, HCAs are usually well-described 
lesions and become visible in the arterial phase with a subtle homogeneous blush of 
contrast enhancement and fade to isodensity in the portal or delayed phase (19, 39). 
Contrast-enhanced CT scans may show peripheral enhancement which reflects the pres-
Management of HCA 143
Chapter
7
ence of a large subcapsular feeding vessel, with a centripetal pattern of enhancement 
(5). Homogeneous enhancement in the arterial phase shown on CT scans obtained after 
i.v. injection of contrast plays an important role in diagnosis. The broad availability of CT, 
as well as, the recent development of the faster multirow detector machine does allow 
multiphasic dynamic contrast-enhanced imaging in relatively shorter scanning times. 
The shorter scanning times allow the capture of distinct phases, i.e. unenhanced phase, 
arterial phase, portal phase and venous phase that provide important information 
for characterisation of a focal liver lesion. In clinical practice, however, the number of 
phases is limited and often kept to a minimum, mainly because of the radiation hazard. 
At the same time, helical scanning and thinner collimation are used, more often. As a 
consequence, smaller hepatic lesions are detected that cannot be characterised with CT 
scanning after monophasic injection of contrast material.
State-of-the-art MRI provides the most comprehensive and non-invasive imaging 
work-up of patients with suspected HCA (19). Grazioli et al. reported a sensitivity and 
specificity in differentiating FNH from HCA and LA of 96.9 and 100% respectively. 
However, histological confirmation was not available in all lesions. Most HCA are almost 
isointense or slightly hyperintense to the surrounding liver on in-phase, gradient echo, 
T1-weighted images, showing decreased signal intensity in the opposed-phase T1-
weighted images because of their fat content (19). On T2-weighted images, 47-74% of 
HCA are predominantly hyperintense to the surrounding liver (5) depending on fat or 
fibrosis within the lesion or because HCA is surrounded by fatty liver (19). The superior-
ity of MRI is because of the differences in techniques of data acquisition, the absence 
of radiation and the possibility of using liver-specific contrast agents which lacks the 
hazards of ionising radiation, in addition to inherently greater tissue contrast with MRI 
(19). Superparamagnetic iron oxide (SPIO) and ultrasmall SPIO uptake is expected, as 
the lesions contains Kupffer cells which lead to a loss of signal intensity on ferumoxides-
enhanced T2-weighted images (40, 41). However, differentiation between HCA and FNH 
with the use of SPIO is often difficult because of overlapping uptake of SPIO in HCA and 
FNH (42, 43). Gadobenate dimeglumine (Gd-BOPTA, Multihance; Bracco imaging, Milan, 
Italy) and gadoxetic acid (Gd-EOB-DTPA, Primovist; Schering, Berlin, Germany) are both 
gadolinium-based MR imaging contrast agents that are taken up by hepatocytes and 
their compound is excreted in the bile (6, 44). The HCA lack bile ducts which may result 
in the absence of Gd-BOPTA and Gd-EOB-DTPA uptake and transport compared to other 
benign hepatic lesions (6, 45). Dynamic gadolinium-enhanced imaging demonstrates 
homogeneous enhancement in the arterial phase after gadolinium and isointensity in 
the delayed phase without washout or capsular enhancement (19, 46). Grazioli et al. 
described a hypointense signal on delayed phase images (47). Although it is described 
by a few studies, including a small number of patients, accurate differentiation of HCA 
from FNH is achievable on delayed MRI after Gd-BOPTA administration (6). Another de-
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velopment in imaging techniques, helpful in differential diagnosis of HCA is the clinical 
introduction of contrast-enhanced ultrasonography (CEUS). This technique allows the 
identification of the early enhancement in the periphery of the tumour, reflecting the 
presence of subcapsular feeding arteries with a mixed or centripetal filling (48, 49). In 
CEUS, microbubble contrast (second generation contrast agent, e.g. Sonovue; Bracco 
Imaging) is being used which delivers a pronounced enhancement in the arterial phase 
in HCA and FNH, but washes out rapidly in the portal venous and delayed phase in HCA 
(50–52). An important benefit of CEUS is the safety aspect, because of lack of radiation 
exposure and nearly absent of contrast-related complications and sensitivity reactions 
when compared to other contrast agents. In addition, the examination is short, less 
expensive than CT or MRI, and could reduce patient waiting time (51, 53, 54). Kim et al. 
reported a sensitivity and specificity in differentiating HCA from FNH ranging from 86 to 
95% and from 74 to 79% respectively (49). Furthermore, a recent pilot study by Van den 
Esschert et al. showed that PET/CT with 18F-fluorocholine can differentiate between HCA 
and FNH (55). However, because of a small number of lesions (10 HCA and 11 FNH), the 
diagnostic accuracy of PET/CT with 18F-fluorocholine in differentiation of HCA from FNH 
needs to be confirmed in large number of patients. However, needle biopsy used to be 
accepted as the gold standard for diagnosing tumours, at present radiology, especially 
contrast-enhanced MRI, has equalled or even exceeded the value of needle biopsy as 
the gold standard. Moreover, MRI seems to be a useful tool for identifying the two major 
subtypes of HCA (L-FABP-negative HCA and inflammatory HCA) (56). Results of our series 
of 48 surgically resected HCA lesions who underwent MRI before resection showed that 
L-FABP-negative HCA, inflammatory HCA and β-catenin-positive HCA to be associated 
with specific MRI patterns. Intratumoural fat deposition and presence of an ‘atoll’ sign 
and/or central scar can be helpful to distinguish between these subtypes (57). Based 
on our own experience, we advocate contrast MRI and CEUS to diagnose HCA. In case, 
contrast MRI and CEUS are not in accordance with the diagnosis of HCA or in case of 
doubt on the diagnosis of HCA, a biopsy is needed (Figure 4).
MAnAgeMent
overall management
Regardless the aetiology and risk factors, all female patients should be advised to stop 
OC and other hormone medication, such as hormone replacement therapy, as regres-
sion of HCA may occur when steroids are withdrawn (58). We reviewed our series of 221 
patients with a clear diagnosis of HCA referred to our hospital between 2000 and 2009. 
We reported 104 of 221 HCA patients in which the course of HCA is noted. The course 
of HCA was unknown in case of lack of radiological imaging after discontinuation of OC, 
Management of HCA 145
Chapter
7
or due to intervention, or due to haemorrhage or in case the data of discontinuation 
of OC was unknown. In 8 of 104 HCA patients, the use of OC was absent. Seventy-six of 
96 (79%) HCA patients in whom the course of HCA after discontinuation of OC is noted 
showed regression of HCA. The HCA lesion showed regression from some millimetres 
to 8.5 centimetres. Some HCA lesions showed total regression of the tumour. Although 
several strategies for managing HCA were described in literature, the best treatment of 
HCA still remains controversial. Expert opinions are very variable regarding treatment 
and follow-up in complex situations, where multiple factors play a role in determining 
the management strategy, like multiple HCA and pregnancy (59). In case of a solitary 
adenoma, most authors advocate surgical resection only if the diameter exceeds 5 
cm after 6 months of follow-up without OC use, if the lesion does not show adequate 
regression after discontinuation of OC or if rebleeding occurs (21, 34, 60, 61). Surgical 
resection is also indicated, if there is any doubt on malignancy or malignant transforma-
tion (59, 62). Observation should be the first treatment choice for lesions smaller than 
5 cm or lesions showing regression during radiological follow-up (Figure 4). Based on 
our own experience, we advocate a first follow-up interval of 6 months for repeated 
MRI to compare adequate diameter and shrinkage. The length of follow-up should be 
determined on a custom-made base. Resection should be considered in case of a young 
Differential diagnosis of HCA 
Contrast MRI and CEUS 
HCA < 5 cm 
Stop OC 
Follow-up if: 
- Regression or 
equal size 
 
 
Resection if:  
-Growth after stop 
OC 
- Malignant 
characteristics 
HCA ≥ 5 cm 
Stop OC 
Observation if: 
-< 5 cm after 6 
months stop OC 
- Rapid regression 
after stop OC 
Consider resection if: 
- Complaints 
- Multiple lesions 
 
Resection if: 
- Growth after stop OC 
- Wish for pregnancy and 
HCA ≥ 5 cm after 6 months 
of stop OC  
- Postmenopausal women 
and HCA ≥ 5 cm after 6 
months of stop OC  
Alternative treatment:  
• TAE: intra-abdominal bleeding and/or to reduce tumor mass 
• RFA: small lesions that show no regression after stop OC and/or multiple lesions not amenable for surgery 
 
Contrast MRI: HCA 
+ 
CEUS *: HCA 
Not in accordance or doubt 
HCA Biopsy 
figure 4. Management decision tree for hepatocellular adenoma.
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female patient with a wish for pregnancy with HCA ≥ 5 cm after 6 months of follow-up. 
Resection should also be considered in case of post-menopausal women with HCA ≥ 5 
cm after 6 months of follow-up or in case of male patients, as these patients have a high 
risk on β-catenin-positive HCA (63).
New and less invasive treatments, such as radiofrequent ablation (RFA) and TAE, have 
been proposed as an alternative treatment. The RFA may be useful in selected cases 
in which radical resection is not possible because of centrally located lesions, multiple 
HCA in both lobes of the liver, those who refuse surgery or in patients with a wish for 
pregnancy (64-66). For small tumours that do not show regression after withdrawal of 
steroids, RFA might be the most favourable treatment because of the least expensiveness 
and most gained quality-adjusted life years (QALY’s) (67). A limited available number of 
studies regarding this topic reported RFA to be a safe and successful application espe-
cially in HCA < 4 cm (64-66, 68, 69). Although used in emergency setting with or without 
intra-abdominal bleeding, TAE may also be used electively to reduce the tumour mass 
of a large HCA (70). The TAE is thought to be a less invasive therapy compared to hepatic 
resection. However, only limited studies are available about TAE as elective treatment for 
unruptured HCA (70, 71).
rupture and bleeding
Management of a ruptured HCA is of major concern because initial bleeding may be 
severe enough to produce haemorrhagic shock. Haemodynamically unstable patients, 
despite adequate resuscitation, require immediate intervention to control haemorrhage 
(24). Intervention should consist of emergency laparotomy or laparoscopic resection. 
However, one should take into account the surgical procedure related to mortality and 
morbidity (67). The TAE as an initial treatment in patients with spontaneous bleeding 
of HCA with or without intra-abdominal rupture may reduce the need for urgent lapa-
rotomy to control bleeding (18, 60, 70, 72). However, no data are available regarding 
the long-term effects of TAE and complication risks (67). There are no data about RFA 
therapy for ruptured adenomas. If there is no regression or even growth of the lesion 
after haemorrhage, a surgical resection should be considered to prevent rebleeding (61).
Pregnancy
Hepatocellular adenoma in pregnant women requires special considerations because of 
the risk of hormone-induced growth and spontaneous haemorrhagic rupture, because 
of increased levels of steroid hormones during pregnancy that may threaten the life 
of both mother and child. The risk of rupture is the highest during the third trimester 
of pregnancy, most probably because of the cumulating level of oestrogens and an 
increase in hyperdynamic circulation combined with an increase in vascularity of the 
liver with growth of the adenoma (22). In literature, the maternal and fetal mortality 
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risks of ruptured HCA during pregnancy are reported to be 44 and 38% respectively 
(22). However, all of these cases were published in the 1970s or 1980s period, in which 
there might have been a delay in diagnosis as the entity of ruptured HCA was not well 
known yet, consequently leading to confusion with other pregnancy-related diseases, 
like pre-eclampsia, pulmonary embolism or gallbladder disease. In the last decennium, 
the introduction and widespread use of highly advanced imaging modalities has prob-
ably decreased the doctors’ delay in the diagnosis of HCA. Intervention during preg-
nancy may be associated with greater risk for both mother and child. Little literature 
is available on the course and management of HCA during pregnancy. We monitored 
12 women with documented HCA during a total of 17 pregnancies. In four cases, HCAs 
grew during pregnancy, requiring a Caesarean section in one patient (two pregnancies) 
and RFA in one patient during the first trimester of pregnancy. All pregnancies had an 
uneventful course with a successful maternal and fetal outcome. We concluded not to 
discourage all women with HCA from pregnancy. Negative advice against pregnancy is 
justified in women who have large tumours or who have experienced complications of 
HCA in previous pregnancies. In that case, surgical resection should be recommended 
before pregnancy (73). Moreover, a series of 48 patients showed that about half of 
women carried at least one pregnancy before HCA was discovered (62).
Multiple hepatocellular adenoma and liver adenomatosis
In 1985, Flejou et al. defined LA as the presence of ≥ 10 adenomas in an otherwise normal 
liver parenchyma. They reported that LA affects men and women equally without rela-
tion to the use of OC or GSD (4). Recent studies reported a gender distribution in favour 
of female patients (74, 75) and an association with OC use, glycogenosis, diabetes, high 
BMI, germline mutations of HNF-1α (L-FABP-negative HCA, a subgroup that seems to be 
associated with steatotis), non-alcoholic fatty liver disease and patients who undergo a 
Fontan procedure (8, 10, 35, 74, 76, 77). Eighteen per cent of patients with LA showed 
steatosis in non-tumoural tissue which affects the management of patients with LA 
as liver steatosis has an impact on the outcome of liver surgery (75, 78). Several other 
authors reported or suggested an increased incidence of multiple adenomas (≥ 2) in 
the setting of liver steatosis (11, 62, 77, 78). Chiche et al. identified two forms of LA: the 
‘massive’ form and the ‘multifocal’ form (74). In the massive form, the liver is enlarged, 
the liver contour is deformed and the parenchyma is tumoural and hypervascularized. 
The liver contains nodules measuring 2-10 cm and this form may be progressive. Liver 
surgery on the massive form can be a therapeutic challenge. In contradiction to mas-
sive form, in the multifocal form, one or two nodules may be larger and may produce 
complications. The liver is not enlarged or deformed. Liver surgery on the multifocal 
form is easier compared to the massive form (74). There is an ongoing debate on the 
management of multiple hepatic adenomas and LA, regarding surveillance, surgical 
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resection or other less invasive treatments, such as RFA and TAE. Proper control of mul-
tiple lesions may be indicated in selected patients, like in patients with a strong wish 
for pregnancy. However, one should still limit surgical resection of adenomas ≥ 5 cm in 
diameter, to prevent the risk of bleeding and malignant transformation or adenomas 
with radiological signs of malignancy. Although, some patients are not amenable for 
surgery because of centrally located tumours or because of the extensive involvement 
of both lobes of the liver in LA. In that case, an alternative minimal invasive treatment, 
like RFA, may be the treatment of choice. The RFA can be performed percutaneously 
or in an open setting (65). However, limited data are available on this topic (64-67, 69). 
The surgical procedure may also be combined with open RFA for the remaining smaller 
lesions as a safe and effective treatment option because of low mortality and morbidity 
rates of this procedure. Furthermore, in small tumours, RFA is the preferred treatment 
because of the short hospital stay, low cost and the best gain in QALY’s as we mentioned 
earlier (67). A case report published in 2009 suggested elective treatment of multiple 
HCA with TAE to prevent rupture and bleeding (79). Regarding the risk of malignant de-
generation (80), Barthelmes reviewed 17 patients of liver transplantation for LA. In these 
series, there is clearly a selection bias, because some of the adenomas were suspected 
of malignant transformation and the patients were listed for transplantation. Outcome 
and survival are known for only 10 patients (81). Three of these patients developed HCC 
in the transplanted liver or developed lung metastasis, one patient died immediately 
post-operatively (81). Although LA is a benign disease, in patients who are not amenable 
for other treatment strategies, such as TAE, RFA or surgical resection, a liver transplan-
tation may be the best option, especially in case of degenerated adenomas. However, 
Dokmak et al. reported that there is no indication for liver transplantation in patients 
with unresectable multiple HCA, because of the low risk of progression or complications 
of residual HCA (21).
concluSion
Despite the great development in the area of HCA, especially in case of radiology, to 
date a decision-making model for the management of HCA as proposed in Figure 4 
might not be justified for all patients, and a more custom-made approach should be 
followed. There are still many unanswered questions:
• What is the risk of bleeding in HCA > 5 cm and does bleeding occur in small lesions?
• A ‘wait and see’ management may be advocated in pregnant women presenting with 
HCA, however, there is no evidence-based algorithm for the evaluation and manage-
ment of HCA during pregnancy.
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• What is the best treatment in case of multiple HCA?
The most important progress concerning HCA contains its subtype classification. Data 
from different centres are needed to correlate the classification system with legitimized 
clinical management and to investigate whether the immunohistochemical markers will 
also be useful on biopsies from liver tumours, suspected of being HCA.
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Although hepatocellular adenoma (HCA) is a benign tumor of the liver, the diagnosis 
can have a great impact on the lives of these mostly young women because of the risk 
of bleeding complications and malignant transformation [1-2]. Female sex, oral contra-
ceptives (OC) use and childbearing age are major factors for developing HCA. However, 
HCA can also occur in females without (previous) use of OC and occurs rarely in men. 
There is still much unknown about the etiology and epidemiology of HCA. Estimates of 
incidence and prevalence of HCA can hardly be made since there are a limited number 
of epidemiological studies as well as a diversity of imaging techniques with different 
imaging characteristics. Due to scarcity of cases there is still absence of an evidence-
based approach for the management of HCA. Clinical dilemmas occur when multiple 
factors play a role for example in case of young women in her childbearing age with 
multiple, bilateral or centrally located lesions and a wish for pregnancy. Advice in the 
management of HCA is mainly based on retrospective studies, case series, incidental 
case reports and expert opinions. However, great progress has been made concerning 
HCA.
State-of-the-art magnetic resonance imaging (MRI) provides the most comprehensive 
and non-invasive imaging work-up of patients with suspected HCA [3]. The use of this 
highly advanced imaging modality reduces the number of biopsies and possible unnec-
essary surgery. Differentiation of HCA from other lesions in the liver is important but still 
can be difficult, especially differentiation of HCA from focal nodular hyperplasia (FNH). 
FNH generally does not require treatment and follow-up, whereas HCA does. When 
doubt remains on radiological imaging, immunohistochemical analysis can provide a 
solution. The morphological diagnosis of FNH is supported by a characteristic ‘map-like’ 
staining pattern of glutamine synthetase (GS) [4]. In cases where there is doubt about 
the diagnosis HCA there is a role for core needle biopsy.
The introduction of a molecular and pathological subtype classification system for HCA 
can be of great clinical importance. The main interest is the complication rate (hemor-
rhage and malignant transformation) related to each subgroup and subtype specific 
characteristics (e.g. number of tumors, body mass index). However, to investigate specific 
clinical and pathological features for each subgroup and related risks data from different 
centers need to be combined. To achieve this, widespread availability of standardized 
immunohistochemical techniques is needed.
Despite the great progress in the field of HCA, the debate whether to manage solitary 
HCA by conservative treatment or invasive treatment goes on. However, the rules for 
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now are as follows: we do believe and still advise all female patients to stop the use 
of OC and other hormone replacement therapies. Resection is indicated for HCA ≥ 5 
cm in diameter after six months of first follow-up because of the risk of bleeding and 
malignant transformation. One should take into account that resection has an invasive 
nature with a risk of postoperative morbidity and mortality. Moreover resection of cen-
trally located large lesions can be difficult and the risk of surgical resection should be 
weighted against the benefits. The idea to resect only large HCA is outdated. Resection 
is also advocated in smaller HCA which show signs of a typical vaguely defined scar 
on MRI, atypical characteristics, in case of growth after discontinuation of OC, HCA in 
men and HCA in context of chronic viral hepatitis. A homogeneous staining pattern of 
GS (which is a β-catenin target gene) and β-catenin positivity is a strong argument for 
resection of the lesion. However, more data are needed since we do not know the steps 
in the process of developing hepatocellular carcinoma out of HCA. New and less invasive 
treatments such as radiofrequent ablation (RFA) and transcatheter arterial embolization 
have been proposed as an alternative treatment. RFA may be useful in selected cases 
in which radical resection is not possible due to lesions located centrally, multiple HCA 
in both lobes of the liver, in those who refuse surgery or in patients with a wish for 
pregnancy [5-7]. However, since the biological behavior of HCA during pregnancy may 
be less threatening than presumed a wait and see management may be advocated in 
lesions < 5 cm in diameter. Livertransplantation might be used exceptionally in case of 
high risk patients with unresectable multiple HCA.
In conclusion, for an optimal care of patients with HCA the combined expertise of sur-
geons, hepatologists, radiologists, pathologists and gynecologists is needed. Treatment 
of solitary and multifocal liver tumors requires a multicenter approach.
There are still many unanswered questions:
• What is the complication risk for patients with multiple HCA of one or different 
subtypes?
• What is the exact incidence and prevalence of HCA worldwide and per region?
• What is the actual risk of hemorrhage and rupture for each subgroup of HCA and 
what is the risk in smaller HCA?
• What is the risk of malignant transformation in β-catenin positive HCA?
• What is the risk of malignant transformation in β-catenin and GS negative HCA?
• What is the mechanism of malignant transformation of HCA?
• Which subtype of HCA lesions will regress, what is the speed of regression and is 
there regression of HCA after menopause?
• What is the best way to follow-up patients with HCA: what is the length and interval 
of follow up?
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• What is the biological behavior of HCA during pregnancy and what is the complica-
tion risk?
future PerSPectiVeS
For the near future it is necessary to confirm the promising results described in this thesis 
and to obtain answers on the questions mentioned above in a large multicenter study.
It would be of great benefit if we could provide a large multicenter prospective 
database to correlate data to perform a legitimized clinical management protocol. The 
consequence for treatment and follow-up of the subtype classification remains to be 
determined. Systematic registries are needed for better knowledge about the different 
subgroups and their behavior, to find surrogate markers and to improve the identifica-
tion of HCA subgroups based on imaging. Moreover, risk factors for each individual sub-
group need to be investigated. Therefore, a multicenter study is warranted to investigate 
specific clinical and pathological features for each subgroup and to propose guidelines 
for the management for each individual patient. It is warranted to establish the actual 
risk of hemorrhage and rupture for each subgroup of HCA and to identify those patients 
who require aggressive treatment. In the near future, international studies will be estab-
lished to collect data from referral centers from different countries to answer questions 
related to diagnosis and treatment of HCA (and HCA subtypes).
The conclusion not to discourage all women with HCA from pregnancy will be inves-
tigated in a large multicenter study in the Netherlands in which pregnant patient with 
HCA will be closely monitored in a prospectively acquired database to give more insight 
in the behavior of HCA during pregnancy. We hypothesize that pregnancy may be al-
lowed in case of one or more known HCA < 5 cm, because HCA < 5 cm will not disturb 
the course of pregnancy. Whether it is justified to deny a young woman a pregnancy, as 
the biological behavior may be less threatening than presumed will be investigated in 
the PALM-study.
Which patients should undergo surgical treatment and which patients should not 
remains a topic largely open for debate. Therefore, future research should focus on the 
comparison of different treatment modalities for the treatment of HCA, including lapa-
roscopic liver resection, ablation therapies, transarterial embolization and conservative 
management.
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In chapter 2 we described the present day-to-day management of hepatocellular ad-
enoma (HCA) in the Netherlands based on expert opinions on diagnosis and treatment 
of HCA. We concluded that the management of HCA is rather uniform, except in some 
cases in which multiple factors play a role such as bleeding, a wish for pregnancy or 
multiple lesions. In the majority of hospitals management of HCA was determined by a 
multidisciplinary approach. The diagnosis was based on contrast-enhanced, multiphase 
spiral CT or MRI series. All patients were advised to stop oral contraceptives (OC) use and 
outpatient control by MRI, CT or ultrasound was performed at least once. Conservative 
treatment was the initial treatment for HCA < 5 cm in diameter in all hospitals. A tumor 
size > 5 cm and abdominal complaints were major criteria for surgical resection. However, 
sometimes resection was performed if there was a wish for pregnancy, potential signs 
of malignancy on imaging, tumor growth or in case of diagnostic doubt. Pregnancy was 
not discouraged in most of the clinics, however most experts wanted to exclude the risk 
of hormone induced rupture and bleeding by resection before pregnancy. In our opinion 
it seems unjustified to discourage all women with HCA < 5 cm from pregnancy. There are 
no randomized controlled studies available that depict a clear decision making model 
for the treatment of hepatic adenomas in various conditions and the management of 
individual patients depends mainly on the physicians or surgeons insight. The need for 
a clear decision making model is obvious. Therefore, future research should be focused 
on the management of HCA in patients with multiple HCA, HCA > 5 cm, pregnancy and 
bleeding lesions.
In chapter 3 we investigated the possibility to distinguish subgroups of HCA based on 
pathological findings and the possibility to correlate pathological findings with imag-
ing characteristics on state-of-the-art MRI. Recently the Bordeaux group established a 
molecular and pathological classification system for HCA. HCA were divided into four 
different subgroups based on morphological criteria, molecular characteristics, and 
by the use of a panel of immunohistochemical markers [1-3]. We validated the clas-
sification system on 57 HCA lesions and concluded that morphology and additional 
imuunohistochemical markers can discriminate between different types of HCA in > 
90% of cases. Multiple HCA of different subtypes can be found in patient. Focal nodular 
hyperplasia (FNH) can be found with high reliability by the use of glutamine synthetase 
(GS), which shows a characteristic ‘map-like’ staining pattern in case of FNH lesions. The 
identification of β-catenin positive lesions is of major interest since β-catenin positive 
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lesions seems to have a risk on malignant transformation [4-6]. However, interpretation 
of nuclear staining for β-catenin can be difficult due to uneven staining distribution or 
focal nuclear staining. In this situation additional molecular biology may be required.
We were able to confirm specific MRI features that can be used to identify different 
subgroups of HCA, especially for the inflammatory and L-FABP-negative HCA. L-FABP-
negative HCA can be recognized with high reliability, and presents as a diffuse decrease 
in signal intensity on out-of-phase signal images because of the presence of intratu-
moral fat. In almost half of the inflammatory HCA lesions we found a typical ‘atoll’ sign 
on MRI, characterized by a hyperintense signal band on T2-weighted pulse sequences 
in the periphery of the lesion (i.e. like an atoll) and isointensity of the center of the le-
sion with respect of the surrounding liver (like the surrounding sea). The presence of a 
vaguely demarcated scar in HCA was significantly associated with nuclear staining of 
β-catenin. In these cases surgical resection or close follow-up is advocated. The clini-
cal consequence for the treatment and follow-up based on the pathological subtype 
classification remains to be determined. A multicenter study is warranted to investigate 
specific clinical and pathological features for each subgroup and to propose guidelines 
for the management for each individual patient.
It is thought that HCA can be complicated by hormone induced growth and subse-
quently, spontaneous hemorrhagic rupture. In chapter 4 we proposed not to discour-
age all women with HCA from pregnancy, based on a study in which we monitored 
twelve women with documented HCA during a total of 17 pregnancies. In 4 cases HCA 
grew during pregnancy, requiring a Caesarean section in 1 patient (2 pregnancies) 
and radiofrequency ablation (RFA) in 1 case during the first trimester of pregnancy. All 
pregnancies had an uneventful course with a successful maternal and fetal outcome. 
However, there is no evidence-based algorithm for the evaluation and management of 
HCA during pregnancy, due to scarcity of cases. The conclusion not to discourage all 
women with HCA from pregnancy has, however, to be proven in a large multicentre 
study in which we will closely monitor pregnant patient with a HCA in a prospectively 
acquired database to give more insight in the behaviour of HCA during pregnancy. We 
hypothesized that pregnancy may be allowed in case of one or more known HCA < 5 cm, 
because HCA < 5 cm will not disturb the course of pregnancy. Whether it is justified to 
deny a young woman a pregnancy, as the biological behavior may be less threatening 
than presumed will be investigated in the ‘Pregnancy And Liver adenoma Management’ 
(PALM)-study.
The safety and efficacy of RFA for the treatment of HCA and liver adenomatosis (≥ 10 
HCA) [7] is investigated in chapter 5. Minimal invasive treatment like RFA has provided 
to be safe and can be used effectively in the treatment of HCA. However, multiple ses-
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sions are often required, and signs of residual HCA might persist in some patients 
despite repetitive treatment. Although surgical resection is the treatment of choice in 
many patients, RFA could be applied selectively for the treatment of HCA in patients not 
amenable for surgery due to the extensive involvement of the liver (e.g. liver adenoma-
tosis) in patients who would require major hepatic resection otherwise or in patients 
with multiple right-sided lesions or patients with multiple HCA in both lobes of the liver. 
Moreover, RFA might also be useful for centrally located HCA in the liver. However, which 
patients should undergo surgical treatment and which patients should not remains a 
topic largely open for debate.
As previous said, HCA can be complicated by hormone induced growth and subse-
quently spontaneous rupture and bleeding of the tumor. chapter 6 describes a system-
atic review on the risk estimate for hemorrhage and rupture as reported in the literature. 
Hemorrhage and rupture is a common complication in patients with HCA. Hemorrhage 
was reported with an overall frequency of 27.2% of cases, and in 15.8% of the total 
number of HCA lesions. In 17.5% of cases rupture and intraperitoneal bleeding were 
reported. The risk of hemorrhage and rupture in HCA < 5 cm seems small. Prospective 
multicenter studies are warranted to establish the actual risk of hemorrhage and rupture 
for each subgroup of HCA as mentioned in chapter 3 and to identify those patients who 
require aggressive treatment.
Last years great progress has been made in the area of HCA, especially regarding the 
pathological subtype classification, radiologic imaging and management of HCA dur-
ing pregnancy. However, defining the right management strategy, once the diagnosis 
of HCA has been established, may be challenging. chapter 7 describes the current 
knowledge about diagnosis and treatment modalities of HCA and a decision-making 
model for HCA is proposed. However, in the near future new variables e.g. pathological 
subtypes, bleeding risks, age, pregnancy and multiple HCA should be included for more 
personalized medicine.
In chapter 8 the studies performed in chapter 2–7 are discussed. In addition, directions 
for further studies are pointed out.
concluSionS
chapter 2: The management of HCA in the Netherlands is rather uniform, except in 
complex cases in which multiple factors may influence policy.
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chapter 3: Subtype classification of HCA has implications for treatment and follow-up.
chapter 4: A ‘wait and see’ management may be advocated in pregnant women pre-
senting with HCA < 5 cm in diameter.
chapter 5: RFA can be used effectively in the treatment of HCA.
chapter 6: Hemorrhage and rupture is a common complication in patients with HCA. 
However the risk of hemorrhage and rupture in HCA < 5 cm seems small.
chapter 7: There is a great development in the field of HCA, especially in case of ra-
diology, pathology and management during pregnancy. A decision-making model is 
proposed based on the current knowledge.
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Nederlandse samenvatting en conclusies
SAMenVAtting
In hoofdstuk 2 onderzochten we de huidige “expert opinies” met betrekking tot de 
diagnostiek en behandeling van het hepatocellulair adenoom (HCA) in Nederland. 
We concludeerden dat het beleid betreffende HCA in Nederland redelijk eenduidig 
is, behalve in situaties waarin meerdere factoren een rol spelen zoals bloeding, een 
zwangerschapswens of multipele laesies. In de meeste ziekenhuizen werd het beleid na 
multidisciplinair overleg bepaald. De diagnose werd gebaseerd op multifasische spiraal 
computed tomography (CT)- of magnetic resonance imaging (MRI)-series na contrast-
toediening. Alle patiënten werd geadviseerd pilgebruik te staken en minstens één maal 
radiologische controle met MRI, CT of echografie uit te laten voeren. In alle ziekenhuizen 
had een conservatief beleid de voorkeur in die situaties waarbij het adenoom een dia-
meter had kleiner dan 5 cm. Een tumorgrootte > 5 cm en buikklachten waren redenen 
om te reseceren. Echter, soms werd een resectie uitgevoerd indien er sprake was van 
een zwangerschapswens, kans op maligne ontaarding, groei van de tumor of indien 
er sprake was van twijfel aan de diagnose. Zwangerschap werd in de meeste klinieken 
niet afgeraden, echter een meerderheid van de centra koos toch voor invasieve therapie 
voorafgaand aan de zwangerschap om het risico op hormoon geïnduceerde ruptuur 
en bloeding teniet te doen. Naar onze mening lijkt het niet gerechtvaardigd om alle 
vrouwen met HCA < 5 cm een zwangerschap te onthouden. Er zijn geen gerandomi-
seerde gecontroleerde studies beschikbaar die een wetenschappelijke onderbouwing 
tonen voor de behandeling van HCA in verschillende omstandigheden. Daarnaast is 
het management van individuele patiënten vooral afhankelijk van het inzicht van de 
behandelende artsen. De behoefte aan een helder besluitvormingsmodel ligt voor de 
hand. Daarom moet toekomstig onderzoek zich richten op het management van HCA 
bij patiënten met multipele HCA, HCA > 5 cm, zwangerschap en bloedende laesies.
In hoofdstuk 3 hebben we leveradenomen onderverdeeld in subgroepen op basis van 
pathologische bevindingen en onderzochten we de mogelijkheid om de pathologische 
bevindingen te correleren aan radiologische karakteristieken van state-of-the-art MRI. 
Recent is een moleculair and pathologisch classificatie systeem voor HCA ingevoerd door 
de Bordeaux groep. HCA werden onderverdeeld in vier grote subgroepen gebaseerd op 
morfologische criteria, moleculaire karakteristieken en door het gebruik van een panel 
van immunohistochemische markers [1-3]. We valideerden het classificatie systeem op 
57 HCA laesies en concludeerde dat subtype classificatie door middel van morfologie 
en aanvullende immunohistochemische markers mogelijk is in > 90% van de HCA. Per 
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patiënt kunnen HCA van verschillende subtypen voorkomen. Focaal nodulaire hyperpla-
sie (FNH) kan met hoge betrouwbaarheid worden aangetoond door gebruikt te maken 
van glutamine synthetase (GS), wat een typisch ‘kaart-achtig’ aankleuringspatroon van 
GS vertoont in het geval van FNH. De identificatie van β-catenine positieve laesies is 
van groot belang omdat β-catenine positieve laesies een kans op maligne transformatie 
lijken te hebben [4-6]. Echter interpretatie van nucleaire aankleuring van β-catenine kan 
moeilijk zijn doordat het aantal positieve cellen beperkt is en de aankleuring focaal is. 
Hierbij is moleculaire diagnostiek aanbevolen.
We confirmeerden specifieke MRI kenmerken die kunnen worden gebruikt voor de 
identificatie van de verschillende subgroepen van HCA, vooral voor het inflammatoire en 
L-FABP-negatieve HCA subtype. Het L-FABP-negatieve subtype kan met hoge betrouw-
baarheid worden herkend en presenteert zich met diffuse afname in signaal intensiteit 
op ‘uit fase’ signaal beelden vanwege de aanwezigheid van vet in de laesie. In de helft van 
de inflammatoire adenomen vonden we een typische ‘atol’ teken op de MRI, gekenmerkt 
door een hyperintense signaal band op T2-gewogen pulse sequenties in de periferie van 
de laesie (zoals een atol) en iso-intensiteit van het centrum van de laesie ten opzichte 
van de omgeven lever (zoals de omgeven zee). De aanwezigheid van een typisch vaag 
afgebakend litteken in het HCA was significant geassocieerd met nuclaire aankleuring 
van β-catenine. In deze casus is chirurgische resectie of strikte follow-up aanbevolen. De 
klinische consequenties van de pathologische subtype classificatie voor de behandeling 
en follow-up moet worden vastgesteld. Een multicenter studie is wenselijk om specifieke 
klinische en pathologische kenmerken voor elk subtype te onderzoeken en om richtlij-
nen vast te stellen voor het management van elke individuele patiënt.
Er wordt gedacht dat HCA kan worden gecompliceerd door hormoon geïnduceerde 
groei en vervolgens spontane hemorragische ruptuur. In hoofdstuk 4 hebben we voor-
gesteld niet alle vrouwen met een HCA een negatief zwangerschapsadvies te geven, 
gebaseerd op een studie waarin we twaalf vrouwen vervolgden met gedocumenteerde 
HCA gedurende een totaal van 17 zwangerschappen. In 4 casus was er sprake van groei 
van het HCA gedurende de zwangerschap. In 1 patiënt (2 zwangerschappen) resulteer-
den dit in een sectio caesarea en in 1 patiënt werd radiofrequente ablatie (RFA) therapie 
toegepast in het eerste trimester van de zwangerschap. Alle zwangerschappen hadden 
een gunstig verloop en een succesvolle maternale en foetale uitkomst. Door de schaarste 
aan zwangere patiënten met HCA is er echter geen evidence-based algoritme voor de 
evaluatie en het management van HCA gedurende de zwangerschap. De conclusie om 
niet alle vrouwen met HCA een zwangerschap te onthouden moet dan ook worden be-
wezen in een grote multicenter studie. In deze studie zullen wij zwangere patiënten met 
HCA nauwlettend volgen om meer inzicht te krijgen in het gedrag van HCA gedurende 
de zwangerschap. We maken hierbij gebruik van een prospectief verkregen database. 
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De hypothese is dat zwangerschap gerechtvaardigd is in geval van één of meerdere 
HCA < 5 cm, omdat HCA < 5 cm het verloop van de zwangerschap niet zal verstoren. Of 
het gerechtvaardigd is om een jonge vrouw een zwangerschap te ontraden, terwijl het 
biologisch gedrag minder bedreigend is dan wordt vermoed, zal worden onderzocht in 
de ‘Pregnancy And Liver adenoma Management’ (PALM)-studie.
We onderzochten de veiligheid en werkzaamheid van RFA voor de behandeling van 
HCA en lever adenomatosis (≥ 10 HCA) [7] in hoofdstuk 5. Een minimaal invasieve be-
handeling zoals RFA is veilig en effectief in de behandeling van HCA. Echter, er zijn vaak 
meerdere sessies nodig en er kan resterend HCA weefsel persisteren in sommige patiën-
ten ondanks herhaalde behandeling. Hoewel chirurgische resectie de behandeling van 
keuze is bij veel patiënten, kan RFA selectief worden toegepast voor de behandeling van 
HCA bij patiënten die niet vatbaar zijn voor een operatie als gevolg van grote betrok-
kenheid van de lever (bijv. lever adenomatosis) en dus een grote leverresectie zouden 
moeten ondergaan, bij patiënten met meerdere rechtszijdige laesies of patiënten met 
multiple HCA in beide leverlobben. Daarnaast kan RFA ook de aangewezen therapie 
zijn voor centraal gelegen HCA in de lever. Welke patiënten een chirurgische behande-
ling moeten ondergaan en welke patiënten niet blijft echter een onderwerp open voor 
discussie.
Zoals eerder beschreven kan HCA worden gecompliceerd door hormoon geïnduceerde 
groei en vervolgens ruptuur en bloeding van de tumor. Hoofdstuk 6 beschrijft een 
systematisch review over de risico-inschatting voor bloeding en ruptuur zoals gerap-
porteerd in de literatuur. Bloeding en ruptuur is een veel voorkomende complicatie bij 
patiënten met HCA. Bloeding werd beschreven in 27,2% van de patiënten, en in 15,8% 
van het totaal aantal HCA laesies. In 17,5% van de patiënten was er sprake van ruptuur en 
intraperitoneale bloeding. Het risico op bloeding en ruptuur in HCA < 5 cm lijkt klein. Een 
prospectieve multicenter studie is nodig om het werkelijke risico op bloeding en ruptuur 
voor elke subgroep van HCA, zoals vermeld in hoofdstuk 3, te bepalen en om vast te 
stellen welke patiënten met HCA een agressieve behandeling dienen te ondergaan.
De afgelopen jaren is er grote vooruitgang geboekt op het gebied van HCA, vooral 
wat betreft de pathologische subtype classificatie, radiologische beeldvorming en 
het management van HCA gedurende de zwangerschap. Het bepalen van de juiste 
managementstrategie zodra de diagnose HCA is gesteld kan echter een uitdaging zijn. 
Hoofdstuk 7 beschrijft de huidige kennis over de diagnose en de behandelingsmoda-
liteiten van HCA. Daarnaast is een beslissingsmodel voor HCA voorgesteld. In de nabije 
toekomst moeten echter nieuwe variabelen zoals pathologische subtypes, bloeding 
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risico’s, leeftijd, zwangerschap en multipele HCA worden opgenomen voor een meer 
geïndividualiseerd beleid.
In hoofdstuk 8 worden de bevindingen uit de hoofdstukken 2–7 bediscussieerd. 
Tevens worden enkele aanknopingspunten voor verder onderzoek gegeven.
concluSieS
Hoofdstuk 2: Het beleid van HCA in Nederland is eenduidig, behalve in complexe casus 
waarin meerdere factoren van invloed kunnen zijn op het beleid.
Hoofdstuk 3: Subclassificatie van HCA maakt het mogelijk beleid voor behandeling en 
follow-up beter te definiëren.
Hoofdstuk 4: Een afwachtend beleid is gerechtvaardigd bij zwangere vrouwen die zich 
presenteren met HCA < 5 cm in diameter.
Hoofdstuk 5: RFA kan effectief worden gebruikt bij de behandeling van HCA.
Hoofdstuk 6: Bloeding en ruptuur is een veel voorkomende complicatie bij patiënten 
met HCA. Het risico op bloeding en ruptuur in HCA < 5 cm lijkt echter klein.
Hoofdstuk 7: Er is een belangrijke ontwikkeling op het gebied van HCA, in het bijzonder 
wat betreft radiologie, pathologie en het management van HCA gedurende de zwanger-
schap. Een besluitvormingsmodel is voorgesteld op basis van de huidige kennis.
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